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1. LIPID METABOLISM 
 
Hypercholesterolemia holds a key role in the development and progression of 
atherosclerosis and is a causative factor for coronary artery disease
1
. 
Hyperlipidemia is a metabolic disorder defined by either elevated levels of plasma 
concentrations of low-density lipoprotein (LDL) cholesterol and triglycerides, or 
decreased levels of the athero-protective lipid biomarker high-density lipoprotein 
(HDL) cholesterol
2
. Lowering of very-low-density lipoprotein- (VLDL-) and low-
density lipoprotein- (LDL-) cholesterol levels leads to a reduction in cardiovascular 
morbidity and mortality
2
. In contrast, high levels of HDL cholesterol are associated 
with a decreased risk of cardiovascular disease
3
.   
 
1.1 Lipoproteins 
Lipoproteins are spherical macromolecular complexes in which hydrophobic 
molecules, in particular triglyceride and cholesteryl ester, are enveloped within a 
monolayer of amphipathic molecules of phospholipids, free cholesterol, and 
apoproteins
4
. The major lipoprotein classes include intestinally derived 
chylomicrons that transport dietary fats and cholesterol, hepatic-derived VLDL, 
intermediate-density lipoprotein (IDL), and LDL that are considered to be pro-
atherogenic, and hepatic- and intestinally derived HDL that are considered to be 





Figure 1. Illustration of the composition of four major classes of lipoproteins
5
. See text for 
explanation. 
 
1.1.1 Chylomicron, VLDL, and LDL 
Apolipoprotein B (apoB) is necessary for the assembly and secretion of 
chylomicrons by the intestine while it is also an essential component for VLDL, IDL, 
and LDL
6
. As shown in Figure 2, the liver secretes VLDL particles, which contain 
triglycerides and cholesterol esters. Capillaries in muscle and adipose tissue 
remove the triglycerides, and the lipid particle is modified into LDL, with its 
Chapter 1 
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cholesteryl ester core and apoB-100 coat. LDLs circulate in the plasma and the 
apoB-100 component binds to LDL receptors on the surface of hepatocytes. 
Through receptor-mediated endocytosis, receptor-bound LDLs enter hepatocytes 
and undergo degradation in lysosomes, and the cholesterol remnants enter a 
cellular cholesterol pool
7
. Plasma levels of apoB containing lipoproteins are 
regulated by both environmental effects on lipid metabolism and by genetic factors 






Figure 2. The basic pathways of cholesterol synthesis and excretion
7
. See text for explanation. 
 
1.1.2 HDL and reverse cholesterol transport 
The major protein of HDL is apolipoprotein A-I (apoA-I), which is synthesized in the 
liver and intestine. HDL metabolism consists of five main processes: (1) apoA-I 
synthesis and secretion into plasma as nascent HDL; (2) uptake of free cholesterol 
from the periphery; (3) maturation into large spherical particles with cholesterol 
esterification; (4) delivery of cholesteryl ester to the liver, steroidogenic organs, and 
apoB-containing lipoproteins; and (5) catabolism of apoA-I
9
. HDL serves an anti-
atherogenic function because of its ability to mediate reverse cholesterol transport 
(RCT), which is a major protective system against atherosclerosis
10,11
. HDL can 
remove cholesterol from the periphery, allowing it to be cleared by the liver and 
then excreted into the bile
12
. Cholesterol efflux from macrophages to HDL is a 
crucial step in RCT and it occurs at all stages of atherosclerosis
13
. As shown in 
Figure 3, the liver secretes lipid-poor apoA-I, which quickly acquires cholesterol via 
the hepatocyte ABCA1 transporter. Lipid-poor apoA-I also promotes the efflux of 
free cholesterol from macrophages via ABCA1. LCAT esterifies free cholesterol to 
cholesteryl esters to form mature HDL, which promotes cholesterol efflux from 
macrophages via the ABCG1 transporter. In macrophages, both ABCA1 and 
ABCG1 are regulated by nuclear receptor LXR. Mature HDL can transfer its 
cholesterol to the liver directly via SR-BI or indirectly via CETP-mediated transfer to 
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apoB-containing lipoproteins, with subsequent uptake by the liver via the LDL-
receptor
14
. Modulation of major macrophage mediators in RCT, such as ABCA1, 
ABCG1, and SR-B1 has been considered as promising strategies for the 






Figure 3. HDL metabolism and reverse cholesterol transport14. See text for explanation. 
 
1.2 Hepatic lipid metabolism 
Atherosclerosis is a liver disease of the heart
18
. Liver is considered as the major 
organ with significant therapeutic importance for the maintenance of metabolic 
homeostasis
19
. A common associated clinical feature of patients with non-alcoholic 
fatty liver disease (NAFLD) is atherogenic dyslipidaemia, i.e. high triacylglycerol, 
low HDL-cholesterol, and increased LDL-cholesterol levels
20
. Liver fat is highly 
significantly and linearly correlated with all components of the metabolic syndrome 
independent of obesity
21
. NAFLD is not merely a marker of atherosclerosis, but 
may also be actively involved in the pathogenesis of atherosclerosis
22,23
. 
The liver consists of different types of cells, including parenchymal cells, namely 
hepatocytes, and a variety of non-parenchymal cells (Figure 4). Non-parenchymal 
cells are comprised of mainly liver sinusoidal endothelial cells and Kupffer cells. 
Liver endothelial cells form a continuous but fenestrated lining of the hepatic 
sinusoids, while Kupffer cells are found in the sinusoidal lumen on top of or 
between endothelial cells
24
. Liver endothelial cells free the bloodstream from a 
variety of macromolecular waste products during inflammation
25
. Kupffer cells are a 
population of hepatic resident macrophages. They constitute 80-90% of the tissue 
macrophages present in the body
26
. Although non-parenchymal cells count for only 
6.5% of the liver volume, they contain 55% of the lipid droplets in the liver and 43% 
of the lysosomes, and specific activities of enzymes are generally higher in non-
parenchymal cells than in parenchymal cells
27 , 28
. Parenchymal and non-
parenchymal cells synchronize crucial roles in liver metabolic homeostasis as well 
as inflammation. The majority of studies upon liver has focused on the array of 
target genes and metabolic pathways within parenchymal cells
29,30
. However, non-
parenchymal cells are also intimately involved in the pathogenesis of various liver 
metabolic diseases including steatohepatitis, non-alcoholic fatty liver, and liver 
fibrosis
31
. Previous studies have shown that diet-induced hypercholesterolemia 
results in marked changes in the hepatic distribution of LDL and significant 
accumulation of cholesteryl ester/lipid droplets in liver endothelial and Kupffer cells, 





. It has also been shown that cross-talk between Kupffer cells 













Cardiovascular diseases are the leading cause of morbidity and mortality in 
industrialized countries
37
. Atherosclerosis is the underlying cause of most 
cardiovascular diseases. Lipid accumulation leads to an inflammatory condition 
clinically causing occlusive vascular disease, myocardial infarction and stroke
38
. 
The atherosclerotic process is initiated when cholesterol-containing low-density 
lipoproteins accumulate in the intima and activate the endothelium. 
 
2.1 Lesion progression 
Macrophages contribute to the pathogenesis of atherosclerosis through their 
accumulation of cholesterol and development into foam cells
39
. Foam cells arise 
either from resident macrophages in the arterial wall or from blood monocytes that 
enter the wall at sites of endothelial damage
40
. Figure 5 illustrates the infiltration 
and inflammation of macrophages in arterial wall. Leukocyte adhesion molecules 
and chemokines promote recruitment of monocytes which differentiate into 
macrophages and up-regulate pattern recognition receptors on these cells, 
including scavenger receptors. Scavenger receptors mediate lipoprotein 
internalization, leading to foam-cell formation, inflammation, and, ultimately, to 
tissue damage
41,42
. Accumulation of cholesterol-loaded “foam cells” is the hallmark 
of the early atherosclerotic lesion
43
. 





Figure 5. Illustration of macrophage infiltration and inflammation in arterial wall41. See text for 
explanation. 
 
The atherosclerotic plaque is a dynamic tissue, where increases in cell number 
(driven by cell proliferation and migration) and decreases in cell number (driven by 
cell death and possibly emigration) are continuous processes
44
. Initial 
atherosclerotic lesions are primarily composed of lipid-loaded macrophages. Stable 
advanced lesion contains a macrophage core, a small necrotic core, if present at 
all, extracellular matrix and a firm fibrous cap of smooth muscle cells (SMCs)
45
. 
Instable advanced atherosclerotic lesions are characterized by a thin fibrous cap 
containing few SMCs and overlying a large necrotic core composed of dead cells, 




2.2 Lesion regression 
While numerous studies have been dedicated to inhibit the development and 
progression of atherosclerosis, recent attention has been drawn to the goal of 
reversing atherosclerosis, meaning regressing pre-existing atherosclerotic plaques. 
The first evidence of dramatic atherosclerotic regression in mice was achieved via 
robust surgical measures to rapidly improve plaque environment
47
. That study 
suggested that the essential prerequisite for promoting regression of 
atherosclerotic lesions is robust improvement of plasma lipoprotein profiles and 
plaque milieu, including large plasma reductions in atherogenic apoB-lipoproteins 
and brisk enhancements in efflux of cholesterol from plaques to the blood 
circulation and subsequently into the liver. Recently, the same group showed that 
the LXR agonist T0901317 promotes egress of monocyte-derived cells from mouse 
aortic plaques, indicating that LXR is required for maximal effects on plaque 
Chapter 1 
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macrophage egression during atherosclerosis regression in mice
48
. In another 
mouse model, apoE*3Leiden mice, LXR agonist was also shown to promote 
regression of moderate lesions
49
. Raffai et al for the first time addressed the apoE-
mediated mechanisms of atherosclerosis regression
50
. They demonstrate that 
apoE promotes the regression of atherosclerosis independently of lowering plasma 
cholesterol levels. Potteaux et al also achieved regression of atherosclerosis after 
apoE complementation in ApoE
–/–
 mice, suggesting that therapies to inhibit 
monocyte recruitment to plaques may constitute a viable strategy to reduce plaque 





3. ANIMAL MODELS IN ATHEROSCLEROSIS 
 
Atherosclerosis is a complex and chronic inflammatory disease in which multiple 
modulating factors may play a role. Its chronicity and complexity make it very 
difficult to study the detailed mechanisms of atherogenesis in unregulated human 
populations. Therefore, animal models with a homogenous genetic background are 
useful for the study of the mechanism of this process
52
. With the development of 
genetic models of atherosclerosis the mouse has become a very accessible model, 
especially with the very large genetic data base about this species in relation to 




3.1 C57BL/6 mice 
The C57BL/6 mouse strain is used as a model for studies of diet-induced 
atherosclerosis
54 , 55 , 56
. C57BL/6 mice fed with a high-fat cholate-containing 
atherogenic diet have a hyperlipidemic response, develop fatty streak lesions, and 
form atheromatous plaques in the aorta and coronary arteries
57
. This murine model 
of atherogenesis represents an alternative to the use of genetically modified mice 
with impaired lipoprotein clearance, thus it may prove beneficial for the evaluation 









 mice are among the most widely used mouse models for characterization of 
atherosclerosis. Due to the absence of hepatic LDL receptors, LDLr
–/–
 mice exhibit 
prolonged half life of plasma VLDL and LDL
59
. These mice display
 
a modestly 
elevated plasma cholesterol level when maintained
 





 mice show strongly elevated
 
plasma 











 mice with targeted deletion of the apoE gene show severe 
hypercholesterolemia. Therefore, ApoE
–/–
 mice form one of the most common 
animal models to study atherogenesis. The
 
most obvious phenotype of ApoE
–/–
 
mice is the spontaneous
 
development of atherosclerotic lesions, even on a 
standard chow
 
diet which is low in fat content and does
 





develop over time from
 
initial fatty streaks to complex 
lesions, and this process can be
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4. DRUG TARGETS AND PHARMACEUTICAL INTERVENTIONS 
 
Lipid-lowering is established as a proven intervention to reduce atherosclerosis and 
its complications. The development of the HMG-CoA reductase inhibitors (statins) 
has lead to important advances in the management of cardiovascular disease
62
. 
However, statins reduce cardiovascular events by only about 20%-40%, and non-
statin therapies (either as monotherapy or in addition to statins) to reduce LDL-
cholesterol by mechanisms that do not involve inhibition of HMG-CoA reductase 
are also likely to be useful for patients in need of LDL reduction
63
. These therapies 
include drug targets such as squalene synthase, microsomal transfer protein (MTP), 
acyl-cholesterol acyl transferase (ACAT), cholesterol ester transfer protein (CETP), 




4.1 Nuclear receptor 
The nuclear receptor (NR) superfamily describes a related but diverse array of 
ligand-activated transcription factors. NR binds DNA and translates physiological 
signals into gene regulation involved in biological processes. Figure 6 shows a 
higher-order network tying nuclear receptor function to reproduction, development, 
central, and basal metabolic functions, dietary-lipid metabolism, and energy 
homeostasis
65
. Several receptors including the peroxisome proliferator activated 
receptors (PPARs), the liver X receptors (LXRs), the farnesoid X receptor (FXR) 
and the retinoid-related orphan receptors (RORs) are called “metabolic receptors” 
and poised to sense and respond to small changes in the flux through the 






Figure 6. The nuclear receptor ring of physiology. The relationship between receptor expression, 





4.2 LXR and LXR agonists 
Liver X receptors (LXRs) are sterol-responsive nuclear receptors that regulate 
expression of genes involved in cholesterol metabolism and homeostasis
67
. LXRs 
act as cholesterol sensors. When cellular oxysterols accumulate as a result of 
increasing concentrations of cholesterol, LXR induces the transcription of genes 
that protect cells from cholesterol overload
68
. LXR agonists have potent anti-
atherogenic effects, shown in different hyperlipidemic mouse models. Several 
studies have demonstrated that activation of LXR with compounds, such as 
T0901317, significantly up-regulates cholesterol efflux activity and inhibits 
development of atherosclerosis, providing direct evidence for an atheroprotective 
effect of LXR agonists
69 , 70
. T0901317 treatment was associated with reduced 
cholesterol absorption and promoted biliary cholesterol excretion
71 , 72 , 73
. 
Furthermore, LXR agonist significantly increased the generation of HDL particles in 
plasma. Table 1 summarizes the studies of LXR agonists performed in mouse 
models to study atherosclerotic progression or regression. 
 
4.3 PNPLA3 
Patatin-like phospholipase domain-containing protein 3 (PNPLA3), also knows as 
adiponutrin (ADPN) or calcium-independent phospholipase A2-epsilon, is an 
enzyme that in humans is encoded by the PNPLA3 gene
74,75
. High human PNPLA3 
activity is associated with increased liver fat content and liver injury. Variation in 
PNPLA3 contributes to ancestry-related and inter-individual differences in hepatic 





Cholesteryl ester transfer protein (CETP) is a 74-kDa hydrophobic plasma 
glycoprotein that has an established role in mediation of neutral lipid transport 
among lipoproteins
78
. In humans, CETP mRNA is expressed predominantly in 
adipose tissue, liver, and spleen, with lower levels of expression in the small 
intestine, adrenal gland, kidney, skeletal muscle, and heart
79,80
. In addition, Van 
Eck et al
81
 have demonstrated that bone marrow-derived cells, including 
macrohpages, are an important contributor to total serum CETP activity and mass 
in mice.  
Cholesteryl ester transfer protein (CETP) is a key modulator not only of the 
intravascular metabolism of HDL and apoA-I but also of triglyceride-rich 
lipoproteins (TRL). CETP modifies the lipid composition of the plasma by mediating 
the transfer of cholesteryl esters from HDL to pro-atherogenic apoB-lipoproteins, 
with heterotransfer of TG mainly from very low-density lipoprotein to HDL, thereby 
decreasing plasma HDL-C concentrations and increasing the proportion of lipids 
present in the atherogenic LDL-C and VLDL-C fractions
82,83 
(Figure 7). The overall 
effect of CETP is to promote a net mass transfer of CE from HDL to TRL and LDL 
and of TG from TRL to LDL and HDL. CETP plays a significant role in reverse 
cholesterol transport (RCT)
84
. Pharmacological inhibition of CETP in humans 
therefore presents a preferential target to improve the lipid profile of dyslipidemic 













Figure 7. Role of CETP in plasma lipoprotein transport82. 
 
4.5 GPR109A, niacin, and niacin derivatives 
The G protein-coupled receptor GPR109A, also known as PUMA-G in mouse and 
HM74A in humans, has been identified as a high-affinity receptor for nicotinic acid, 
also known as niacin
86,87
. GPR109A is dominantly expressed in adipose tissue and 
spleen
88,89
. It is also highly expressed in macrophages and other immune cells, 
such as lymphocytes
90,91,92,93
. The lipid-lowering effect of niacin on plasma (V)LDL-
TG is the consequence of a direct interaction between niacin and its receptor 
GPR109A in adipose tissue
94
.  
Niacin is the most effective agent currently available to treat dyslipidaemic 
disorders
95
. It lowers plasma levels of pro-atherogenic lipids, including 
chylomicrons, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), 
and triglycerides (TG) in normolipidemic as well as hypercholesterolemic subjects
96
. 
Several clinical trials have shown that nicotinic acid reduces cardiovascular 
disease and myocardial infarction incidence, providing a solid rationale for the use 
of nicotinic acid in the treatment of atherosclerosis
97,98
. The effects of niacin on lipid 
metabolism in human have been summarized in Figure 8. Recently, we showed 
that niacin also reduces the hepatic expression and plasma levels of the pro-
atherogenic cholesteryl ester transfer protein (CETP) in mouse models
99
. A 
summary of studies on effects of niacin on lipid metabolism and CETP regulation in 
















Despite its established cardiovascular benefits, the clinical use of niacin has 
been limited due to the cutaneous flushing, a well-recognized adverse skin effect 
from nicotinic acid therapy
101
. The niacin receptor GPR109A expressed in the skin 
is a critical mediator of nicotinic acid-induced flushing
102
. Nicotinic acid stimulates 
GPR109A in epidermal Langerhans cells and keratinocytes, causing the cells to 
produce vasodilatory prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2), which 
leads to cutaneous vasodilation
103,104,105,106
. For the past decade, the pharmacology 
of GPR109A has been studied and its full or partial agonists, including acipimox, 
acifran, 3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4-carboxylic acid, 
and pyrazine-2-carboxylic acid, have been developed in an attempt to achieve the 






5. THESIS OUTLINE 
 
Atherosclerosis is a chronic disease causing many cardiovascular complications, 
among which atherosclerotic coronary heart disease is the leading cause of 
morbidity and mortality worldwide. Atherosclerosis is a progressive inflammatory 
disease which has an onset by vascular obstruction from the deposits of plaque, 
subsequently developing into athero-thrombosis and abnormal blood flow. The 
evidence to support a cholesterol-atherosclerosis link has been revealed in the 
past three decades. There is a growing consensus that therapeutic lowering of 
plasma cholesterol level will reduce the risk of cardiovascular incidence. In 
Chapter 1, established mechanisms underlying lipid metabolism and 
atherosclerotic pathology are reviewed, including the important players involved in 
plasma / hepatic lipoprotein metabolism pathways and atherosclerotic plaque 
progression / regression process. 
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The first part of the thesis focuses on the hepatic lipid metabolism and the 
pharmaceutical interventions in the liver. In Chapter 2, we have composed the 
hepatic cell type-specific expression profile of NRs to provide the most complete 
quantitative assessment of NRs distribution in liver reported to date. We have 
identified several liver-enriched orphan NRs as potential novel targets for 
pharmaceutical interventions in liver. In Chapter 3, we have determined the 
hepatic expression profile of NAFLD-related gene PNPLA3 and its metabolic 
effects. PNPLA3 is highly responsive to metabolic changes in hepatocytes within 
the liver and its relative change in expression level suggests an essential function 
in lipogenesis. In Chapter 4 the mechanism underlying the hepatic and plasma 
CETP-lowering effect of niacin in mice is investigated. The clinical use of niacin has 
been limited due to the cutaneous flushing effect, which is mediated by the nicotinic 
acid receptor GPR109A. Therefore, in Chapter 5, we assessed the properties of 
two partial agonists for GPR109A compared to niacin. We showed that these two 
partial agonists are promising drug candidates to achieve the beneficial lipid-
lowering effects while successfully avoiding the unwanted flushing side effect. 
The second part of the thesis focuses on the concept of atherosclerotic lesion 
regression, shedding insights in the roles of LXR activation and application of 
mouse models in regression studies. In both Chapter 6 and Chapter 7 it is 
examined whether rapidly improved plasma lipoprotein profiles combined with LXR 
activation can lead to atherosclerotic lesion regression. In Chapter 6 LDLr
–/–
 mice 
are used and it is shown that intact LDL receptor function is crucial to overcome 
LXR-induced hyperlipidemia. In Chapter 7 we used ApoE
–/– 
mice reconstituted with 
bone marrow from C57BL/6 mice as a novel mouse model with chow diet feeding, 
providing an alternative model to investigate atherosclerotic plaque regression 
without robust surgical measures. Both of these two chapters demonstrate that 
rapidly optimized plasma lipoprotein profiles combined with LXR agonist induce 
favorable gene expression profiles leading to regression of pre-existing 
atherosclerotic plaques. 
In Chapter 8, the results obtained from all the experiments mentioned above 



































T0901317 C57BL/6 Chow 7 days ↑ ↑ ↑ ↑   110 
T0901317 LDLr–/– AD 8 weeks → ↓ → 
(transient 
increase) 
↑ Inhibited progression  111 
T0901317 C57BL/6 Chow 3 days ↑  → ↑   112 
T0901317 C57BL/6 Chow 6 days ↑ ↑ ↑ ↑   113 
T0901317 LDLR–/– WTD Baseline: 8 weeks WTD 
Regression study:  
6weeks WTD±T0901317 
↓ ↓ ↑ → Inhibited progression. 
 
Macrophage content ↓ 
Collagen content ↑ 
Regression 114 
T0901317 LDLr–/– WTD 12 weeks ↑ ↑ ↑ ↓ Inhibited progression 
 
Macrophage content ↓ 







T0901317 ApoE–/– AD 
 
Baseline: AD 8 weeks 
Regression study:  
6weeks AD±T0901317 
↑ → ↑ ↑ Regression  
 
Macrophage content ↓ 
Regression  116,117 
 
T0901317 ApoE*3Leiden   Baseline: WTD 18 weeks 
Regression study:  
8weeks Chow±T0901317 
→ ↑ ↑ → Regression  49 
T0901317 C57BL/6 Chow 4 days Hepatic TC 
→ 
 Hepatic TG ↑    118 
T0901317 LXRα–/–;LDLr–/– WTD 12 weeks →  →  Inhibited progression → 
 
119 
T0901317 LXRβ–/–;LDLr–/– WTD 12 weeks →  ↑  Inhibited progression Inhibited 
progression 
119 
T0901317 LDLr–/– WTD 12 weeks →  ↑  Inhibited progression Inhibited 
progression 
119 
T0901317 C57BL/6 Chow 4 weeks ↑ ↓ ↓ ↑   120 
T0901317 LDLr–/– WTD 4 weeks ↑ ↑ ↑ →   120 
T0901317 ApoE–/– AD 6 weeks ↑  ↑ ↑ Inhibited progression Inhibited 
progression 
121 
GW3965 LDLr–/– AD 12 weeks ↓  → → Inhibited progression Inhibited 
progression 
69 
GW3965 ApoE–/– Chow 12 weeks → ↓ ↑ → Inhibited progression  69 
                                                                                                    General introduction 
 
 21 
GW3965 C57BL/6 Chow 3 days →  → ↑   112 
GW3965 C57BL/6 Chow 6 days ↑ ↑ ↑ ↑   113 
GW3965 C57BL/6 Chow 12 days ↑ ↑  ↑   122 
GW3965 ApoB/CETP Tg Chow 12 days  ↑ ↑  ↑   122 
GW3965 LXR–/–;ApoE–/– Chow 12 days ↑ →  →   122 
GW3965 LXRα–/–;ApoE–/– WTD 11 weeks ↓ → → ↑ Inhibited progression Inhibited 
progression 
123 
GW3965 ApoE–/– WTD 11 weeks ↓  ↑ ↑ Inhibited progression Inhibited 
progression 
123 




  Inhibited 
progression 
124 
GW3965 C57BL/6 Chow 10 days ↑   ↑   125 
GW3965 LDLr–/– Chow 10 days ↑   ↑   70 
GW3965 APOE*3Leiden AD 20 weeks → 
 
 ↑  inhibited progression 
 
Collagen content ↓ 
 126 
ATI-111 LDLr–/– AD 8 weeks ↓ ↓ ↓ → inhibited progression inhibited 
progression 
70 
AZ-876 APOE*3Leiden AD 20 weeks Low dose: 
→ 
 
High dose: ↓ 
 Low dose: → 
 
High dose: ↑ 
 Inhibited progression 
upon low/high dose 
 
Lesion composition → 
 126 










Macrophage content ↓  




DMHCA ApoE–/– WTD 11 weeks ↓ ↓ ↓ → Inhibited progression Inhibited 
progression 
118 
DMHCA C57BL/6 Chow 15 days ↓  →    118 
DMHCA C57BL/6 WTD 15 days →  →    118 




↑: increased; ↓: decreased; →: unchanged. 











































C57BL/6 AD 4 →  → ↓     128 
C57BL/6 WTD 12    ↓ ↓    129 
C57BL/6 Chow 30 min after 
i.p. injection 
    ↓    93 
C57BL/6 Chow 3 ↓ ↓ ↓   cAMP ↓ 
ABCA1 ↓ 
  130 
C57BL/6;Gpr109a–/– Chow 3 → → →   cAMP → 
ABCA1 → 
  130 
C57BL/6 Chow 2 ↓ → → ↓     131 
Human CETP Tg Chow 2 → ↓ ↑ ↓     131 
Human apo B100 Tg Chow 2 ↓ ↓ ↓ →     131 
Human CETP/apoB100 Tg Chow 2 ↓ ↓ ↑ ↓     131 
E3L mice WTD 3 ↓ ↓ → ↓     99 
E3L.CETP
 
mice WTD 3 ↓ ↓ ↑ ↓  TG, TC, FC, CE ↓ 
Plasma CETP ↓ 
Hepatic CETP ↓ 
  99 
LDLr–/–;Gpr109a+/+ HFD 10 → → →  At 2 weeks: ↓ 
 At 10 weeks: → 
→  ↓ ↓ 132 
LDLr–/–;Gpr109a–/– HFD 10 → → →  At 2 weeks: ↓ 
 At 10 weeks: → 
→  → → 132 
ApoE–/– AD 14 →  → →   →  128 
 
↑: increased; ↓: decreased; →: unchanged. 
WTD: Western-type diet; AD: Atherogenic diet; HFD: High-fat Diet; Tg: transgenic 
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Background & Aims: Liver utilizes nuclear receptors (NRs) for hepatic functions, 
and NRs have been increasingly appreciated by hepatic researchers. Liver 
consists of parenchymal and non-parenchymal cells which synchronize crucial 
roles in liver metabolic homeostasis. To gain insight into the pharmacological 
potential of the remaining liver-enriched orphan NRs, we have composed the 
hepatic cell type-specific expression profile of NRs.  
Methods and Results: C57BL/6 mice liver parenchymal, endothelial, and Kupffer 
cells were isolated using collagenase perfusion and counter-flow centrifugal 
elutriation. The hepatic expression pattern of 48 NRs was generated by real-time 
quantitative PCR. FXRalpha, COUP-TF3, HNF4alpha, LXRalpha, and CAR were 
the most abundantly expressed NRs in parenchymal cells. In contrast, NGFIB, 
COUP-TF2, LXRs, FXRalpha, and COUP-TF3 were the most highly expressed 
NRs in endothelial and Kupffer cells. Interestingly, members of orphan receptor 
COUP-TF family showed distinct expression patterns. COUP-TF3 was highly and 
exclusively expressed in parenchymal cells, with an expression level higher than 
LXRalpha, while COUP-TF2 was moderately and exclusively expressed in 
endothelial and Kupffer cells. Another orphan receptor TR4 is ubiquitously 
expressed in liver at a comparable level as PPARgamma, suggesting that TR4 
may function as a lipid sensor as PPARgamma in liver and macrophages.  
Conclusions: Our study provides the most complete quantitative assessment of 
NRs distribution in liver reported to date. It is suggested that orphan NRs such as 
COUP-TF2, COUP-TF3, and TR4 may be of significant importance as novel 
targets for pharmaceutical interventions in liver.  
Keywords: Nuclear receptor, liver, parenchymal cell, endothelial cell, Kupffer cell 
 
 




The nuclear receptor (NR) superfamily describes a related but diverse array of 
ligand-activated transcription factors. NR binds DNA and translates physiological 
signals into gene regulation involved in biological processes including metabolism. 
Liver is considered as the major organ with significant therapeutic importance for 
the maintenance of metabolic homeostasis. Liver utilizes many NRs for hepatic 
functions, and NRs have been increasingly appreciated by researchers in the 
hepatic field [1]. Many of the liver-enriched NRs with identified ligands have been 
demonstrated to be important sensors and regulators. Toxin-activated NRs, such 
as CAR and PXR, are key sensors to regulate xenobiotic clearance in the liver [2]. 
Lipid-activated NRs, such as PPAR and LXR, are attractive targets for therapeutic 
agents to regulate glucose metabolism, lipid metabolism, and inflammation [3]. 
However, the function of orphan NRs whose endogenous and synthetic ligand(s) is 
unknown has not been fully exploited. It is thus of interest to quantitatively assess 
the expression and distribution of NRs in liver to discover the pharmacological 
potential of the remaining liver-enriched orphan NRs. 
The liver consists of different types of cells, including parenchymal cells, namely 
hepatocytes, and a variety of non-parenchymal cells. Non-parenchymal cells are 
comprised of mainly liver sinusoidal endothelial cells and Kupffer cells. Liver 
endothelial cells form a continuous but fenestrated lining of the hepatic sinusoids, 
while Kupffer cells are found in the sinusoidal lumen on top of or between 
endothelial cells [4]. Liver endothelial cells free the bloodstream from a variety of 
macromolecular waste products during inflammation [5]. Kupffer cells are a 
population of hepatic resident macrophages. They constitute 80-90% of the tissue 
macrophages present in the body [6]. Although non-parenchymal cells count for 
only 6.5% of the liver volume, they contain 55% of the lipid droplets in the liver and 
43% of the lysosomes, and specific activities of enzymes are generally higher in 
non-parenchymal cells than in parenchymal cells [7,8]. Parenchymal and non-
parenchymal cells synchronize crucial roles in liver metabolic homeostasis as well 
as inflammation. The majority of studies upon NRs in liver has focused on the array 
of target genes and metabolic pathways within parenchymal cells [9,10]. However, 
non-parenchymal cells are also intimately involved in the pathogenesis of various 
liver metabolic diseases including steatohepatitis, non-alcoholic fatty liver, and liver 
fibrosis [11]. Previous studies have shown that diet-induced hypercholesterolemia 
results in marked changes in the hepatic distribution of LDL and significant 
accumulation of cholesteryl ester/lipid droplets in liver endothelial and Kupffer cells, 
suggesting a prominent role of liver non-parenchymal cells in removing modified 
LDL from blood [12-14]. Other studies showed that depletion of liver Kupffer cells 
and targeted inactivation of scavenger receptor A and CD36 expressed in Kupffer 
cells reduced hepatic inflammation and tissue destruction associated with diet-
induced hepatic steatosis, indicating the role for liver macrophages in hepatic lipid 
metabolism and insulin sensitivity [15,16]. It has been shown that cross-talk 
between Kupffer cells and hepatocytes regulates glycogenolysis [17] and hepatic 
lipid storage [18]. It is thus of interest to further investigate the potential cross-talk 
between NRs in non-parenchymal and parenchymal cells involved in hepatic 
metabolism regulation.  
NRs may have different distribution patterns in liver parenchymal and non-
parenchymal cells. It has been shown that RXRalpha and RXRbeta expression 
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levels are 5- to 10-fold higher in Kupffer cells than in other non-parenchymal cells 
while all the subtypes of RAR family have similar expression level in both cell types 
[19]. Hoekstra et al have also demonstrated that for studies of certain NRs and 
their regulation in liver, their cellular localization should be taken into account, 
allowing proper interpretation of metabolic changes which are directly related to 
their intra-cellular expression level [20]. Therefore, a systematic assessment of NR 
distribution in liver is necessary in order to determine their distinctive contributions 
in parenchymal, endothelial, and Kupffer cells.  
To our knowledge, there has been no study illustrating the full expression 
pattern of 48 NRs in different liver cell types. In the current study, mouse liver 
parenchymal and non-parenchymal cells were isolated using counter-flow 
centrifugal elutriation, and gene expression profiling of NRs in parenchymal, 
endothelial, and Kupffer cells was performed to compose the hepatic expression 
pattern. NRs with abundant expression in non-parenchymal cells were identified as 
novel targets for pharmaceutical interventions in the liver. 
 
 
MATERIALS AND METHODS 
 
Animals  
Female C57BL/6 mice over 8 weeks old were fed on regular chow diet containing 
4.3% (w/w) fat without supplemented cholesterol (RM3, Special Diet Services, 
Witham, UK) for 8 weeks. Animal care and procedures were performed in 
accordance with the national guidelines for animal experimentation. All protocols 
were approved by the Ethics Committee for Animal Experiments of Leiden 
University. 
 
Parenchymal and non-parenchymal cell isolation  
Liver cells were isolated from mice at the same time of the day (10-11 AM). Mice 
were anesthetized, liver tissue was dissociated, and parenchymal cells were 
isolated after collagenase perfusion, while non-parenchymal cells were collected as 
described previously [21]. 
 
Endothelial and kupffer cell separation  
The endothelial cells and Kupffer cells were further separated by counter-flow 
centrifugal elutriation which consists of a J2-MC centrifuge (Beckman, California, 
USA) connected with a peristaltic pump (LKB, Bromma, Sweden). The elutriation 
was performed at 4°C at a speed of 3250 RPM. Endothelial and Kupffer cells were 
separated at flow rate of 25 mL/min and 70 mL/min respectively.  
 
RNA isolation and gene expression analysis  
Total RNA was isolated using acid guanidinium thiocyanate (GTC)-phenol-
chloroform extraction. Quantitative real-time PCR was carried out using ABI Prism 
7700 Sequence Detection system (Applied Biosystems, CA, USA) according to the 
manufacturer’s instructions. Beta-actin was used as an internal housekeeping gene. 
The primer sequences for all NRs assessed in the current study were obtained 
from literature [22] and available on the NURSA website at www.nursa.org. The 
relative expression of each NR was calculated as ∆∆Ct=(CtBeta-actin – CtNR). The 
numerical fold changes were calculated and the amount of target mRNA relative to 
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housekeeping genes was expressed as 2
−(∆∆Ct)
. Relative expression mean and 
standard error of the mean (SEM) were calculated using ∆∆Ct formula. 
 
Statistical analysis  
Statistical analyses were performed using ANOVA for independent samples after 
confirmation of gaussion distribution using the test of Golmogorov and Smirnov 
(Instat GraphPad software, San Diego, USA). Statistical significance was defined 





Expression of NRs in liver 
Real-time quantitative PCR was performed to analyze the relative mRNA 
expression of 48 NRs in mouse liver. The expression profile revealed that 36 (75%) 
of the 48 NRs were expressed in liver, while the other 12 NRs were undetectable 
(Ct>34), including DAX, ERbeta, ERRbeta, HNF4gamma, NOR1, NURR1, PNR, 
PR, RORbeta, SF-1, TLX, and VDR. FXRalpha was identified as the most 
abundantly expressed NR in liver. The 10 most highly expressed NRs in liver were 
ranked in the following order: FXRalpha > COUP-TF3 > HNF4alpha > LXRalpha > 
CAR > LXRbeta > RXRalpha > SHP > PXR > NGFIB (Fig. 1A). There were 15 NRs 
expressed at a moderate level, including PPARalpha > RORgamma > COUP-TF2 
> REV-ERBalpha > LRH-1 > RXRbeta > RXRgamma > AR > ERRalpha > 
RORalpha > REV-ERBbeta > GR > TR4> ERalpha > PPARgamma (Fig. 1B). 
Interestingly, the second most highly expressed NR in the liver was the orphan 
receptor COUP-TF3, with mRNA level slightly higher than HNF4alpha and 
LXRalpha. Another member from this orphan receptor family, COUP-TF2, was 
moderately expressed in liver, with expression level similar to LRH-1 but 3.5-fold 
higher than PPARgamma. Expression of COUP-TF1 in liver was very low, 
approximately 40-fold lower than that of COUP-TF2. 
 
Expression of NRs in liver parenchymal, endothelial, and Kupffer cells  
To generate cell type-specific expression patterns of NRs in liver, parenchymal, 
endothelial, and Kupffer cells were isolated using centrifugal elutriation. The cell 
separation was confirmed by real-time quantitative PCR characterization of specific 
gene markers. Expression of parenchymal cell marker CYP7A1 was detected only 
in parenchymal cell fraction (Fig. 2A), indicating the success of parenchymal cell 
separation and no contamination of parenchymal cells in non-parenchymal cell 
fractions. Similarly, expression of endothelial cell marker PECAM-1 (Fig. 2B) and 
macrophage marker CD68 (Fig. 2C) were only detected in non-parenchymal cell 
fractions and significantly higher in endothelial (p<0.001) or Kupffer (p<0.01) cell 


























































































































































Fig. 1. Expression of NRs in liver. Relative mRNA expression levels of 10 most highly expressed NRs 
(A) and 15 moderately expressed NRs (B) in total liver, as determined by real time quantitative PCR in 
C57BL/6 mice and ranked in decreasing order according to gene expression levels. Gene expression 


















































































Fig. 2. Expression of cell markers in isolated cell fractions. Relative mRNA expression levels of 
liver parenchymal cell marker CYP7A1 (A), endothelial cell marker PECAM-1 (B), and Kupffer cell 
marker CD68 (C) as determined by quantitative PCR in isolated liver parenchymal cell (PC), endothelial 
cell (EC), and Kupffer cell (KC) fractions. Values are means ± SEM (N=6). **P<0.01, ***P<0.001. 






























































































































































Fig. 3. Expression of NRs in parenchymal and non-parenchymal cells. Expression profile of 10 
most highly expressed NRs (A) and 15 moderately expressed NRs (B) in liver parenchymal cells (PC), 
endothelial cells (EC), and Kupffer cells (KC), as determined by quantitative PCR and ranked in 
decreasing order according to gene expression levels in PC. 
 
The hepatic expression pattern of 48 NRs in parenchymal, endothelial, and 
Kupffer cells was generated by real-time quantitative PCR. Among the 36 NRs 
expressed in liver, 33 (92%) of them were expressed in parenchymal cells. The 
same 10 NRs were most highly expressed in parenchymal cells as those in whole 
liver (Fig. 3A). The 15 NRs moderately expressed in parenchymal cells were 
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shown in Fig. 3B. In non-parenchymal cells, 29 (78%) of the liver-expressed NRs 
were detected. NGFIB, COUP-TF2, LXRalpha, LXRbeta, FXRalpha, and COUP-
TF3 were identified as the most abundantly expressed NRs in both endothelial and 
Kupffer cells.  
 
Comparison of NR expression in liver parenchymal and non-parenchymal 
cells 
To further characterize the potential relationship between NRs, the liver-expressed 
NRs were grouped into three clusters according to the substantial differences in 
their distribution patterns over parenchymal and non-parenchymal cells. 
Twenty NRs showed dominant expression in parenchymal cells. HNF4alpha, 
CAR, SHP, PXR, PPARalpha, RORgamma, ERalpha, and TRbeta were 
exclusively expressed in parenchymal cells. FXRalpha, COUP-TF3, and RXRalpha 
showed significantly dominant expression in parenchymal cells, which was 20- to 
10-fold higher than in non-parenchymal cells (p<0.001). LRH-1, REV-ERBalpha, 
RXRbeta, RXRgamma, AR, ERRalpha, RORalpha, GR, and TR2 showed an 
averagely 5-fold higher expression in parenchymal than in endothelial and Kupffer 
cells (p<0.01).  
Expression of four NRs, including COUP-TF1, COUP-TF2, RARalpha, and 
RARbeta, was low in parenchymal cells but significantly higher in non-parenchymal 
cells, namely in both endothelial and Kupffer cells. In contrast to the exclusive 
expression of COUP-TF3 in parenchymal cells, COUP-TF1 was exclusively 
expressed in endothelial and Kupffer cells. COUP-TF2 showed approximately 5-
fold higher expression in non-parenchymal cells than in parenchymal cells (Fig. 4A). 
In contrast to NRs discussed above which were mainly characterized by 
significantly high expression in either parenchymal or non-parenchymal cells, five 
NRs were observed as ubiquitously expressed in all three cell types, including 
LXRbeta and NGFIB which were highly expressed in the liver, and REV-ERBbeta, 
PPARgamma, and TR4 which were moderately expressed. For these five NRs, 
there was no significant difference in expression level in parenchymal, endothelial, 
and Kupffer cells. Total expression of LXRbeta in liver was 2-fold lower than 
LXRalpha. However, expression of LXRbeta was comparable to LXRalpha in 
Kupffer cells and 3-fold higher than LXRalpha in endothelial cells (Fig. 4B). 
Interestingly, two orphan receptors which were not highly expressed in whole 
liver showed considerable expression in non-parenchymal cells. The expression of 
COUP-TF2 in endothelial and Kupffer cells was similar to that of NGFIB (Fig. 4C), 
despite a 3-fold lower total expression in liver than NGFIB. In addition, TR4 was 2-
fold higher expressed in endothelial and Kupffer cells than PPARgamma (Fig. 4D), 
although the total expression of TR4 in liver was slightly lower than PPARgamma.  

































































































































Fig. 4. Relative mRNA expression levels of COUP-TFs (A), LXRs (B), NGFIB versus COUP-TF2 (C), 
and PPARgamma versus TR4 (D) in liver parenchymal cells (PC), endothelial cells (EC), and Kupffer 





Real-time quantitative PCR is a standardized method in the NR field to 
characterize the expression pattern of individual receptors in tissue or cells. It 
provides a simple but powerful way to obtain comprehensive understanding of the 
distribution and relational biological functions of NRs [23]. Real-time quantitative 
PCR has been applied in numerous studies to profile the expression pattern of NRs 
in tissues representing diverse anatomical systems under various pharmacological 
conditions and genotypes [24,25]. However, there has been no study establishing 
NR expression pattern in different liver cell types. Liver is a highly differentiated 
organ which composes of parenchymal cells and non-parenchymal cells. They play 
independent but also co-operative roles in health and disease. Thus, separation of 
liver cells are essential to discover the pharmacological potential of cell type-
specific NRs. In the current study, mouse liver parenchymal, endothelial, and 
Kupffer cells were isolated using counter-flow centrifugal elutriation. This 
separation method has been confirmed as an ideal gentle process to isolate 
parenchymal and non-parenchymal cells with high purity and maintained cell 
function [26]. In the following sections, discussion focuses on NRs expressed at 
high to moderate levels in the liver, assuming that high mRNA levels are likely to 
be more relevant for NR function. Majority of the abundantly expressed NRs in liver 
are expressed dominantly in parenchymal cells, with exception of LXRbeta, NGFIB, 
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COUP-TF2, and TR4. 
LXRalpha has emerged as an important drug target for metabolic regulation of 
cholesterol efflux based upon its high expression in macrophages. The present 
study showed that LXRalpha and LXRbeta are both abundant in total liver and liver 
macrophages, which is in accordance with published data implying similar efficacy 
of the two LXR subtypes in stimulating macrophage cholesterol efflux [27]. In 
addition, our observation that LXRbeta is 2-fold lower expressed in parenchymal 
cells compared to LXRalpha supports the hypothesis that LXRalpha is the primary 
isotype responsible for the undesirable effects of LXR pan-agonists via activating 
SREBP-1c in parenchymal cells [28], and LXRbeta-specific agonists may 
preferentially activate macrophage cholesterol efflux without or to a lesser extent 
causing adverse hypertriglyceridemia. 
NGFIB, also known as Nur77, is highly and ubiquitously expressed in 
parenchymal and non-parenchymal cells. It has been revealed that NGFIB is highly 
expressed in vascular endothelial cells and plays a role in angiogenesis and 
vascular inflammation by negatively regulating endothelial cell activation [29]. 
Meanwhile, NGFIB regulates lipid metabolism and the inflammatory response in 
macrophages [30]. The ubiquitously high expression of NGFIB over different liver 
cell types supports further investigation of NGFIB in both hepatic lipid metabolic 
process and vascular modulation in multiple tissues. 
Interestingly, members of the orphan receptor family COUP-TFs showed 
distinguished distributions in liver. COUP-TF3 was abundantly and exclusively 
expressed in liver parenchymal cells, while the other two members, COUP-TF1 
and COUP-TF2, were expressed exclusively in non-parenchymal cells. Despite the 
moderate to high expression level in the liver, the physiological functions of COUP-
TFs have not been fully exploited, and the ligand for COUP-TFs has not been 
identified. Our data suggest the physiologic importance of COUP-TF3 in 
hepatocytes, and that of COUP-TF2 in endothelial cells and macrophages. 
Previous studies have shown that the activity of COUP-TFs is associated with the 
transcriptional regulations of a number of genes expressed mainly in the liver [31]. 
COUP-TF2 and COUP-TF3 have been generally considered to be repressors or 
regulators for transcription of NRs such as RARs, TRs, PPARs, and HNF4alpha 
[32]. Distribution pattern from the present study further suggests that COUP-TF3, 
given its high expression in liver parenchymal cells, may have a potential role in 
hepatic lipid and xenobiotic metabolism regulation via cross-talking with other liver-
enriched NRs. Our study identifies COUP-TF2 as highly expressed in endothelial 
cells, which is in accordance with published data upon the role of COUP-TF2 in 
angiogenesis and generation of haematopoietic cell clusters [33]. In addition, 
COUP-TF2 was shown to have a potential role in regulation of cholesterol 
homeostasis [34]. The observation from current study that expression of COUP-
TF2 is as high as NGFIB in Kupffer cells raises interest to further investigate 
whether COUP-TF2 is involved, similarly as NGFIB, in lipid metabolism in 
macrophages.  
TR4 is also an orphan receptor. Similarly as COUP-TFs, TR4 employs 
repression and gene-silencing events to control basal activities or hormonal 
responsiveness of numerous target genes [35]. TR4 is ubiquitously expressed in 
the liver at a comparable level as PPARgamma, with a 2-fold higher expression in 
Kupffer cells compared to PPARgamma. This suggests that TR4 may function as a 
lipid sensor as PPARgamma. Recently published data have revealed an important 
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signaling pathway where TR4 modulates CD36 expression in macrophages and 
controls CD36-mediated foam cell formation [36]. CD36 is a target gene of 
PPARgamma. Given the comparable expression patterns of TR4 and 
PPARgamma, it is of interest to investigate the potential regulatory cross-talk 
between these two NRs in liver and macrophages. 
In conclusion, we composed the cell type-specific expression pattern of 48 NRs 
in mouse liver parenchymal, endothelial, and Kupffer cells. Our study provides the 
most complete quantitative assessment of NR distribution in the liver reported to 
date. The results may give a predictive indication for further investigation. It is 
suggested that certain orphan NRs such as COUP-TF2, COUP-TF3, and TR4 
which are highly expressed in a specific liver cell type may be of significant 
importance in hepatic function and metabolism. Further investigation into the 
biology of these receptors will be necessary to understand the functional 
implication of their hepatic expression patterns. Ultimately, cell-specific targeting 
systems have been developed for liver [37,38], and the identification of hepatic cell-
specific NRs may lead to the development of cell-specific therapeutic molecules to 
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Background & Aims: Recent studies have suggested that variations in PNPLA3 
are associated with non-alcoholic fatty liver disease (NAFLD). To gain insight in the 
potential function of PNPLA3 in liver, we have determined the effect of metabolic 
shifts on the hepatic expression profile of PNPLA3 in mice. 
Methods and Results: PNPLA3 expression in wild-type C57BL/6 and NAFLD-
susceptible LDL receptor knockout (LDLR-/-) mice was determined using 
microarray and real-time PCR analysis. PNPLA3 expression in livers is 50- to 100-
fold lower as compared to (cardiac) muscle and adipose tissue in regular chow 
diet-fed mice. Feeding a Western-type diet stimulated the hepatic relative PNPLA3 
expression level 23-fold (P<0.001) both in C57BL/6 mice and LDLR-/- mice, 
suggesting that PNPLA3 does become an important player in hepatic lipid 
metabolism under conditions of lipid excess. Subjecting mice to fasting fully 
reversed the effect of the Western-type diet on hepatic PNPLA3 expression. Under 
these conditions, also the expression level of PNPLA3 in adipose tissue is 90% 
decreased (P<0.001). Cellular distribution analysis revealed that PNPLA3 is 
expressed in hepatocytes, but not liver endothelial and Kupffer cells. Microarray-
based gene profiling showed that the expression level of PNPLA3 in hepatocytes is 
correlated to that of genes associated with the lipogenic pathway such as ME1, 
SPOT14, and SCD1. 
Conclusions: It appears that the NAFLD-related gene PNPLA3 is highly 
responsive to metabolic changes in hepatocytes within the liver and its relative 
change in expression level suggests an essential function in lipogenesis. 








Atherosclerosis is the primary cause of cardiovascular diseases such as ischemic 
(coronary) heart disease, diabetes, and myocardial infarction, which form the major 
cause of mortality and morbidity in the Western world. Although atherosclerosis is a 
progressive disease of the arteries, recent studies have indicated that the 
occurrence of non-alcoholic fatty liver disease (NAFLD) is also a strong risk factor 
for atherosclerotic lesion development in humans [1,2]. 
NAFLD is characterized by the accumulation of lipid in liver cells (hepatic 
steatosis) and is the most common cause of liver disease with a prevalence of 15-
25% in the general population [3-5]. The intra-hepatic lipid balance is maintained 
by different processes including receptor-mediated uptake of lipids from the blood, 
hepatic degradation of lipids, de novo synthesis of lipids, secretion of lipids into the 
bile and the blood compartment, and hepatic storage of lipids. Perturbations in the 
activity of essential mediators functioning in these processes can induce 
disturbances in the intra-hepatic lipid homeostasis. More specifically, when the 
input of lipid exceeds the output of lipid from the liver this will induce excessive 
storage of lipid and thus lead to the development of hepatic steatosis. NAFLD may 
slowly progress into non-alcoholic steatohepatitis (NASH), which is characterized 
by excessive liver inflammation. NASH is an established risk factor for the 
development of end-stage liver disease (i.e. cirrhosis), a condition that can 
generally only be treated by performing a liver transplantation. 
Interestingly, recent genome-wide association studies have suggested that 
variations in the patatin-like phospholipase domain containing 3 (PNPLA3) gene 
contribute to differences in hepatic lipid content and the susceptibility to NAFLD [6-
8]. PNPLA3, formerly also known as adiponutrin and iPLAε, is predominantly 
expressed in adipose tissue and is highly responsive to changes in energy balance 
[9]. It belongs to the patatin-like phospholipase family of proteins that also contains 
the key protein involved in the hydrolysis of triglycerides to diglycerides in 
adipocytes, adipose triglyceride lipase (ATGL; PNPLA2). Although PNPLA3 
possesses lipase and acylglycerol transacylase activities in adipocytes in vitro [10], 
the function of PNPLA3 in the liver in vivo remains to be determined. To gain more 
insight in the potential function of PNPLA3 in liver, in the current study we have 
determined the effect of metabolic shifts on the hepatic expression profile of 
PNPLA3 in mice. 
 
 
MATERIALS AND METHODS 
 
Animals  
Wild-type C57BL/6 mice and homozygous LDL receptor knockout (LDLR-/-) mice 
were obtained from The Jackson Laboratory as mating pairs and bred at the 
Gorlaeus Laboratories, Leiden, The Netherlands. Mice were maintained on a  
regular chow diet containing 5.7% (wt/wt) fat and no cholesterol or were fed a 
semi-synthetic Western-type diet containing 15% (wt/wt) cacao butter and 0.25% 
(wt/wt) cholesterol (Diet W, Hope Farms, Woerden, The Netherlands).  Mice were 
fed ad libitum or fasted overnight (~16 hours) before whole body perfusion with 
PBS and subsequent sacrifice. Organs were isolated and immediately frozen in 
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liquid N2 and stored at -80°C until RNA extraction. Animal experiments were 
performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center for Drug 
Research in accordance with national laws. All experimental protocols were 
approved by the Ethics Committee for Animal Experiments of Leiden University. 
 
Hepatic cell separation  
Mice were anaesthetized and the vena cava inferior was cannulated. Subsequently, 
the vena porta was ligated and the liver was perfused for 10 min (14 ml/min) with 
oxygenated Hanks’ buffer pH 7.4, containing HEPES (1.6 g/l). The perfusion was 
continued for 10 min with Hanks’/HEPES buffer containing 0.05% (w/v) 
collagenase (type IV, Sigma) and 1 mM CaCl2. Hepatocytes were isolated after 
mincing the liver in Hanks’ buffer containing 0.3% BSA, filtering through nylon 
gauze and centrifugation for three times 10 min at 50 × g. The pellets consisted of 
pure (>99%) hepatocytes (PC) as judged by light microscopy. The supernatants 
were centrifuged for 10 min at 500 × g in order to harvest the non-parenchymal 
cells. By the modified method as described previously [11], liver endothelial cells 
(EC) and Kupffer cells (KC) were isolated at 4°C by density-gradient centrifugation 
and centrifugal elutriation (3250 rev/min at 26 ml/min for endothelial cells and 65 
ml/min for Kupffer cells). The purity of the cell preparations was checked by 
peroxidase staining, which showed that Kupffer and endothelial cells were >80% 
and >95% pure, respectively. 
 
Serum lipid analyses  
Serum concentrations of total cholesterol and triglycerides were determined using 
enzymatic colorimetric assays (Roche Diagnostics). The cholesterol and 
triglyceride distribution over the different lipoproteins in serum was analysed by 
fractionation of 30 µl serum of each mouse using a Superose 6 column (3.2×30 
mm, Smart-system, Pharmacia). Total cholesterol and triglyceride content of the 
effluent was determined using enzymatic colorimetric assays (Roche Diagnostics). 
 
Analysis of gene expression by real-time quantitative PCR 
Quantitative gene expression analysis on perfused organs was performed as 
described [12]. In short, total RNA was isolated according to Chomczynski and 
Sacchi [13] and reverse transcribed using RevertAid™ reverse transcriptase. Gene 
expression analysis was performed using real-time SYBR Green technology 
(Eurogentec). Beta-actin was used as the standard housekeeping gene. Relative 
gene expression numbers of were calculated by subtracting the threshold cycle 
number (Ct) of the gene of interest from the Ct of beta-actin and raising 2 to the 
power of this difference. 
 
Microarray analysis  
The Mouse Genome Survey Arrays used in the study contained 33.012 different 
probes representing 26.514 genes, which included transcripts from the public 
domain as well as from the Celera library. Total RNA from hepatocytes from LDLR-
/- mice fed a regular chow diet or Western-type diet for 2, 4, or 6 weeks ad libitum 
was isolated according to Chomczynski and Sacchi [13]. Double stranded cDNA 
was prepared from 2 µg of total RNA. An in vitro transcription (IVT) reaction was 
used to synthesize 50-100 µg of UTP-digoxigenin-labeled cRNA. Equal amounts of 
cRNA (10 µg) from 2 pooled RNA samples of 2 mice (total of 4 mice) per time point 
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was hybridized to Mouse Genome Survey Arrays for 16 hours at 55°C. 
Subsequently, an alkalic phosphatase-linked digoxigenin antibody was incubated 
with the array and the phosphatase activity was initiated to start the 
chemiluminescent signal. The chemiluminescent (cRNA) and fluorescent (spot 
backgound) signals of the cRNA and standard controls spots were scanned for 5 
and 25 seconds using an AB1700 Chemiluminescence Analyzer (Applied 
Biosystems). Using the software supplied with the AB1700 apparatus, the spot 
chemiluminescent signal was normalized over the fluorescent signal of the same 
spot (using the standard control signals) to obtain the normalized signal value that 
was used for further analysis. In the analysis, the median value of the normalized 
signal of two independent arrays for each time point was calculated as an 
indication for the relative gene expression number at that time point. Profile 
similarity search was performed using a Euclidean distance-based comparison. 
 
Statistical analysis 
The significance of differences in relative gene expression numbers between 
fasted or ad libitum fed mice and between mice on a chow or a Western-type diet 
was calculated using a two-tailed unpaired Student’s t-test on the differences in Ct 
(Ct β-actin – Ct PNPLA3). The difference in Ct values was tested for normality 
using Graphpad Instat 3 software (Graphpad Instat Software, San Diego, CA). The 
significance of differences in serum lipid levels between the different groups of 
mice was tested using analysis of variance and the Student-Newman-Keuls 
multicomparison test (Graphpad Instat Software, San Diego, CA). Probability 





The relative expression level of PNPLA3 in livers from wild-type C57BL/6 mice and 
low-density lipoprotein receptor knockout (LDLR-/-) mice, an established diet-
induced atherosclerosis and NASH mouse model [14,15], under ad libitum feeding 
conditions was determined to gain insight in the basal role for hepatic PNPLA3. 
The mRNA expression of PNPLA3 in livers of regular chow-fed C57BL/6 mice and 
LDLR-/- mice as measured with quantitative real-time PCR was extremely low, 
since the threshold cycle for the fluorescent signal in the real-time quantitative PCR 
was rather high (Ct=30-32). In parallel, Baulande et al. showed that PNPLA3 
mRNA was virtually undetectable in livers from SWISS mice under ad libitum 
feeding conditions [16]. As a result, the hepatic expression level of PNPLA3 was 
50- to 1000-fold lower as compared to the level of expression detected in (cardiac) 
muscle, brown and white adipose tissue isolated from LDLR-/- mice (Fig.1), 




























































Fig. 1. Relative mRNA levels of PNPLA3 in livers and other metabolic tissues from C57BL/6 wild-type 




The human association studies suggested that PNPLA3 expression in liver is 
positively related to obesity and liver fat content [7]. Previously, it has been shown 
that feeding a Western-type diet containing fat and cholesterol not only stimulates 
atherosclerotic lesion development, but also induces obesity and fatty liver 
development in LDLR-/- mice [17]. We therefore determined the effect of Western-
type diet feeding on the expression of PNPLA3 in livers of wild-type and LDLR-/- 
mice. Two weeks of feeding a Western-type diet containing 0.25% 9w/w) 
cholesterol and 15% (w/w) high fat, which for humans compares to an unhealthy 
high fat diet [18], induced an increase in plasma total cholesterol and triglyceride 
levels in C57BL/6 and LDLR-/- mice (Fig.2A). In LDLR-/- mice, the increase in 
plasma cholesterol could be primarily attributed to a rise in the level of the pro-
atherogenic lipoproteins very-low-density lipoprotein (VLDL) and LDL, while in 
C57BL/6 mice Western-type diet feeding led to an increase in the plasma level of 
both pro- (VLDL/LDL) and anti-atherogenic high-density lipoproteins (HDL)(Fig.2B). 
Importantly, an increase in dietary lipid levels was associated with a significant 23-
fold stimulation (P<0.001) of the relative expression level of PNPLA3 in livers of 
both C57BL/6 and LDLR-/- mice (Fig.3). The marked induction of its expression 
upon Western-type diet feeding suggests that PNPLA3 probably does play an 
important role in hepatic lipid metabolism under conditions of lipid excess. 
Furthermore, it thus seems that hepatic PNPLA3 levels in mice are positively 
related to plasma/liver fat content, similarly as observed in the human situation [7]. 
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Fig. 2. A) Plasma total cholesterol and triglyceride levels, and B) plasma lipoprotein cholesterol and 
triglyceride distribution in C57BL/6 wild-type mice and LDL receptor knockout (LDLR-/-) mice fed a chow 
diet (white bars / open circles) or an atherogenic Western-type diet (WTD; black bars / closed circles) 
for two weeks. Fractions 2-6 represent VLDL, fractions 7-13 represent LDL, and fractions 14-20 











































Fig. 3. Relative mRNA levels of PNPLA3 in livers from C57BL/6 wild-type mice and LDL receptor 
knockout (LDLR-/-) mice fed a chow diet (white bars) or an atherogenic Western-type diet (WTD; black 
bars) for two weeks. Values are expressed as fold compared to the chow diet and represent 
means+SEM of 5 mice. *** P<0.001 compared to chow diet values. 
 
In accordance with a possibly important role for PNPLA3 in the protection 
against tissue lipid excess, several studies have shown that adipose tissue 
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PNPLA3 levels become virtually undetectable upon food restriction (i.e. external 
lipid depletion) [16,19,20]. To investigate whether external lipid depletion does also 
induce changes in hepatic PNPLA3 levels, we determined the effect fasting on 
PNPLA3 mRNA levels in livers and white adipose tissue of chow-fed (basal 
conditions) and Western-type diet-fed (lipid excess). Hepatic PNPLA3 expression 
was decreased by fasting in chow-fed C57BL/6 mice, while it actually increased in 
chow-fed LDLR-/- mice (Fig.4A). Strikingly, the 23-fold increase in the PNPLA3 
expression in liver upon feeding the Western-type diet was completely abolished 
after a subsequent 16 hour fasting period, resulting in a relative hepatic expression 
level of PNPLA3 in fasted Western-type diet-fed mice identical to that of chow-fed 
animals (Fig.4A). As anticipated, fasting induced a ~90% decrease in white 
adipose tissue PNPLA3 mRNA expression of mice that were fed either the regular 
chow or the atherogenic Western-type diet (Fig.4B). Combined, these data show 
that fasting induces a similar response in PNPLA3 expression in fatty liver and 
white adipose tissue, suggesting that PNPLA3 may have a comparable function in 
































































































Fig. 4. A) Relative mRNA levels of PNPLA3 in livers from C57BL/6 wild-type mice and/or LDL receptor 
knockout mice (LDLR-/-) that were fed a chow diet (CHOW) or an atherogenic Western-type diet (WTD) 
for two weeks ad libitum (Fed) or that were subsequently subjected to 16h of fasting (Fasted). B) 
Relative mRNA levels of PNPLA3 in white adipose tissues (WAT) from LDLR-/- mice. Values represent 
means+SEM of 5 mice. *** P<0.001 compared to ad libitum fed values. 
 
The liver consists of several different cell types which each play a distinct role in 
hepatic metabolism. In earlier experiments we have observed that for studies on 
the function of genes it is important to take their intra-hepatic cellular localization 
into account [12,21]. Feeding mice a Western-type diet enriched in cholesterol 
induces hepatic inflammation [15], ultimately leading to an increased number of 
macrophages within the liver. To exclude that the rise in hepatic PNPLA3 
expression upon Western-type diet feeding could be attributed to an influx of 
monocytes in response the hepatic inflammation, we examined the relative 
PNPLA3 expression level in isolated hepatocytes, liver endothelial, and Kupffer 
cells (tissue macrophages). Importantly, expression of PNPLA3 was detected 
(although at low levels; Ct=31) in hepatocytes from C57BL/6 mice, while it was 
absent (Ct>35) in both liver endothelial and Kupffer cells (Fig.5). This suggests that 
effects measured in total liver PNPLA3 expression actually represent changes in 
the relative expression of PNPLA3 specifically in hepatocytes. 
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Fig. 5. Relative mRNA levels of PNPLA3 in hepatocytes (HEP), liver endothelial (EC), and Kupffer cells 
(KC). For comparison, the relative expression levels of the hepatocytes-specific gene cholesterol 
7alpha-hydroxylase (CYP7A1), and the respective non-parenchymal and macrophage markers platelet 
endothelial cell adhesion molecule-1 (PECAM-1) and CD68 are also indicated. Values represent 
means+SEM of 4-6 different cell isolations. n.d., not detectable. 
 
Previously, we have performed microarray-based gene expression profiling of 
hepatocytes isolated from livers of LDLR-/- mice to identify genes involved hepatic 
lipid metabolism specifically under conditions of high lipid pressure [22]. In our 
original analysis we used a quite stringent signal-to-noise ratio threshold to identify 
genes as being expressed. Because PNPLA3 did not reach the required signal-to-
noise threshold value in normal fed LDLR-/- mice, our primary analysis suggested 
that PNPLA3 is not expressed in isolated hepatocytes. Re-analysis of our original 
data-set without the signal-to-noise limitation showed that out of a total of 27.857 
transcripts detected PNPLA3 was the most highly upregulated one upon feeding 
mice the atherogenic Western-type diet. Verification by real-time quantitative PCR 
showed a very similar expression profile as observed in the microarray with a 
marked ~50-fold higher PNPLA3 expression in hepatocytes after two weeks of 
Western-type diet feeding, which remained elevated until the end of the feeding 
period (6 weeks)(Fig.6A). 
To gain insight in the possible role for PNPLA3 in hepatocytes, we performed 
profile similarity analysis on the microarray data in which we compared the time-
dependent expression profile of PNPLA3 to that of all transcripts detected (Fig.6B). 
In Table 1 the 10 genes whose time-dependent expression profile closely 
resembled that of PNPLA3 in hepatocytes are shown, including fatty acid binding 
protein 5 (FABP5), several unassigned FABP5-like proteins, malic enzyme 1 (ME1), 
stearoyl-CoA desaturase 1 (SCD1), and SPOT14. Interestingly, the expression of 
glucose-6-phosphate dehydrogenase 2 (G6PD2) and PNPLA3 followed the most 
similar pattern. As observed for PNPLA3, the expression of G6PD2 was extremely 
low under basal feeding conditions, while it was markedly induced by the Western-
type diet. As a result, the relative expression level of PNPLA3 and G6PD2 in 
hepatocytes of LDL receptor knockout mice after different times of Western-type 
diet feeding was significantly correlated (R=0.96; P=0.038; Fig.6C). No expression 
of G6PD2 was observed in livers of C57BL/6 wild-type mice on a chow or Western-
type diet (Ct>35), suggesting that in contrast to in the LDL receptor knockout mice 
the expression of G6PD2 in C57BL/6 does not reach a detectable level even under 
conditions of lipid excess. However, real-time PCR profiling of other genes that 
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were subject to coordinate regulation with PNPLA3 in hepatocytes of LDL receptor 
knockout mice showed that feeding the Western-type diet led to a significant 
stimulation of the relative expression level of FABP5 (3.1-fold; P=0.032), ME1 (2.6-
fold; P=0.046), SCD1 (5.4-fold; P=0.002), and SPOT14 (3.1-fold; P=0.046) in livers 
of C57BL/6 wild-type mice (Fig.7). It thus seems that the expression of PNPLA3 in 
liver of both LDL receptor knockout mice and C57BL/6 wild-type mice is 
coordinately regulated with that of key lipogenic genes. 
 
Table 1. Ten genes whose time-dependent expression profile was most comparable to that of PNPLA3 
in hepatocytes of LDL receptor knockout mice. 
 
Fold change on Western-type 
diet compared with chow diet 








Patatin-like phospholipase domain 
containing 3 (PNPLA3) 
47.7 38.0 72.1 
mCG50373 
Glucose-6-phosphate dehydrogenase 2 
(G6PD2) 
15.6 10.6 16.8 
mCG5289 Fatty acid binding protein (unassigned) 16.6 10.4 11.9 
mCG22653 Fatty acid binding protein (unassigned) 16.5 10.6 11.1 
mCG16174 PDZK1 interacting protein 1 (PDZK1IP1) 10.2 8.4 11.4 
mCG22278 Fatty acid binding protein (unassigned) 19.3 7.4 7.7 
mCG9729 Fatty acid binding protein (unassigned) 14.3 9.2 7.2 
mCG7050 
Thyroid hormone responsive SPOT14 
homolog (THRSP) 
16.5 8.1 6.9 
mCG11880 Malic enzyme 1 (ME1) 8.1 8.4 10.6 
mCG131749 
Stearoyl-Coenzyme A desaturase 1 
(SCD1) 
7.3 8.1 10.6 
mCG1638 
Fatty acid binding protein 5, epidermal 
(FABP5) 
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Fig. 6. A) Real-time quantitative PCR validation (closed circles) of the Western-type diet (WTD)-induced 
changes in the expression of PNPLA3 in hepatocytes from LDL receptor knockout mice, as observed 
with microarray analysis (open circles). B) Graphical representation of the results from the profile 
similarity analysis on the 27.857 transcripts present on the microarray. A higher similarity coefficient 
indicates a lower degree of profile comparison with the input gene PNPLA3. Marked dots represent 
PNPLA3 and glucose-6-phoshate dehydrogenase 2 (G6PD2), respectively. C) Correlation of the relative 
mRNA levels of PNPLA3 and G6PD2 in hepatocytes from LDL receptor knockout mice. Values are 
significantly correlated (P=0.038; R=0.96) and are relative to the expression on chow diet. 
 












































Fig. 7. Relative mRNA levels in livers of C57BL/6 wild-type mice that were fed a chow diet (CHOW) or 
an atherogenic Western-type diet (WTD) for two weeks ad libitum of genes showing a coordinate 
regulation with PNPLA3 in hepatocytes of LDL receptor knockout mice. Values represent means+SEM 






Non-alcoholic fatty liver disease (NAFLD), the presence of hepatic steatosis due to 
non-alcoholic causes, is a commonly observed phenomenon in Western societies. 
Although factors such as obesity, diabetes, and insulin resistance promote the 
accumulation of triglycerides in the liver, it has become clear that genetic variation 
is also a prominent risk factor for the development of NAFLD. Recent association 
studies have identified PNPLA3 as a possible important player in liver lipid 
metabolism as variations in the PNPLA3 gene are linked to an increased 
susceptibility for NAFLD [6-8]. However, no data are present on the exact role of 
PNPLA3 within the liver. In the current study, we have shown that PNPLA3 is 
expressed in the primary metabolic cell type in the liver, namely the hepatocytes, 
but not in liver endothelial cells or tissue macrophages (Kupffer cells). The 
relatively low hepatic expression of PNPLA3 upon chow diet feeding argues 
against a major role for this protein under basal conditions. As PNPLA3 among 
27.857 transcripts is the most highly induced gene in hepatocytes upon exposure 
to exogenous lipid (i.e. upon Western-type diet feeding) we anticipate, however, 
that it does play a major role in liver under conditions of high lipid exposure. 
A microarray profile similarity search indicated that the Western-type diet-
induced change in the expression profiles of PNPLA3 and glucose-6-phosphate 
dehydrogenase (G6PD) type 2 was highly similar in hepatocytes of LDL receptor 
knockout mice. G6PD is a cytosolic enzyme that takes part in the pentose 
phosphate pathway. It transforms glucose-6-phosphate into 6-phosphoglucono-δ-
lactone and NADP to NADPH that is subsequently used for the biosynthesis of fatty 
acids, making it a key enzyme involved in the synthesis of triglycerides from 
glucose (lipogenesis) [23,24]. As the PNPLA3 expression pattern follows that of 
G6PD2 it is suggested that PNPLA3 may also play an important role in hepatocyte 
lipogenesis. Importantly, other genes that had a comparable time-dependent 
expression profile as observed for PNPLA3 in hepatocytes in LDL receptor 
knockout mice and that are also significantly upregulated in livers of wild-type mice 
upon feeding a Western-type diet, i.e. SPOT14 and malic enzyme, are also 
established mediators of lipogenesis [24]. In agreement with a related function for 
PNPLA3 and G6PD2 in lipid metabolism, they respond similarly to changes in 
metabolic conditions. Moldes et al. have shown that PNPLA3 expression is 
significantly stimulated in adipose tissue upon infusion of insulin [25]. In parallel, 
Kastrouni et al. detected an enhanced activity of G6PD in adipose tissue upon 
administration of insulin, which is related to an increased transcription rate of the 
G6PD gene [26]. G6PD expression in liver and brain is significantly decreased 
upon fasting [27]. In accordance with the functional overlap between G6PD and 
PNPLA3, in the current study we observed that fasting also significantly diminished 
the expression level of PNPLA3 in adipose tissue and livers from Western-type 
diet-fed mice. Combined, these findings suggest that the mRNA expression level of 
PNPLA3 and G6PD is tightly controlled by the same upstream regulator. The 
lipogenic transcription factor sterol regulatory element binding protein 1 (SREBP-1) 
has been identified as a possible regulator of G6PD expression in liver [24,28]. It 
will therefore be interesting to study whether SREBP can also act as a 
transcriptional regulator of hepatic PNPLA3 expression. 
In conclusion, we have shown that, in mice, the NAFLD-related gene PNPLA3 
is expressed in hepatocytes within the liver and that its relative expression level is 
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highly influenced by the intra-hepatic lipid status. Furthermore, our studies suggest 
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Background & Aims: The anti-dyslipidemic drug niacin has been recently shown 
to reduce the hepatic expression and plasma levels of CETP. Since liver 
macrophages contribute to hepatic CETP expression, the aim of the current study 
was to investigate the role of macrophages in the CETP-lowering effect of niacin in 
mice. 
Methods and Results: In vitro studies showed that niacin does not directly 
attenuate CETP expression in macrophages. Treatment of human CETP 
transgenic mice, fed with a Western-type diet, with 2% (w/w) niacin for 4 weeks 
significantly reduced hepatic cholesterol concentration (-20%), hepatic CETP gene 
expression (-20%), and plasma CETP mass (-30%). Concomitantly, niacin 
decreased hepatic expression of CD68 (-44%) and ABCG1 (-32%), both of which 
are specific markers for the hepatic macrophage content. The decrease in hepatic 
CETP expression was significantly correlated with the reduction of hepatic 
macrophage content. Furthermore, niacin treatment attenuated atherogenic diet-
induced inflammation in liver, as shown in decreased expression of MCP-1 (-32%) 
and TNFalpha (-43%). Post hoc analysis showed that niacin also decreased the 
macrophage content in APOE*3-Leiden.CETP transgenic mice on a Western-type 
diet. 
Conclusions: Niacin decreases hepatic CETP expression and plasma CETP 
mass by attenuating liver inflammation and macrophage content in response to its 
primary lipid-lowering effect, rather than by attenuating CETP expression in the 
macrophage. 
Keywords: CETP, niacin, macrophages, lipoprotein, liver, inflammation 
 
 




The anti-dyslipidemic drug niacin, also known as nicotinic acid, lowers plasma 
levels of pro-atherogenic lipids/lipoproteins, including very-low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) as well as triglycerides (TG). The lipid-
lowering effect of niacin has been widely recognized as an action on adipose 
tissue
1
. Niacin rapidly inhibits intracellular TG lipolysis, reduces the mobilization of 
free fatty acids (FFA) from adipose tissue to liver, and lowers plasma FFA levels 
acutely. In addition, niacin reduces hepatic synthesis and secretion of VLDL into 
the circulation
2
. Concomitantly, niacin increases the level of anti-atherogenic high-
density lipoprotein (HDL) in normolipidemic as well as hypercholesterolemic 
subjects
3
. Several clinical trials have shown that niacin reduces cardiovascular 
disease and myocardial infarction incidence, providing an emerging rationale for 
the use of niacin in the treatment of atherosclerosis
4,5
. 
Recently, we showed that niacin increases HDL by reducing the hepatic 
expression and plasma levels of the pro-atherogenic cholesteryl ester transfer 
protein (CETP)
6
. CETP, as a lipid transfer protein, has an established role in 
cholesterol metabolism
7
. It modifies the arterial intima cholesterol content via 
altering the concentration and function of plasma lipoproteins. Human population 
investigations favor low CETP as atheroprotective; this is supported by animal 





. We have demonstrated, by using 
APOE*3-Leiden.CETP versus APOE*3-Leiden mice, that niacin markedly reduces 
hepatic CETP expression and plasma CETP mass. Since CETP expression is 
driven by liver X receptor (LXR) activation, the reduction in hepatic CETP 
expression may be secondary to reduced liver lipid levels. However, the exact 
mechanism behind the hepatic CETP-lowering effect of niacin is still unresolved.  
The liver consists of several different types of cells, including hepatocytes and 
non-parenchymal cells such as resident macrophages, also known as Kupffer cells. 
Kupffer cells reside in the sinusoidal space of the liver and represent approximately 
80-90% of the body’s resident macrophages
10,11
. Kupffer cells are derived from 
monocytes that arise from bone marrow progenitors and migrate from the 
circulation
12
. Interestingly, Van Eck et al
13
 have shown a 47-fold higher expression 
of CETP mRNA in liver Kupffer cells than in hepatocytes. CETP expression in 
Kupffer cells contributes approximately 50% to the total hepatic CETP expression, 
indicating that bone marrow-derived CETP is an important contributor to hepatic 
CETP expression and plasma CETP mass. As the niacin receptor GPR109A is 
expressed in macrophages
14,15
, it is important to determine whether there is a 
direct action of niacin on liver macrophages. Therefore, the aim of the current study 
was to investigate the mechanism underlying the hepatic CETP-lowering effect of 
niacin in CETP transgenic mice. 
 
 
MATERIALS AND METHODS 
 
Animals  
Female CETP transgenic mice expressing the human CETP transgene under the 
control of its natural flanking regions (CETP Tg; C57BL/6 background) were used 
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in the present study. The animals were fed with semi-synthetic Western-type diet 
(WTD) containing 15% (w/w) fat and 0.25% (w/w) cholesterol (Diet W, Special Diet 
Services, Witham, UK) for 3 weeks (run-in), after which the diet for the treatment 
group was supplemented with 2% niacin (Sigma-Aldrich) for 4 weeks, while the 
control group was continuously fed with WTD. After euthanization, mice were bled 
via orbital exsanguination, and perfused in situ through the left cardiac ventricle 
with ice-cold PBS (pH 7.4) for 20 minutes. Tissues were dissected and snap-frozen 
in liquid nitrogen. One lobe of the liver was dissected free of fat and stored in 3.7% 
neutral-buffered formalin (Formal-fixx, Shandon Scientific Ltd., UK) for histological 
analysis. Animal care and procedures were performed in accordance with the 
national guidelines for animal experimentation. All protocols were approved by the 
Ethics Committee for Animal Experiments of Leiden University. 
 
Culture of bone marrow-derived macrophages 
Bone marrow-derived macrophages were obtained from CETP transgenic mice. 
Single-cell suspensions were harvested as described above. Cell concentration 
was adjusted to 8 x 10
6
 cells/mL, and cells were placed on a non-tissue culture 
treated Petri dish in RPMI1640 (PAA Laboratories) containing 20% (v/v) fetal calf 
serum (FCS), 2 mM/L L-glutamine, 100 U/mL
 
penicillin, 100 µg/mL streptomycin, 
1% (v/v) non-essential amino acids, 1% (v/v) pyruvate, and 30% (v/v) L929-
conditioned media. Cells were cultured in a humidified
 
incubator with 5% CO2
 
at 
37°C for 7 days. After bone marrow cell differentiation, adherent macrophages 
were harvested and cultured on 12-well plate in DMEM (PAA Laboratories) 
containing 10% (v/v) FCS, 2 mM/L L-glutamine, 100 U/mL
 
penicillin, and 100 
µg/mL streptomycin at a density of 0.5 x 10
6
 cells/mL. After 24 hours, non-adherent 
cells were removed, and macrophages were incubated in the absence or presence 
of niacin (Sigma-Aldrich) at a concentration of 0.1 µM, 1 µM, and 10 µM for 24 
hours. Total RNA was extracted and gene expression analysis was performed as 
described above. 
 
Hepatic lipid analysis  
Lipid analysis was performed when the animals received 4 weeks of WTD with or 
without 2% niacin. Mice were fasted overnight prior to euthanization. Lipids were 
extracted from liver using the Folch method. Briefly, 100 mg of tissue was 
homogenized with chloroform/methanol (1:2). The homogenate was centrifuged to 
recover the upper phase, which was further washed with chloroform-0.9% NaCl 
(1:1, pH 1.0). After centrifugation, the lower chloroform phase containing lipids was 
evaporated and the retained lipids were resolubilized in 2% Triton X-100 by 
sonification. Protein contents were analyzed by BCA assay (Pierce Biotechnology, 
Thermo Fisher Scientific BV, IL, USA). Total cholesterol content of lipid extracts 
was measured using the enzymatic colorimetric assay with 0.025 U/mL cholesterol 
oxidase, 0.065 U/mL peroxidase, and 15 µg/mL cholesteryl esterase (Roche 
Diagnostics, Mannheim, Germany). Data were expressed as milligrams of lipid per 
milligram of protein. 
 
RNA isolation and gene expression analysis 
Total RNA from liver was isolated using acid guanidinium thiocyanate (GTC)-
phenol-chloroform extraction. Briefly, 500 µL of GTC solution (4 M guanidine 
isothiocyanate, 25 mM sodium citrate, 0.5% N-lauroylsarcosine) was added to 
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each sample, followed by acid phenol:chloroform extraction. The RNA in aqueous 
phase was precipitated with isopropanol. The quantity and purity of the isolated 
RNA were examined using ND-1000 Spectrophotometer (Nanodrop, Wilmington, 
DE, USA). One microgram of the isolated RNA from each sample was converted 
into cDNA by reverse transcription with RevertAid™ M-MuLV Reverse 
Transcriptase (Promega, Madison, WI, USA). Negative controls without addition of 
reverse transcriptase were prepared for each sample. Quantitative real-time PCR 
was carried out using ABI Prism 7700 Sequence Detection system (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
36B4, Beta-actin, and GAPDH were used as internal housekeeping genes. 
Amplification curves were analyzed using 7500 Fast System SDS software V1.4 
(Applied Biosystems, Foster City, CA, USA). The relative expression of each gene 
was expressed as comparative numerical fold changes 2
−(∆∆CT)
. Standard error of 
the mean (SEM) and statistical significance were calculated using ∆∆Ct formula. 
 
CETP mass determination in plasma 
Plasma CETP mass was determined by ELISA, using a commercially available 




Macrophage content in livers of APOE*3-Leiden.CETP mice treated with or without 
1% of niacin6 was analyzed by immunohistochemistry staining. The liver was 
embedded in O.C.T™ Compound (Tissue-Tek, Sakura finetek, Tokyo, Japan), and 
subsequently sectioned using a Leica CM 3050S cryostat at 8 µm intervals. After 
incubation with blocking solution (5% goat serum), macrophages were detected 
using F4/80 antibody (rat antibody directed against murine macrophages, AbD 
Serotec, Oxford, UK). A rabbit anti rat IgG/HRP was used as second antibody 
(Dako, Heverlee, Belgium). Sections were developed using NovaRED Peroxidase 
Substrate Kit (Vector Laboratories, Peterborough, UK) according to the 




Statistical analyses were performed by the unpaired Student’s t-test for 
independent samples (Instat GraphPad software, San Diego, USA). Statistical 





Niacin reduces hepatic lipid content, plasma CETP mass, and hepatic CETP 
expression 
CETP Tg mice were utilized to analyze the effects of niacin on hepatic CETP 
expression and plasma levels of CETP. Four weeks of niacin treatment significantly 
reduced hepatic cholesterol concentration by 20% (p=0.005, Figure 1). In addition, 
in line with our previous data
6
, niacin treatment resulted in a significant 30% 
reduction (p=0.0002) in plasma CETP mass (Figure 1). In parallel, gene expression 

























































































Figure 1. Effect of niacin on hepatic cholesterol concentration, plasma CETP mass, and hepatic 
CETP expression in CETP Tg mice. After 4 weeks of Western-type diet (WTD) feeding with or without 
2% niacin supplement, mice were euthanized and lipids were extracted from liver. Total cholesterol 
concentration was measured. Plasma CETP mass was determined by ELISA. Total RNA was isolated 
from liver. Relative mRNA expression of CETP was determined by quantitative PCR and presented as 















































































Figure 2. Effect of niacin on LXR-target genes in CETP Tg mice. Total RNA was isolated from liver. 
Relative mRNA expression of the LXR-target genes SREBP-1c, ApoE, and LPL were determined by 
quantitative PCR and presented as fold-change relative to control group. Values are means ± SEM (6 
mice per group). ns, not significant. 
 
Niacin does not directly regulate LXR activity in the liver 
To evaluate whether niacin decreased hepatic CETP expression by attenuating 
LXR activation, we measured the effect of niacin on the LXR target genes SREPB-
1c, ApoE, and LPL. The hepatic expression of these three genes remained 
unchanged after niacin treatment (Figure 2), indicating that the reduction of hepatic 
CETP expression was not due to a direct regulation of niacin on LXR. 
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Niacin does not directly regulate CETP expression in bone marrow-derived 
macrophages 
To assess whether niacin directly attenuates CETP expression in macrophages, 
bone marrow-derived macrophages isolated from CETP Tg mice were exposed to 
various concentrations of niacin (0.1 µM, 1 µM, and 10 µM) for 24 hours. Niacin 
treatment did not alter CETP expression (Figure 3). In addition, niacin did not affect 
expression of the LXR-regulated targets SREBP-1c or apoE, or the cholesterol 
metabolism-related genes ABCA1, ABCG1, SR-B1, CD36 (data not shown). 
 
CETP



























Figure 3. Effect of niacin on CETP expression in bone marrow-derived macrophages from CETP 
Tg mice. Bone marrow-derived macrophages isolated from CETP Tg mice were incubated in medium in 
the absence or presence of niacin at a concentration of 0.1 µM, 1 µM, and 10 µM for 24 hours. Total 
RNA was extracted and CETP mRNA expression was assessed by quantitative PCR and presented as 
fold-change compared to PBS-control group. Values are presented as means ± SEM (5 independent 
cell isolations). ns, not significant. 
 
Niacin reduces macrophage content and inflammation in the liver 
Since these data indicated that niacin may reduce hepatic CETP expression by 
reducing the liver macrophage content, we evaluated the effect of niacin on CD68 
and ABCG1, both of which have been defined as reliable markers to assess the 
hepatic macrophage content
16 , 17 , 18
. Interestingly, niacin treatment significantly 
decreased hepatic expression of CD68 by 44% (p=0.027) and ABCG1 by 32% 
(p=0.001) (Figure 4A). In addition, niacin did not affect the CETP/ABCG1 and 
ABCG1/CD68 expression ratios (Figure 4A). This suggests that niacin does not 
directly reduce the expression of CETP or ABCG1 by on macrophages, in line with 



























































































































































































Figure 4. Effect of niacin on hepatic macrophage gene expression in CETP Tg mice. Total RNA 
was extracted from liver and relative mRNA expression of CD68, ABCG1, MCP-1, and TNFalpha were 
assessed by quantitative PCR and presented as fold-change relative to control group (A). Ratio 
between the expression level of CETP and CD68, ABCG1 and CD68 were calculated (A). Correlation 
between hepatic CETP and CD68 / ABCG1 expression upon niacin treatment was linearly plotted (B). 
Values are means ± SEM (6 mice per group). ns, not significant. *P<0.05; **P<0.01. 










































































































































Figure 5. Effect of niacin on hepatic macrophage gene expression and number of macrophages 
in APOE*3-Leiden.CETP mice. Total RNA was extracted from liver and relative mRNA expression of 
CD68 and ABCG1 were assessed by quantitative PCR and presented as fold-change relative to control 
group (A). Correlation between hepatic CETP and CD68 / ABCG1 expression upon niacin treatment 
was linearly plotted (B). Macrophage content in the liver was visualized via immunohistochemistry 
staining with F4/80 antibody, and the number of positive cells were counted and expressed as 
percentage of control group. Representative pictures are shown (C). Values are means ± SEM (8 mice 
per group). ns, not significant. *P<0.05; **P<0.01.  
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reducing CETP expression. In accordance with the decreased liver macrophage 
content, gene expression of the inflammatory markers MCP-1 and TNFalpha in the 
liver both decreased substantially by 32% (p=0.016) and 43% (p=0.011), 
respectively, after niacin treatment (Figure 4A), suggesting attenuated high-fat diet-
induced inflammation in liver. 
The comparable reductions of hepatic CETP, liver macrophage markers, and 
liver inflammation markers suggest that the decrease of hepatic CETP expression 
is caused by a reduced amount of inflammatory macrophages in liver. Indeed, 
linear regression showed a very significant and strong positive correlation between 
hepatic CETP and CD68 expression (p<0.01; R
2
=0.78), as well as between hepatic 
CETP and ABCG1 expression (p<0.05, R
2
=0.68).  
Consistent with our current results, post-hoc analysis on livers of APOE*3-
Leiden.CETP mice treated with 1% niacin, from our previous study, in which the 
CETP-lowering effect of niacin was first observed
6
, revealed similar significant 
reductions in hepatic gene expression of CD68 (-51%, p=0.007) and ABCG1 (-45%, 
p=0.001) (Figure 5A). In addition, there were also significant correlations between 
hepatic CETP and CD68 (p<0.001; R
2
=0.75) or ABCG1 (p<0.001; R
2
=0.85) 
expression (Figure 5B). The reduction of hepatic macrophage content was further 
visualized by staining of F4/80-positive cells, where niacin significantly reduced the 





To explain the CETP-lowering effect of niacin, we set out to investigate the effect of 
niacin on macrophages. Our observations in vitro showed that niacin at various 
concentrations did not reduce CETP expression in cultured macrophages derived 
from CETP Tg mice. Neither did niacin alter cholesterol metabolism-related genes, 
such as ABCA1, ABCG1, and SR-B1. We thus conclude that niacin does not 
directly regulate expression of CETP or other lipid-related genes in macrophages, 
albeit that secondary effects of niacin in an in vivo setting, e.g. related to a 
reduction in the fatty acid flux from adipose tissue to (liver) macrophages, can not 
be ruled out. 
Luo et al
19
 have previously demonstrated that CETP is trans-activated by 
nuclear receptor LXR, suggesting its role in regulating CETP expression in vivo. 
We also proposed in our previous study that niacin may decrease the hepatic 
CETP mRNA expression via LXR responsive element in the CETP promoter 
following decreased cholesterol content. However, our current in vitro data showed 
that niacin did not directly regulate expression of LXR-regulated target genes, such 
as ABCA1. Our in vivo data further confirmed that niacin did not regulate the 
expression of classical LXR targets such as SREBP-1c, apoE, or LPL in liver. In 
addition, although niacin treatment reduced the gene expression of ABCG1 in liver, 
it did not affect the ABCG1/CD68 expression ratio, indicating that niacin does not 
directly reduce the expression of ABCG1 on macrophages. The reduction in 
ABCG1 in vivo is thus probably not simply the consequence of reduced LXR 
activation. Therefore, it is suggested that either direct or indirect regulation of LXRs 
in the liver is not the main mechanism by which niacin reduces CETP expression. 
The liver is a unique immunological site responding to inflammation. Antigen-
rich blood from the gastrointestinal tract and the peripheral circulation enters the 
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hepatic parenchyma, passes through a network of liver sinusoids and is scanned 
by immune cells including macrophages and lymphocytes
20
. Thus, liver 
macrophages have profound implications in many aspects of the hepatic 
inflammatory response
21
. Plasma pro-atherogenic lipoproteins, mainly (V)LDLs, are 
important determinants of liver inflammation. Recent evidence has indicated an 
increased hepatic inflammation and macrophage content upon high-fat diet-
induced hyperlipidemia. In C57Bl/6J mice fed a high-fat diet, up-regulation of 
hepatic expression of CD68 was found associated with increased hepatic lipid 
content
22
. Another study showed that in the LDLr
–/–
 mice fed a high-fat diet, an 
increase of CD68 expression in the liver was correlated with increased plasma 
VLDL cholesterol levels. Omitting cholesterol from the diet rapidly reduced plasma 
TG and VLDL-cholesterol accumulation, associated with significantly lowered 
CD68 expression in liver together with other inflammatory genes
23
. In humans, a 
similar correlation between increased presence of CD68-positive Kupffer cells and 
the histological severity of human hepatic lipid content in fatty liver has been 
reported
24
. Such correlations between altered macrophage content and circulatory 
inflammatory factors define macrophage infiltration as a common response against 
hepatic and circulatory inflammation.  
In the current study, niacin treatment reduced cholesterol content in the liver. In 
line with this attenuated liver fat accumulation, we further observed a significant 
reduction of pro-inflammatory markers MCP-1 and TNFalpha in liver. MCP-1 is one 
of the best characterized pro-inflammatory chemokines in liver. It has been 
reported that dietary fat and cholesterol, inappropriately high in the Western-type 
diet, are potent metabolic stress inducers of hepatic expression of the MCP-1 
gene
25
. An increase in MCP-1 expression contributes to macrophage infiltration 
and hepatic steatosis in mice
26
. The pro-inflammatory cytokine TNFalpha is also 
critically involved in the pathophysiology of liver steatosis, and this cytokine is 
primarily secreted by Kupffer cells and liver-infiltrating macrophages
27
. Taken 
together, the results suggested an attenuated liver inflammation after niacin 
treatment. 
In line with the attenuated diet-induced inflammation in the liver, the hepatic 
gene expression of CD68 and ABCG1 were also reduced upon niacin treatment. 
CD68 has been defined as a reliable macrophage marker and widely used for 
quantification of macrophage content in numerous studies
28,29,30
. ABCG1 has also 
been shown to be a good marker to assess Kupffer cell content in the liver, since 
ABCG1 is not expressed in hepatocytes
31,32
. In the current study, a reduction in the 
hepatic MCP-1 expression was associated with decreased CD68 and ABCG1 gene 
expression in liver, and also a reduced number of macrophages in liver, indicating 
an attenuated macrophage infiltration and/or an increased macrophage efflux from 
the liver into the liver and thus a decreased liver macrophage content. More 
importantly, the significant positive correlation between hepatic CETP and both 
CD68 and ABCG1 expression observed in both the current study and in the 
present post-hoc analysis of our previous study suggests that the liver macrophage 
is a primary contributor to hepatic and total plasma CETP mass, and that the 
hepatic CETP reduction induced by niacin treatment is a direct consequence of a 
reduced macrophage content of the liver.  
Figure 6 illustrates the proposed mechanism underlying the action of niacin on 
hepatic CETP expression. We propose that the primarily reduced hepatic 
cholesterol accumulation via the lipid-lowering effect of niacin leads to attenuated 
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hepatic inflammation, and thus less macrophage infiltration into and/or increased 
macrophage emigration out of the liver. The decreased amount of hepatic 
macrophages leads to an overall reduction in hepatic CETP expression and a 
lower plasma CETP level. 
 
niacin
efflux ↑ infiltration ↓
macrophage
lipids ↓ CETP ↓
 
 
Figure 6. Proposed mechanism underlying the action of niacin on hepatic CETP expression and 
plasma CETP mass. We propose that the primarily reduced hepatic cholesterol accumulation via the 
lipid-lowering effect of niacin leads to attenuated hepatic inflammation, and thus less macrophage 
infiltration into and/or increased macrophage emigration out of the liver. The decreased amount of 
hepatic macrophages, which are significant contributors of CETP, leads to an overall reduction in 
hepatic CETP expression and a lower plasma CETP level. 
 
In conclusion, our study sheds new light on the mechanism underlying the 
CETP-lowering effect of niacin in CETP transgenic mice. We have shown that 
niacin does not directly alter macrophage CETP expression, but attenuates liver 
inflammation and the macrophage content in response to its primary lipid-lowering 
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Background & Aims: Nicotinic acid, also known as niacin, is the most effective 
agent currently available to treat dyslipidaemic disorders. However, its clinical use 
has been limited due to the cutaneous flushing, which is mediated by the nicotinic 
acid receptor HCA2. In the current study, we assessed the in vitro and in vivo 
properties of two partial agonists for HCA2, LUF6281 and LUF6283, to evaluate 
their anti-dyslipidemic potentials and cutaneous flushing side effect compared to 
nicotinic acid. 
Methods and Results: Radioligand competitive binding assay showed the Ki 
values for LUF6281 and LUF6283 were 3 µM and 0.55 µM, respectively. [
35
S]-
GTPγS binding determined the rank order of their potency: nicotinic acid > 
LUF6283 > LUF6281. Both LUF6281 and LUF6283 avoided the unwanted flushing 
side effect as tested in C57BL/6 mice. Furthermore, both agonists significantly 
reduced plasma VLDL-cholesterol concentration in mice. In the liver, both agonists 
resulted in a more than 40% reduction in the expression levels of ApoB and MTP 
as compared to the control group, indicating inhibited hepatic VLDL production. 
Conclusions: The current study demonstrates that two HCA2 partial agonists of 
the pyrazole class are promising drug candidates to achieve the beneficial lipid-
lowering effects while successfully avoiding the unwanted flushing side effect. 
Keywords: HCA2 partial agonists, niacin, lipoprotein, VLDL, liver, flushing 
 
 




Nicotinic acid, also known as niacin, is the most effective agent currently available 
to treat dyslipidaemic disorders
1
. It lowers plasma levels of pro-atherogenic lipids, 
including chylomicrons, very-low-density lipoproteins (VLDL), low-density 
lipoproteins (LDL), and triglycerides (TG) in normolipidemic as well as 
hypercholesterolemic subjects
2
. Several clinical trials have shown that nicotinic 
acid reduces cardiovascular disease and myocardial infarction incidence, providing 
a solid rationale for the use of nicotinic acid in the treatment of atherosclerosis
3,4
. 
The G protein-coupled receptor GPR109A, also known as PUMA-G in mouse and 
HM74A in humans, has been identified as a high-affinity receptor for nicotinic 
acid
5 , 6
. We now know that the endogenous ligand for GPR109A is 3-
hydroxybutyrate, and this receptor has recently been renamed as hydroxy-
carboxylic acid receptor 2 (HCA2)
7
. 
Despite its established cardiovascular benefits, the clinical use of nicotinic acid 
has been limited due to the cutaneous flushing, a well-recognized adverse skin 
effect from nicotinic acid therapy. Flushing has been cited as the major reason for 
the discontinuation of this therapy, estimated at rates as high as 25%-40%
8
. The 
nicotinic acid receptor HCA2 expressed in the skin is a critical mediator of nicotinic 
acid-induced flushing
9
. Nicotinic acid stimulates HCA2 in epidermal Langerhans 
cells and keratinocytes, causing the cells to produce vasodilatory prostaglandin D2 




For the past decade, the pharmacology of HCA2 has been studied and full or 
partial agonists for HCA2 have been developed in an attempt to achieve the 
beneficial effects of nicotinic acid while avoiding the unwanted flushing side effect
14
. 
Based on the structure-activity relationship of nicotinic acid-related molecules, 
several potent agonists for HCA2 have been identified, including acipimox, acifran, 
3-pyridine-acetic acid, 5-methylnicotinic acid, pyridazine-4-carboxylic acid, and 
pyrazine-2-carboxylic acid
15,16
. However, the challenge remains that HCA2 partial 
agonists failed to demonstrate the beneficial effects on LDL-cholesterol, 
triglycerides or HDL-cholesterol despite the absence of flushing events in clinical 
studies
17
. Further understanding of the medicinal chemistry of HCA2 is needed to 
pharmacologically dissociate the antilipolytic and vasodilatory effects of nicotinic 
acid by acting on HCA2
16
. 
In the current study, we assessed the properties of two HCA2 partial agonists, 
LUF6281 and LUF6283, of the pyrazole class, which were developed in our 
laboratory
18
. We first characterized these two compounds in vitro, using a 
radioligand binding assay, [
35
S]-GTPγS assay and ERK phosphorylation assay. 
The ERK phosphorylation assay was included because it has been suggested that 
ERK1/2 phosphorylation downstream from HCA2 correllates positively with skin 
flushing
19
. Then, we assessed the cutaneous flushing effect and the therapeutic 








MATERIALS AND METHODS 
 





H]-nicotinic acid (60 Ci/mmol) was obtained from BioTrend (Koehln, Germany). 
[
35
S]-GTPγS (1250 Ci/mmol) was obtained from Perkin Elmer (Waltham, MA). 
 
Cell culture and membrane preparation 
Human embryonic kidney (HEK) 293T cells stably expressing human HCA2 were 
cultured in DMEM supplemented with 10% newborn bovine serum, 0.4 mg/mL 
G418, 50 IU/mL penicillin and 50 µg/mL streptomycin. The cells were harvested by 
scraping in cold PBS, centrifuged at 1000 xg for 10 minutes and resuspended in 
cold 50 mM Tris-HCl buffer, pH 7.4. Then a DIAX 900 electrical homogenizer 
(Heidolph, Schwabach, Germany) was used for 15 seconds to obtain cell lysis. The 
suspension was centrifuged at 225000 xg for 20 minutes at 4 °C and the 
supernatant was discarded. The pellet was resuspended in Tris-HCl, and the 
homogenization and centrifugation steps were repeated. The membranes were 
resuspended in cold assay buffer (50 mM Tris HCl, 1 mM MgCl2, pH 7.4) and the 
protein content was determined using BCA assay (Thermo Scientific, Waltham, 
USA). During membrane preparation the suspension was kept on ice at all times. 




H]-nicotinic acid displacement assay 
Membranes of our stable HEK293T-HCA2 cell line (50 µg protein per tube) were 
incubated for 1 hour at 25 °C with 20 nM [
3
H]-nicotinic acid and with increasing 
concentrations of the test compounds in assay buffer (50 mM Tris HCl, 1 mM 
MgCl2, pH 7.4). The total assay volume was 100 µL. To assess the total binding, a 
control without test compound was included. The non-specific binding was 
determined in the presence of 10 µM unlabeled nicotinic acid. Final DMSO 
concentration in all samples was ≤ 0.25%. The incubation was terminated by 
filtering over GF/B filters using a 24-sample harvester (Brandel, Gaithersburg, 
USA). The filters were washed 3 times with 2 mL cold buffer (50 mM Tris HCl, pH 
7.4). Filters were transferred to counting vials and counted in a Perkin Elmer LSA 
Tri-Carb 2900TR counter after 2 hours of extraction in 3.5 mL Emulsifier Safe liquid 




S]-GTPγS binding assay 
This assay was performed in 96-well format in 50 mM Tris-HCl, 1 mM EDTA, 5 
mM MgCl2, 150 mM NaCl, pH 7.4 at 25 °C with 1 mM DTT, 0.5% BSA and 50 
µg/mL saponin freshly added. HEK-HCA2 membranes (5 µg protein per well in 25 
µL) were pre-incubated with 25 µL of 40 µM GDP and 25 µL increasing 
concentrations of the test compounds, for 30 minutes at room temperature. Then, 
25 µL [
35
S]-GTPγS was added (final concentration 0.3 nM) and the mixture was 
incubated for 90 minutes at 25 °C with constant shaking. The incubation was 
terminated by filtration over GF/B filterplates on a FilterMate harvester 
(PerkinElmer). The filters were dried and 25 µL Microscint 20 (PerkinElmer) was 
added to each filter. After ≥3 hours of extraction the bound radioactivity was 
determined in a Wallac Microbeta Trilux 1450 counter (PerkinElmer, MA, USA). 
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ERK1/2 phosphorylation assay 
The assay was performed using AlphaScreen SureFire Phospho-ERK1/2 kit 
(PerkinElmer, MA, USA), following the kit protocol. Briefly, a 96-well cell culture 
plate was coated with poly-D-lysine and HEK cells stably expressing human HCA2 
were seeded at 50000 cells/well in 200 µL DMEM supplemented with 10% 
newborn bovine serum, 0.4 mg/mL G418, 50 IU/mL penicillin and 50 µg/mL 
streptomycin. After overnight incubation the cells were serum starved for 4 h in the 
same medium lacking the serum, and then the medium was replaced by 90 µL 
prewarmed PBS and incubated for an additional 30 minutes. Increasing 
concentrations of the test compounds were diluted in prewarmed PBS and 10 µL 
was added per well for stimulation. After 5 minutes the stimulation solution was 
removed from the plates, the wells were washed once in ice-cold PBS and 100 µL 
lysis buffer was added per well. After 15 minutes of incubation and shaking at room 
temperature, the lysates were mixed by pipetting and 4 µL was transferred to a 
384-well OptiPlate (PerkinElmer, MA, USA). The reaction mix was prepared 
according to the kit protocol (60 µL reaction buffer and 10 µL activation buffer with 
1 µL of the donor and acceptor beads each) and 7 µL mix was added to each 
proxyplate well. After 2 h the plate was read on an EnVision multilabel plate reader 
(PerkinElmer, MA, USA). 
 
Data analysis 
Analysis of the results was performed using Prism 5.0 software (GraphPad 
Software Inc., La Jolla, USA). Nonlinear regression was used to determine IC50 
values from competition binding curves. The Cheng-Prusoff equation was then 




S]-GTPγS and pERK curves were analysed by 
nonlinear regression to obtain EC50 values. 
 
In vivo experiments 
 
Animals 
Female C57BL/6 mice of 12 weeks old were used. Animals were fed a regular 
cholesterol-free chow diet containing 4.3% (w/w) fat (RM3, Special Diet Services, 
Witham, UK). Mice received either vehicle (50% DMSO in PBS) or HCA2 partial 
agonists LUF6281 and LUF6283 (400 mg/kg/day) once a day for 4 weeks via oral 
gavage. After euthanization, mice were bled via orbital exsanguination and 
perfused in situ through the left cardiac ventricle with ice-cold PBS (pH 7.4) for 20 
minutes. Liver was dissected free of fat and snap-frozen in liquid nitrogen. Animal 
care and procedures were performed in accordance with the national guidelines for 
animal experimentation. All protocols were approved by the Ethics Committee for 
Animal Experiments of Leiden University. 
 
Measurement of skin flushing in mouse 
Cutaneous flushing in C57BL/6 mice was assessed by monitoring the change of 
the skin temperature at the mouse paw location. Temperature measurements were 
recorded using a non contact infrared thermometer (Pro Exotics PE-1 Infrared 
Temp Gun, Littleton, USA). The probe was held at a distance of 1 to 2 mm from the 
metacarpal pad of mouse paw, and temperature readings were taken from a 
circular area approximately 3 mm in diameter. Animals were habituated to handling 
and to the infrared probe before use. Skin temperature was initially recorded from 
Chapter 5 
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the abdominal area, tail, ear, and paw, after which it was determined that mouse 
paw skin temperature gave the most reliable and consistent results. During the 
experiment, the animals were dosed with either vehicle (50% DMSO in PBS) or 
partial agonists LUF6281 and LUF6283 (400 mg/kg/day) via oral gavage (10:00-
11:00 AM), and the paw temperature was measured every 10 minutes for a period 
of 60 minutes in total. Three readings from the center area of mouse paw were 
recorded routinely for each time point. Baseline paw temperature was recorded 
right before animals were dosed. All the administration was performed in conscious 
mice to avoid the interference of the anesthetics on skin temperature. 
 
Plasma lipid analysis 
The distribution of cholesterol over different lipoproteins in plasma was determined 
by fast protein liquid chromatography (FPLC) through a Superose 6 column (3.2 x 
30 mm; Smart-System, Pharmacia, Uppsala, Sweden). Cholesterol content of the 
lipoprotein fractions was measured using the enzymatic colorimetric assay (Roche 
Diagnostics, Mannheim, Germany). 
 
RNA isolation and gene expression analysis. 
Total RNA from the liver was isolated using acid guanidinium thiocyanate (GTC)-
phenol-chloroform extraction. Briefly, 500 µL of GTC solution (4 M guanidine 
isothiocyanate, 25 mM sodium citrate, 0.5% N-lauroylsarcosine) was added to 
each sample, followed by acid phenol:chloroform extraction. The RNA in aqueous 
phase was precipitated with isopropanol. The quantity and purity of the isolated 
RNA were examined using ND-1000 Spectrophotometer (Nanodrop, Wilmington, 
DE, USA). One microgram of the isolated RNA from each sample was converted 
into cDNA by reverse transcription with RevertAid™ M-MuLV Reverse 
Transcriptase (Promega, Madison, WI, USA). Negative controls without addition of 
reverse transcriptase were prepared for each sample. Quantitative real-time PCR 
was carried out using ABI Prism 7700 Sequence Detection system (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
36B4, Beta-actin, and GAPDH were used as internal housekeeping genes. The 
gene-specific primer sequences used are listed in Table 1. Amplification curves 
were analyzed using 7500 Fast System SDS software V1.4 (Applied Biosystems, 
Foster City, CA, USA). The relative expression of each gene was expressed as fold 
changes 2
−(∆∆CT)
 compared to baseline group. Standard error of the mean (SEM) 
and statistical significance were calculated using ∆∆Ct formula. 
 
Statistical analysis 
Mean values between 2 groups were analyzed with 2-tailed unpaired Student’s t-
test. Data sets containing multiple groups were analyzed by ANOVA (Instat 
GraphPad software, San Diego, USA). Statistical significance was defined as 
p<0.05. Data are expressed as means ± SEM. 
 
Table 1. Murine primers for quantitative real-time PCR analysis 
Gene Forward primer Reverse Primer 
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 
Beta-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
GAPDH TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 
ApoB ATGTCATAATTGCCATAGATAGTGCCA TCGCGTATGTCTCAAGTTGAGAG 
MTP AGCTTTGTCACCGCTGTGC TCCTGCTATGGTTTGTTGGAAGT 




In this study, we assessed the in vitro and in vivo properties of two HCA2 ligands, 
LUF6281 and LUF6283, to evaluate their anti-dyslipidemic potentials and 
cutaneous flushing side effect compared to nicotinic acid. The chemical structures 
of these compounds are shown in Figure 1. For in vitro experiments we used 













 Nicotinic acid       LUF6281     LUF6283 
 
Figure 1. Chemical structures of nicotinic acid, LUF6281, and LUF6283. 
 
First, the affinity of the compounds to HCA2 was determined by a competitive 
binding assay using radiolabeled nicotinic acid (Figure 2). The Ki values 
determined for LUF6281 and LUF6283 were 3 µM and 0.55 µM, respectively 
(Table 2). 
Next, we compared the potencies and intrinsic efficacies of nicotinic acid, 
LUF6281 and LUF6283 by measuring their ability to stimulate [
35
S]-GTPγS binding. 
The results clearly showed that LUF6281 and LUF6283 were partial agonists, with 
intrinsic efficacies of 55 (±4.1) and 76 (±3.4) %, respectively (N=7). The rank order 
of their potency was nicotinic acid > LUF6283 > LUF6281, with EC50 values of 0.41, 
3.1 and 8.6 µM, respectively (Figure 3; Table 2). 
 
Table 2. In vitro biochemical characterization of GPR109A agonists nicotinic acid, LUF6281, and 











Nicotinic acid 0.04 (±0.02) 0.41 (±0.11) 0.02 (±0.004) 
LUF6281 3.1 (±0.5) 8.60 (±1.00) 1.37 (±0.31) 
LUF6283 0.55 (±0.01) 3.10 (±0.13) 0.32 (±0.06) 
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Figure 2. Competitive radioligand binding assay using 20 nM [
3
H]-nicotinic acid revealing the relative 
affinities of nicotinic acid, LUF6481 and LUF6483. The assay was performed on HEK293T-HCA2 
membranes (50 µg/tube). The results from one representative experiment are shown (of N=3). 
 




























Figure 3. Dose-response curves of nicotinic acid, LUF6481 and LUF6483 in a [
35
S]-GTPγS binding 
assay, showing the relative potencies and intrinsic efficacies. Nicotinic acid is a full agonist, whereas 
LUF6481 and LUF6483 are partial agonists in this assay. The assay was performed on HEK293T-HCA2 


































Figure 4. Dose-response curves of nicotinic acid, LUF6481 and LUF6483 in an ERK 1/2 
phosphorylation assay, showing the relative potencies and intrinsic efficacies. All ligands are full 
agonists in this assay. The assay was performed on attached HEK293T-HCA2 cells. Data from one 
representative experiment are shown (of N=3-5). 
                                                    Characterization of niacin receptor partial agonists 
 81 
The second functional assay monitored ERK1/2 phosphorylation of the 
compounds upon HCA2 activation. Results from this assay showed that the intrinsic 
efficacy was the same for all compounds (Figure 4; Table 2). The EC50 values 
obtained here were 20 nM for nicotinic acid, 1.6 µM for LUF6281 and 0.26 µM for 
LUF6283. Thus, all compounds seemed to be more potent in the pERK1/2 assay 
than in the [
35
S]-GTPγS assay, but this difference was much more pronounced for 
nicotinic acid (20-fold) than for LUF6283 (12-fold) and LUF6281 (4-fold) (Table 2).   
To examine the vasodilatory effects of these compounds in vivo, we used 
C57BL/6 mice to assess the cutaneous flushing as determined by an increase in 
mouse paw skin temperature. In mice, the normal paw skin temperature was 
approximately 26.4°C (n = 30). Mice were divided into 3 groups: the control group 
received vehicle (50% DMSO in PBS), while the treatment groups received 
LUF6281 and LUF6283 (400 mg/kg/day) respectively via oral gavage. Surprisingly, 
DMSO induced a time-dependent temperature increase in the control group, with a 
maximum 3.6 °C (n = 10) that occurred at 20 minutes after oral gavage (Figure 5). 
Similar effects of DMSO have been reported in the literature, and might be due to a 
release of histamine
21,22,23,24,25
. However, neither of the treatment groups displayed 
significant temperature raise. At 20 minutes, LUF6281 and LUF6283 induced a 
maximal temperature increase of only 0.5 or 1.0 °C (n = 10 per group), which was 
significantly lower than the temperature raise observed in the control group (p < 
0.001; Figure 5) and comparable to the temperature raise induced by PBS at the 
same time point (data not shown). The results suggested that both of the HCA2 

























Figure 5. Mouse flushing after administration of nicotinic acid, LUF6281, and LUF6283. The cutaneous 
vasodilation was determined by change in paw skin temperature in C57BL/6 mice. Mice received 
vehicle (DMSO), LUF6281, or LUF6283 (400 mg/kg/day) via oral gavage. Data are expressed as the 
increase of skin temperature at 20 min after dosing compared to before treatment (n=10 per group). ns, 
not significant. ***P<0.001. 
 
To evaluate the beneficial antilipolytic potentials of the LUF compounds, we 
tested their effects on plasma lipid homeostasis in C57BL/6 mice. Although 
treatment with LUF compounds for 4 weeks did not alter plasma total cholesterol or 
triglycerides concentration, separation of plasma lipoproteins by FPLC in 
combination with analysis of the lipid content across the FPLC fractions showed 
that LUF6281 sharply reduced plasma VLDL-cholesterol concentration by 77.4% 
(p<0.01) and LUF6283 also significantly reduced plasma VLDL-cholesterol level by 





























Figure 6. Effects of LUF6281 and LUF6283 on plasma VLDL concentration in C57BL/6 mice. Mice were 
fed with regular chow diet and received either vehicle (DMSO) or GPR109A partial agonists LUF6281 
and LUF6283 (400 mg/kg/day) once a day for 4 weeks. Plasma lipoproteins were separated by FPLC 
and cholesterol level was measured in each fraction. VLDL represents the sum of cholesterol 
concentrations from fraction 2 to 7 (VLDL fractions. Values are means ± SEM (n=10 per group). 
*P<0.05; **P<0.01. 
 
To further understand the mechanism whereby LUF compounds largely 
reduced the plasma VLDL concentration, hepatic gene expression levels in 
response to compound treatment were assessed by real-time quantitative PCR. 
Both LUF6281 and LUF6283 modulated the relative RNA expression level of 
hepatic VLDL production-associated genes in mouse. Concomitant with the plasma 
VLDL-lowering effect, treatment of both LUF compounds resulted in a more than 
40% reduction in the expression levels of apolipoprotein B (apoB) (p<0.05) and 
microsomal triglyceride transfer protein (MTP) (p<0.05) as compared to the control 























































Figure 7. Effects of LUF6281 and LUF6283 on hepatic gene expression in C57BL/6 mice. Total RNA 
was extracted from liver, and relative mRNA expression levels of ApoB and MTP were determined by 
quantitative PCR and presented as fold-change relative to control group. Values are means ± SEM 
(n=10 per group). *P<0.05; **P<0.01. 




Previous studies have shown that HCA2 mediates nicotinic acid-induced cutaneous 
flushing
26
. It seems that the early phase of flushing depends on HCA2 expressed 
on Langerhans cells, whereas the late phase is mediated by HCA2 expressed on 
keratinocytes
12
. Derivatives of nicotinic acid have been developed to 
pharmacologically dissociate the antilipolytic and vasodilatory effects by acting as 
partial and, in the case of MK-0354, biased agonists on HCA2
18,19,27
. The pyrazole 
MK-0354 stimulates the G protein pathway that leads to antilipolysis in adipocytes, 
but does not cause ERK1/2 phosphorylation
27
. This compound showed promising 
results in mice, since no vasodilation was observed and antilipolytic activity was 
retained, but in clinical trials this compound failed since it had no effect on plasma 
lipid levels
17
. In the current study, we characterized the affinity and efficacy of two 
HCA2 partial agonists LUF6281 and LUF6283 previously reported by us
18
 and we 
evaluated the cutaneous flushing effect and the therapeutic lipid-lowering potential 
of these agonists in C57BL/6 mice. 
We show that nicotinic acid, LUF6281 and LUF6283 may all have a certain bias, 
since these compounds all seem to have a higher potency for ERK1/2 
phosphorylation than for G protein activation. Furthermore, LUF6281 and LUF6283 
were both partial agonists in the [
35
S]-GTPγS assay but seemed full agonists in the 
pERK1/2 assay. The fold difference in potency depended on the compound; 
nicotinic acid was 20-fold more potent for ERK phosphorylation, LUF6283 was 12-
fold more potent and LUF6281 was only 5-fold more potent. The high potency of 
nicotinic acid for activation of the MAP kinase pathway may explain why this 
compound causes flushing so effectively. Unlike MK-0354, our pyrazole 
compounds are still active in the ERK1/2 assay, but we hypothetized that their 
relatively low potency on this pathway might attenuate the flushing response. 
Indeed, our in vivo findings confirm that the pyrazoles do not provoke the flushing 
response as nicotinic acid does, although it remains unclear what causes this 
improvement.  
In addition, our data suggested that LUF6281 and LUF6283 exerts lipid-
lowering effect via inhibiting hepatic VLDL production. LUF6281 and LUF6283 both 
markedly reduced the hepatic gene expression of apoB and MTP. ApoB is the 
structural lipoprotein of VLDL, LDL and chylomicrons. ApoB and the MTP are 
essential for the assembly and secretion of apoB-containing lipoproteins
28
. The 
assembly and secretion pathway of VLDL in the liver involves the transfer of lipid 
by MTP to apoB during translation and then the fusion of apoB-containing 
precursor particles with triglyceride droplets to form mature VLDL
29,30
. The link 
between hepatic ApoB / MTP gene expression level, hepatic VLDL secretion and 
plasma VLDL concentration has been illustrated in the literature
31,32
. 
In conclusion, the current study demonstrated two HCA2 partial agonists of the 
pyrazole class as promising drug candidates to achieve the beneficial lipid-lowering 
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Background & Aims: LXR activation leads to a number of favorable changes in
 
lipid metabolism. LXR agonists have been shown to attenuate the progression of 
atherosclerosis. It is thus interesting to examine whether rapidly improved plasma 
lipoprotein profiles combined with LXR activation can lead to atherosclerotic lesion 
regression. 
Methods and Results: LDLr
–/– 
and C57BL/6 mice were fed with atherogenic diet to 
induce atherosclerotic development, after which the diet was switched to chow diet 
with or without supplementation of LXR agonist T0901317. In LDLr
–/–
 mice, LXR 
activation did not induce atherosclerotic plaque regression. In C57BL/6 mice, LXR 
agonist dramatically improved plasma lipoprotein profile, including large reductions 
in (V)LDL and brisk enhancements in HDL. T0901317 induced favourable hepatic 
gene expression profiles. T0901317 significantly increased hepatic expression of 
ABCA1, ABCG1, and SR-BI, suggesting enhanced reverse cholesterol transport. 
Subsequently, T0901317 supplemented in chow diet significantly reduced the pre-
existing atherosclerotic plaque size (-43%). 
Conclusions: The current study shows that 1) intact LDL receptor function is 
crucial to overcome LXR-induced hyperlipidemia; and 2) rapidly optimized plasma 
lipoprotein profiles combined with LXR agonist induced favorable gene expression 
profiles can induce regression of pre-existing atherosclerotic plaques. 
Keywords: LXR, T0901317, lipoprotein, atherosclerosis, regression 
 
 




Hypercholesterolemia holds a critical role in the development of atherosclerosis
1
. 
Lowering of very-low-density lipoprotein- (VLDL-) and low-density lipoprotein- 
(LDL-) cholesterol levels leads to reduction in cardiovascular morbidity and 
mortality in individuals at risk for cardiovascular events
2,3
. High-density lipoprotein 
(HDL) is an anti-atherosclerotic lipoprotein based on its ability to mediate reverse 
cholesterol transport (RCT), which is a major protective system against 
atherosclerosis
4
. HDL can remove cholesterol from the periphery, allowing it to be 
cleared by the liver and then excreted into the bile
5
. Cholesterol efflux from 
macrophages to HDL is a crucial step in RCT
6
. Modulation of the major molecular 
mediators in RCT, such as ATP binding cassette transporter A1 (ABCA1), ATP 
binding cassette transporter G1 (ABCG1), and scavenger receptor class B1 (SR-
B1) has consistent beneficial effects on RCT and atherosclerosis
7,8
. Agents that 
raise HDL and promote RCT, including statins, fibrates, nicotinic acids, and liver X 




LXRs play an important role in the maintenance
 
of cellular and systemic 
cholesterol homeostasis
10
. Pharmacological activation of LXRs in vivo leads to a 




. Synthetic LXR agonists 
promote biliary sterol secretion, reduce cholesterol absorption, and increase fecal 
sterol excretion
13,14
. In addition, LXR activation significantly enhances the ABCA1- 
and ABCG1-mediated cholesterol efflux to nascent HDL particles and inhibits the 
atherosclerosis development in animal models
15,16
. 
While numerous studies have been dedicated to inhibit the progression of 
atherosclerosis, recent attention has been focused on reversing atherosclerosis, 
which is the regression of existing atherosclerotic plaque. The first evidence of 
dramatic atherosclerotic regression in mice was achieved by Trogan et al via 
robust surgical measures, such as aortic transplantation, to rapidly improve the 
plaque environment
17
. This study suggested that the essential prerequisite 
promoting regression of atherosclerosis lesion is the robust improvement in plasma 
lipoprotein profiles and plaque milieu, including large reductions in plasma 
atherogenic apoB-lipoproteins and brisk enhancements in efflux of cholesterol from 
plaques. Recently, the same group has demonstrated that LXR expression in the 
plaque is required for maximal effects on plaque macrophage egression during 
atherosclerosis regression in mice
18
. 
LXR activation has been shown to significantly up-regulate cholesterol efflux 
activity and inhibit development of atherosclerosis, providing direct evidence for an 
anti-atherogenic effect of LXR agonists
19 , 20
. However, in these studies, LXR 
agonists are only shown to attenuate the progression of atherosclerosis in mouse 
models, while their potential to abrogate pre-existing cardiovascular disease and to 
stabilize the established atherosclerotic lesions has not been widely addressed. It 
is thus interesting to examine whether rapidly improved plasma lipoprotein profiles 
combined with therapeutic LXR agonist-induced activation of RCT and cholesterol 
efflux could lead to atherosclerotic lesion regression. In the current study, we 
specifically evaluated the potential of LXR agonist T0901317 to regress diet-
induced pre-existing atherosclerotic plaque in LDLr
–/–





MATERIALS AND METHODS 
 
Animals  
For the study on LDLr
–/–
 mice, male homozygous LDL receptor-deficient mice 
(LDLr
–/–
; C57BL/6 background) of 12 weeks old were used. The animals were fed 
with semi-synthetic Western-type diet (WTD) containing 15% (w/w) fat and 0.25% 
(w/w) cholesterol (Diet W, Special Diet Services, Witham, UK) for 6 weeks to 
induce the development of atherosclerotic lesions. For the study on C57BL/6 mice, 
female C57BL/6 mice of 12 weeks old were used. The animals were fed with semi-
synthetic cholate-containing cholesterol-enriched atherogenic diet containing 15% 
(w/w) cocoa butter, 1% (w/w) cholesterol, and 0.5% cholate (AB Diets, Woerden, 
The Netherlands) for 16 weeks to induce the development of atherosclerotic 
lesions. After the formation of initial atherosclerotic plaques in both studies, diet 
was switched to regular cholesterol-free chow diet containing 4.3% (w/w) fat (RM3, 
Special Diet Services, Witham, UK) for 3 weeks, with or without supplementation of 
LXR agonist T0901317 (10 mg/kg/day; MSD Oss, The Netherlands). After 
euthanization, mice were bled via orbital exsanguination, and perfused in situ 
through the left cardiac ventricle with ice-cold PBS (pH 7.4) for 20 minutes. Tissues 
were dissected and snap-frozen in liquid nitrogen. Heart and one lobe of the liver 
were dissected free of fat and stored in 3.7% neutral-buffered formalin (Formal-fixx, 
Shandon Scientific Ltd., UK) for histological analysis. Animal care and procedures 
were performed in accordance with the national guidelines for animal 
experimentation. All protocols were approved by the Ethics Committee for Animal 
Experiments of Leiden University. 
 
Plasma lipid analysis 
Plasma lipid analysis was performed at different time points throughout the 
experiments. At the endpoint, mice were not fasted prior to euthanization. Plasma 
concentrations of total cholesterol (TC) and triglycerides (TG) were measured 
using the enzymatic colorimetric assay (Roche Diagnostics, Mannheim, Germany). 
The distribution of cholesterol over different lipoproteins in plasma was determined 
by fast protein liquid chromatography (FPLC) through a Superose 6 column (3.2 x 
30 mm; Smart-System, Pharmacia, Uppsala, Sweden). Cholesterol content of the 
lipoprotein fractions was determined as described above. 
 
Hepatic lipid analysis 
Lipids were extracted from the liver using the Folch method. Briefly, 100 mg of 
tissue was homogenized with chloroform/methanol (1:2). The homogenate was 
centrifuged to recover the upper phase, which was further washed with chloroform-
0.9% NaCl (1:1, pH 1.0). After centrifugation, the lower chloroform phase 
containing lipids was evaporated and the retained lipids were resolubilized in 2% 
Triton X-100 by sonification. Protein contents were analyzed by BCA assay (Pierce 
Biotechnology, Thermo Fisher Scientific BV, IL, USA). Cholesterol content of lipid 
extracts was determined as described above. Data were expressed as milligrams 
of lipid per milligram of protein. 
 
RNA isolation and gene expression analysis 
Total RNA from the liver was isolated using acid guanidinium thiocyanate (GTC)-
phenol-chloroform extraction. Briefly, 500 µL of GTC solution (4 M guanidine 
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isothiocyanate, 25 mM sodium citrate, 0.5% N-lauroylsarcosine) was added to 
each sample, followed by acid phenol:chloroform extraction. The RNA in aqueous 
phase was precipitated with isopropanol. The quantity and purity of the isolated 
RNA were examined using ND-1000 Spectrophotometer (Nanodrop, Wilmington, 
DE, USA). One microgram of the isolated RNA from each sample was converted 
into cDNA by reverse transcription with RevertAid™ M-MuLV Reverse 
Transcriptase (Promega, Madison, WI, USA). Negative controls without addition of 
reverse transcriptase were prepared for each sample. Quantitative real-time PCR 
was carried out using ABI Prism 7700 Sequence Detection system (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
36B4, Beta-actin, and GAPDH were used as internal housekeeping genes. The 
gene-specific primer sequences used are listed in Table 1. Amplification curves 
were analyzed using 7500 Fast System SDS software V1.4 (Applied Biosystems, 
Foster City, CA, USA). The relative expression of each gene was expressed as fold 
changes 2
−(∆∆CT)
 compared to baseline group. Standard error of the mean (SEM) 
and statistical significance were calculated using ∆∆Ct formula. 
 
Table 1. Murine primers for quantitative real-time PCR analysis 
Gene Forward primer Reverse Primer 
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 
Beta-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
GAPDH TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 
ABCA1 GGAGTTCTTTGCCCTCCTGAG AGTTTGCGAATTGCCCATTC 
ABCG1 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 
ABCG5 TGGCCCTGCTCAGCATCT ATTTTTAAAGGAATGGGCATCTCTT 
ABCG8 CCGTCGTCAGATTTCCAATGA GGCTTCCGACCCATGAATG 
SR-BI GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 
LPL CCAGCAACATTATCCAGTGCTAG CAGTTGATGAATCTGGCCACA 
FAS GGCATCATTGGGCACTCCTT GCTGCAAGCACAGCCTCTCT 
CYP7A1 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 
SREBP-1c GGAGCCATGGATTGCACATT CCTGTCTCACCCCCAGCATA 
CD68 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA 
 
Histological analysis 
Accumulation of lipids in the liver and the atherosclerotic plaques at the aortic root 
in the heart was analyzed. The liver and heart was cut latitudinally and embedded 
in O.C.T™ Compound (Tissue-Tek, Sakura finetek, Tokyo, Japan), and 
subsequently sectioned using a Leica CM 3050S cryostat at 10 µm intervals. 
Cryostat sections were stained with Oil-red O (Sigma-Aldrich) to identify lipids, and 
counterstained with hematoxylin (Sigma-Aldrich) to assist in tissue visualization. 
Quantitative analysis of the atherosclerotic lesion area at the aortic root was 
performed in a blinded fashion. Mean lesion area (in µm
2
 per aortic root per mouse) 
was calculated from ten Oil-red O stained cryostat sections, starting at the 
appearance of the tricuspid valves. 
 
Statistical analysis 
Statistical analyses were performed by the unpaired Student’s t-test for 
independent samples (Instat GraphPad software, San Diego, USA). Statistical 













 mice are an established mouse model to study atherogenesis
21 , 22
. To 
evaluate the potential of LXR agonists to regress pre-existing atherosclerotic 
lesions, we fed the LDLr
–/–
 mice with high-fat high-cholesterol Western-type diet 
(WTD) for 6 weeks to develop atherosclerotic plaques. Subsequently, a group of 
mice was sacrificed to obtain baseline data, whilst the remainder of the mice was 
switched to a low-fat cholesterol-free chow diet without or with LXR agonist 
T0901317 supplementation for 3 weeks.  
WTD markedly increased plasma total cholesterol from basal level 235 mg/dL to 
1220 mg/dL. Subsequently, when the atherogenic WTD was switched back to 
cholesterol-free chow diet alone, plasma total cholesterol concentration decreased 
significantly within one week, and after 3 weeks dropped back to almost basal level 
(400 mg/dL; Figure 1A). In contrast, T0901317 treatment supplemented in chow 
diet further increased plasma total cholesterol level up to approximately 2000 
mg/dL, which was 1.6-fold higher than baseline (p<0.001) and 5-fold higher than 
the group fed with chow diet alone (p<0.001) (Figure 1A). As determined by FPLC 
lipoprotein separation, the largely enhanced plasma total cholesterol concentration 
after T0901317 treatment was due to markedly elevated plasma VLDL-cholesterol 
(23-fold; p=0.001) and LDL-cholesterol levels (3-fold; p=0.04) (Figure 1B). 
6 weeks of atherogenic WTD-feeding induced atherosclerotic lesion 




 at aortic root as baseline, visualized by 
oil Red-O staining of cryosections (Figure 1C). After the diet was switched to 
regular chow diet alone, lesion size surprisingly progressed (3-fold; p<0.001) 
despite of the significantly normalized plasma lipoprotein profile in this group 
(Figure 1C). In the mice treated with T0901317, lesion size also increased 3-fold 
(p<0.01) compared to baseline. However, despite its 5-fold higher plasma total 
cholesterol level compared to mice fed with chow diet alone, the increase in the 
lesion size from T0901317-treated mice was not larger than the chow group 
(Figure 1C). It is interesting that the atherosclerotic lesion progression in LDLr
–/–
 
mice was not concomitant with the changes in plasma lipoprotein profiles. We thus 
measured the ratio between the increase in lesion size and the plasma total 
cholesterol concentration. T0901317 induced 7-fold less lesion progression per unit 
of plasma cholesterol concentration compared to mice fed with chow diet alone 
(p<0.001) (Figure 1D). 
Taken together, switching atherogenic WTD to cholesterol-free chow diet 
rapidly normalized plasma lipoprotein profiles, but this measure alone was not 
enough to attenuate atherosclerotic lesion progression or induce lesion regression 
in LDLr
–/–
 mice. LXR agonist treatment in LDLr
–/–
 mice failed to normalize plasma 
lipoprotein profiles, and thus failed to induce regression of pre-existing 
aterhosclerotic lesion. This may be due to the absence of hepatic LDL receptors, 
thus LDLr
–/–
 mice exhibit prolonged half lives of plasma VLDL and LDL
23
. 
Furthermore, the absence of LDL receptor-mediated uptake leads to increased 
(V)LDL synthesis, which is further enhanced by LXR activation
24 , 25
. However, 
T0901317 significantly attenuated the lesion progression per increase of plasma 
cholesterol concentration. 
 































































































































 mice were fed WTD for 6 weeks, after which 
a group of mice was sacrificed (Baseline), whilst the remainder of the mice was switched to regular 
chow diet without (Chow) or with LXR agonist T0901317 supplementation (T09) for 3 weeks. Plasma 
total cholesterol concentration was measured (A). Plasma lipoproteins were separated by FPLC and 
cholesterol level was measured in each fraction. VLDL represents the sum of cholesterol concentrations 
from fraction 2 to 7 (VLDL fractions); LDL represents the sum of cholesterol concentrations from fraction 
8 to 14 (LDL fractions); HDL represents the sum of cholesterol concentrations from fraction 15 to 22 
(HDL fractions) (B). Cryostat sections of the aortic root in heart were stained with oil-red O to identify 
lipids, and the lesion size was quantified (C). The ratio between the change in lesion size and the 






LXR agonist dramatically improved plasma lipoprotein profile in C57BL/6 
mice 
Because the plasma basal level of (V)LDL-cholesterol in C57BL/6 mice is lower 
than in LDLr
–/–
 mice, we set out to evaluate the effects of LXR agonist on plaque 
regression in C57BL/6 mice. The C57BL/6 mouse model has been used to study 
diet-induced atherosclerosis
26,27,28
. This murine model of atherogenesis represents 
an alternative to the use of genetically modified mice with impaired lipoprotein 
clearance, i.e. LDLr
–/–
 mice, for the evaluation of anti-hyperlipidemic agents, 
including LXR agonists
29
. Here we fed C57BL/6 mice with cholate-containing 
cholesterol-enriched atherogenic diet for 16 weeks to induce atherosclerotic plaque 
development. Subsequently, a group of mice were sacrificed to obtain baseline 
data, whilst the remainder of the mice was switched to low-fat cholesterol-free 
chow diet without or with LXR agonist T0901317 supplementation for 3 weeks.  
Atherogenic diet markedly increased plasma total cholesterol level from basal 
30 mg/dL to approximately 300 mg/dL (10-fold; p<0.001). When diet was switched 
to chow diet alone, plasma total cholesterol level decreased significantly within one 
week, and after 3 weeks dropped back to 65 mg/dL (-80%, p<0.001), close to its 
basal level (Figure 2A). In this mouse model, the presence of T0901317 in chow 
diet did not elevate the cholesterol levels, and actually a similar 3-fold reduction in 
plasma total cholesterol concentration was noticed as compared to chow group 
(p<0.001) (Figure 2A). T0901317 did not significantly increase plasma triglycerides 
levels as compared to chow group (Figure 2B). As determined by FPLC lipoprotein 
separation, the largely reduced plasma total cholesterol concentration was majorly 
due to markedly decreased plasma VLDL- and LDL-cholesterol levels. Switching to 
regular chow diet alone significantly reduced plasma (V)LDL-cholesterol 
concentration (4-fold, P < 0.001). T0901317 treatment in C57BL/6 mice did not 
induce elevated (V)LDL-cholesterol levels, and actually reduced plasma (V)LDL-
cholesterol concentration dramatically (28-fold compared to baseline, P < 0.001) 
(Figure 2C).  
In contrast to a decreased plasma HDL-cholesterol level in C57BL/6 mice fed 
with chow diet alone, T0901317 significantly increased the plasma HDL-cholesterol 
concentration (+30%; p<0.05), which was 2-fold higher (p<0.01) than group with 
chow diet alone (Figure 2C). The ratio between HDL- and non-HDL-cholesterol 
concentration was dramatically increased by T0901317 treatment (13-fold; p<0.001) 
(Figure 2C). 
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Figure 2. Effects of LXR agonist on plasma lipids in C57BL/6 mice. C57BL/6 mice were fed 
atherogenic diet for 16 weeks, after which a group of mice was sacrificed (Baseline), whilst the 
remainder of the mice was switched to regular chow diet without (Chow) or with LXR agonist T0901317 
supplementation (T09) for 3 weeks. Plasma total cholesterol (A) and triglycerides (B) concentration 
were measured. Plasma lipoproteins were separated by FPLC and cholesterol level was measured in 
each fraction. VLDL represents the sum of cholesterol concentrations from fraction 2 to 7 (VLDL 
fractions); LDL represents the sum of cholesterol concentrations from fraction 8 to 14 (LDL fractions); 
HDL represents the sum of cholesterol concentrations from fraction 15 to 22 (HDL fractions) (B). The 
ratio between HDL- and non-HDL-cholesterol concentration was calculated (C). Values are means ± 
SEM (8 mice per group). *P<0.05; **P<0.01; ***P<0.001. 
 
LXR agonist dramatically reduced hepatic cholesterol concentration in 
C57BL/6 mice 
Atherogenic diet feeding induced severe liver steatosis in C57BL/6 mice, indicated 
by enlarged liver size (figure not shown) and intensive accumulation of lipids shown 
by oil-Red O staining (Figure 3B). However, switching to regular chow diet rapidly 
reduced liver steatosis. Chow diet alone reduced the hepatic cholesterol content 
significantly (-27%, P<0.05), while T0901317 supplemented in chow further 
reduced hepatic cholesterol content (-63%, P<0.001 compared to baseline; -50%, 
P<0.01 compared to chow group) (Figure 3A). The reduction of cholesterol content 
was visualized as attenuated neutral lipid staining in liver cryosections (Figure 3B). 
In addition to the reduced hepatic cholesterol content, hepatic gene expression of 
macrophage marker CD68 also decreased (-70%, P<0.001) compared to baseline 
(Figure 3C), indicating largely attenuated hepatic macrophage content and 














































































Figure 3. Effects of LXR agonist on hepatic lipids in C57BL/6 mice. Lipids were extracted from liver 
and hepatic cholesterol concentration was measured (A). Cryostat sections of the liver were stained 
with oil-red O to identify lipids, and counterstained with hematoxylin to assist in tissue visualization 
(original magnification: x4) (B). Total RNA was extracted from liver and relative mRNA expression of 
CD68 was assessed by quantitative PCR and presented as fold-change relative to baseline group (C). 
Values are means ± SEM (8 mice per group). *P<0.05; **P<0.01; ***P<0.001. 
 
LXR agonist regulated hepatic gene expression in C57BL/6 mice 
As expected, T0901317 treatment strongly up-regulated the hepatic expression of 
the LXR target genes FAS (p<0.001), SREBP-1c (p<0.001) (Figure 4A), and the 
hepatic triglyceride level (data now shown). This LXR agonist-induced hepatic 




T0901317 significantly up-regulated the hepatic expression of LDL-receptor 
compared to group fed chow diet alone (1.7-fold, P<0.05) (Figure 4B), suggesting 
enhanced LDL uptake by the liver in C57BL/6 mice. In addition, T0901317 
significantly up-regulated the hepatic expression of ABCG5 (4-fold, P<0.05), 
ABCG8 (2.6-fold, P<0.01), and CYP7A1 (1.7-fold, P<0.01) compared to group with 
chow diet alone (Figure 4B), suggesting promoted biliary cholesterol secretion after 
LXR activation. 
 






























































































































































































Figure 4. Effects of LXR agonist on hepatic gene expression profiles in C57BL/6 mice. Total RNA 
was extracted from liver, and relative mRNA expression of FAS, SREBP-1c (A), LDL receptor, ABCG5, 
ABCG8, and CYP7A1 (B) were determined by quantitative PCR and presented as fold-change relative 
to baseline group (C). Values are means ± SEM (8 mice per group). *P<0.05; **P<0.01; ***P<0.001. 
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In line with the elevated plasma HDL-cholesterol level, T0901317 significantly 
increased the hepatic expression of ABCA1 (+75%, P<0.05), ABCG1 (2.3-fold, 
P<0.01), and SR-BI (+70%, P<0.05) compared to chow group (Figure 5), 
suggesting that LXR activation promoted cholesterol efflux and reverse cholesterol 
transport. T0901317 also significantly increased the hepatic expression of 
lipoprotein lipase (LPL) (4.5-fold, P<0.001) (Figure 5), indicating an enhanced 




































































































































Figure 5. Effects of LXR agonist on hepatic expression of reverse cholesterol transport-related 
genes in C57BL/6 mice. Total RNA was extracted from liver, and relative mRNA expression of ABCA1, 
ABCG1, SR-BI, and LPL were determined by quantitative PCR and presented as fold-change relative to 
baseline group (C). Values are means ± SEM (8 mice per group). *P<0.05; **P<0.01; ***P<0.001. 
 
LXR agonist induced atherosclerotic plaque regression in C57BL/6 mice 
After atherogenic diet feeding, C57BL/6 mice developed initial atherosclerotic 




 at aortic root as baseline (Figure 6). Three 
weeks after the diet was switched to chow diet alone, the lesion size stayed 
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, despite of a significantly normalized 
plasma lipoprotein profile. In contrast, T0901317 treatment supplemented in chow 





 (-43%, P<0.05), indicating that LXR agonist treatment successfully 





























Figure 6. Effects of LXR agonist on atherosclerotic lesion development in C57BL/6 mice. Cryostat 
sections of the aortic root in heart were stained with oil-red O to identify lipids, and the lesion size was 





In the current study, we evaluated the potential of LXR agonist T0901317 to 
regress diet-induced pre-existing atherosclerotic plaque in LDLr
–/–
 and C57BL/6 
mouse models. Our results show that LXR activation is crucial for atherosclerotic 
lesion regression. In C57BL/6 mouse with diet-induced lesion, LXR agonist 
supplemented in chow diet rapidly optimized plasma lipoprotein profiles and 
promoted reverse cholesterol transport, and subsequently induced regression of 
pre-existing atherosclerotic plaques.  
The LXR agonist exhibited opposite effects on plasma lipoprotein and 
atherosclerotic lesion development in LDLr
–/–
 and C57BL/6 mice. The unfavorable 
lipoprotein profile induced by LXR agonist in LDLr
–/–
 mice prevented its beneficial 
effects on atherosclerotic lesion formation. The absence of the LDL receptor and 
thus impaired LDL clearance and increased VLDL secretion in LDLr
–/– 
mice 
hampered the LXR agonist-induced lowering of plasma (V)LDL-cholesterol. The 
LDL receptor-mediated cholesterol uptake and feedback regulation are crucial 
when evaluating LDL-lowering effects of compounds
35
. Recent studies have shown 
that when LDL receptor gene was transferred back into hypercholesterolemic 
LDLr
–/–
 mice to restore sustained expression of LDL-receptor protein in the liver, 
there was a drastic reduction in plasma cholesterol and non-HDL cholesterol levels 
and a pronounced regression of advanced atherosclerotic lesions
36,37
. Thus, it is 
proposed that intact LDL receptor is crucial for creating a lipoprotein profile which 
permits the regression of atherosclerotic lesions. 
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Cholesterol-enriched diets are often used to induce or accelerate 
atherosclerotic lesion progression in murine models. It appears that the induction of 
persistent hypercholesterolemia to levels higher than approximately 300 mg/dL is 
required for the development of experimental atherosclerosis in mouse
38
. In the 
current study, atherogenic diet feeding induced persistent hypercholesterolemia 
and initial atherosclerotic plaque development. After switching atherogenic diet to 
regular chow diet, there was a rapid and dramatic reduction in plasma total 
cholesterol level in both LDLr
–/–
 and C57BL/6 mice, indicating that, with dietary 
cholesterol being the major proatherogenic component, low-fat cholesterol-free 
chow diet can largely improve plasma lipoprotein profile to achieve a regressive 
environment. However, despite the improved plasma lipoprotein profile, chow diet 
alone did not induce lesion regression in C57BL/6 mice, while in LDLr
–/–
 mice the 
lesion size even increased. Similar observations were reported in literature where 
switching high-fat atherogenic diet to a standard
 
chow diet led to markedly reduced 
plasma (V)LDL-cholesterol without significant reduction in lesion size
39
, or with 
even significantly increased lesion size
40
. Taken together, our data further 
confirmed that improved plasma lipoprotein profile induced by chow diet alone is 
not enough to trigger atherosclerotic plaque regression. 
The LXR agonist induced plaque regression is due to multiple metabolic effects. 
The LXR agonist T0901317 not only reduced plasma (V)LDL-cholesterol levels, but 
also significantly increased HDL-cholesterol level, leading to a 10-fold increased 
ratio between anti-atherogenic HDL and pro-atherogenic (V)LDL-cholesterol. This 
indicates that LXR agonist, supplemented in chow diet, rapidly optimizes the 
plasma lipoprotein profile and achieves a regressive plasma environment in 
C57BL/6 mice. In addition, the LXR agonist increased the hepatic expression of 
ABCG5, ABCG8, and CYP7A1, indicating down-regulated cholesterol absorption 
and up-regulated biliary sterol secretion
41
. Furthermore, the LXR agonist increased 
the hepatic expression of ABCA1, SRBI, and ABCG1, suggesting increased HDL 




In conclusion, the current study shows that 1) intact LDL receptor function is 
crucial to overcome LXR-induced hyperlipidemia; and 2) rapidly optimized plasma 
lipoprotein profiles combined with LXR agonist induced favorable gene expression 
profiles can induce regression of pre-existing atherosclerotic plaques in C57BL/6 
mice. In addition, our study shows that C57BL/6 mice with diet-induced 
atherosclerotic lesions may provide an alternative model to investigate plaque 
regression without robust surgical measures. Further investigations in more 
humanized animal models may similarly show the potential beneficial effects of 
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Background & Aims: While numerous studies have been dedicated to inhibit the 
development and progression of atherosclerosis, recent attention has been drawn 
to the goal of reversing atherosclerosis, meaning regressing of pre-existing 
atherosclerotic plaques. The aim of this study is to investigate the potential of 
combined macrophage-specific apoE production and LXR agonist treatment to 
induce atherosclerotic plaque regression. 
Methods and Results: ApoE
–/–
 mice were fed with regular chow diet for 16 weeks 
and then switched to an atherogenic diet for another 3 days or 3 weeks to develop 
initial or advanced atherosclerotic lesions. We used bone marrow transplantation 
technique, reconstituting ApoE
–/–
 mice with bone marrow from C57BL/6 mice, to 
restore apoE function in macrophages and normalize plasma lipoprotein profiles. 
Combined with LXR agonist T0901317, we evaluated the potential of LXR 
activation to regress diet-induced pre-existing atherosclerotic plaques. 
Conclusions: Our study shows that 1) ApoE
–/–
 mice reconstituted with bone 
marrow from C57BL/6 mice represents a promising mouse model with chow diet 
feeding to study atherosclerosis regression, providing an alternative model to 
investigate plaque regression; and 2) rapidly optimized plasma lipoprotein profiles, 
combined with LXR agonist treatment, induced favorable gene expression profiles 
that can induce significant regression of both initial and more advanced 
atherosclerotic plaques. 








Hypercholesterolemia plays a key role in the development of atherosclerosis and is 
a causative factor for coronary artery disease
1
. Hyperlipidemia is a metabolic 
disorder defined by elevated levels of plasma low-density lipoprotein (LDL)-
cholesterol and triglycerides concentrations, and/or decreased levels of the athero-
protective high-density lipoprotein (HDL)-cholesterol and its major protein 
component apolipoprotein AI (apoA-I)
2
. Lowering of very-low-density lipoprotein 
(VLDL)- and low-density lipoprotein (LDL)-cholesterol levels leads to a reduction in 
cardiovascular morbidity and mortality2. In contrast, high levels of HDL-cholesterol 
are associated with a decreased risk of cardiovascular disease
3
. HDL serves anti-
atherogenic functions because of its ability to mediate reverse cholesterol transport 
(RCT)
4
. RCT involves the HDL mediated removal of cholesterol from the periphery, 
allowing it to be cleared by the liver and then excreted into bile
5
. Modulation of 
major macrophage mediators in RCT, such as ATP-binding cassette transporter A1 
(ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor 




Hematopoietic cells, in particular monocytes and macrophages, play integral 
roles at all stages of atherosclerosis. The lipid-laden macrophage-derived foam 
cells are present from the earliest discernable fatty-streak lesions to advanced 
plaques, and are key factors in the pathology of plaques
9
. Much of the work 
exploring the role of macrophages in atherosclerosis has been carried out using 
the murine bone marrow transplantation model in which recipient mice prone to 
atherosclerosis development are reconstituted with donor bone marrow cells from 






) mice are one of the most common animal models to 
study atherogenesis. ApoE
–/–





most obvious phenotype of ApoE
–/–
 mice is the spontaneous
 
development of atherosclerotic lesions, even on a regular chow
 
diet which is low in 
fat content and does
 




develop over time from
 
initial fatty streaks to complex lesions, and this process can 
be
 
strongly accelerated by a high-fat, high-cholesterol diet
12
. 
ApoE is a major component of several classes of plasma lipoproteins
13
. 
Increasing evidence from both animal and human studies suggests that apoE is 
able to protect not only against hyperlipidemia, but also against atherosclerosis via 
a variety of mechanisms, including promoting efficient uptake of triglyceride-rich 
lipoproteins from the circulation by peripheral tissues for utilization or by liver for 
excretion, maintaining normal macrophage lipid homeostasis, and enhancing RCT 
from macrophage foam cells in the atherosclerotic lesion
14 , 15 , 16
. Although the 
majority of apoE in plasma originates from the liver, apoE is synthesized by a 
variety of peripheral tissues and cell types, including macrophages
17
. Previous 
studies have shown that reconstruction of macrophage-specific expression of apoE 
reduces atherosclerosis in ApoE
–/–
 mice, whereas reconstitution of C57BL/6 mice 
with macrophages from ApoE
–/–
 mice increases atherosclerosis, suggesting that 
apoE produced by macrophages was
 




While numerous studies have been dedicated to inhibit the development and 
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progression of atherosclerosis, recent attention has been drawn to the goal of 
reversing atherosclerosis, meaning regressing of pre-existing atherosclerotic 
plaques. The first evidence of dramatic atherosclerotic regression in mice was 
achieved via robust surgical measures to rapidly improve the plaque environment
20
. 
This study suggested that the essential prerequisite for promoting regression of 
atherosclerotic lesions is robust improvement of plasma lipoprotein profiles and 
plaque milieu, including large plasma reductions in atherogenic apoB-lipoproteins 
and brisk enhancements in efflux of cholesterol from plaques to the liver. Recently, 
Feig et al showed that the LXR agonist T0901317 promotes egress of monocyte-
derived cells from mouse aortic plaques, indicating that LXR is required for 
maximal effects on plaque macrophage egression during atherosclerosis 
regression in mice
21
. Liver X receptors (LXRs) are sterol-responsive transcription 
factors which regulate expression of genes involved in cholesterol metabolism and 
homeostasis
22
. LXRs act as cholesterol sensors. When cellular oxysterols 
accumulate as a result of increasing concentrations of cholesterol, LXR induces the 
transcription of genes that protect cells from cholesterol overload
23
. LXR activation 
has been shown to significantly promote biliary sterol secretion and reduce 
cholesterol absorption
24,25
, up-regulate cholesterol efflux to HDL particles
26,27
, and 
inhibit development of atherosclerosis, providing direct evidence for an anti-
atherogenic effect of LXR agonists
28,29,30
. However, in those studies, LXR agonists 
are only shown to attenuate the progression of atherosclerosis in mouse models, 
while their potential to abrogate pre-existing cardiovascular disease and to stabilize 
established atherosclerotic lesions has not been widely addressed. It is thus 
clinically interesting to examine whether rapidly improved plasma lipoprotein 
profiles combined with therapeutic LXR agonist could induce atherosclerotic lesion 
regression.  
In the current study, we used bone marrow transplantation technique, 
reconstituting ApoE
–/–
 mice with bone marrow from C57BL/6 mice, to restore apoE 
function in macrophages and normalize plasma lipoprotein profiles. Combined with 
LXR agonist T0901317, we evaluated the potential of LXR activation to regress 
diet-induced pre-existing atherosclerotic plaques. 
 
 
MATERIALS AND METHODS 
 
Animals  
Female homozygous ApoE-deficient (ApoE
–/–
; C57BL/6 background) mice of 12 
weeks old were used. To study the effects on initial atherosclerotic plaques, mice 
were fed with semi-synthetic Western-type diet (WTD) containing 15% (w/w) fat 
and 0.25% (w/w) cholesterol (Diet W, Special Diet Services, Witham, UK) for 3 
days to induce the development of initial atherosclerotic lesions. To study the 
effects on advanced atherosclerotic plaques, the animals were fed with WTD for 3 
weeks to induce the further development of advanced atherosclerotic lesions. After 
the formation of atherosclerotic plaques, in both studies, bone marrow 
transplantation was performed and the diet was switched to regular cholesterol-free 
chow diet containing 4.3% (w/w) fat (RM3, Special Diet Services, Witham, UK) for 
6 weeks, with or without supplementation of the LXR agonist T0901317 (10 
mg/kg/day; MSD Oss, The Netherlands). After euthanization, mice were bled via 
orbital exsanguination, and perfused in situ through the left cardiac ventricle with 
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ice-cold PBS (pH 7.4) for 20 minutes. Tissues were dissected and snap-frozen in 
liquid nitrogen. Heart was dissected free of fat and stored in 3.7% neutral-buffered 
formalin (Formal-fixx, Shandon Scientific Ltd., UK) for histological analysis. Animal 
care and procedures were performed in accordance with the national guidelines for 
animal experimentation. All protocols were approved by the Ethics Committee for 
Animal Experiments of Leiden University. 
 
Bone marrow transplantation 
From one week before bone marrow transplantation, recipient female ApoE
–/–
 mice 
were kept on antibiotics-containing drinking water (83 mg/L ciprofloxacin, 67 mg/L 
polymyxin B sulfate, 6.5 g/L sucrose). To induce bone marrow aplasia, recipient 
ApoE
–/– 
mice were exposed to a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) 
total body X-ray irradiation, using an Andrex Smart 225 Röntgen source (YXLON 
International, Copenhagen, Denmark) with a 6-mm aluminum filter. Bone marrow 
from donor female C57BL/6 mice was harvested by flushing the femurs and tibias 
with PBS (pH 7.4). Single-cell suspensions were prepared by passing the cells 
through a 70 µm cell strainer (BD, Breda, The Netherlands). 0.5 x 10
7
 donor bone 
marrow cells were injected intravenously into the lateral tail vein of each irradiated 
recipient mouse. All transplanted mice were housed in sterilized filter-top cages 
with drinking water containing antibiotics throughout the whole experiment. After 
the mice were euthanized at 6 weeks of regular chow diet feeding, the 
hematological chimerism of the transplanted mouse was assessed by polymerase 
chain reaction (PCR) analysis of DNA harvested from bone marrow to detect the 
presence of the apoE allele. 
 
Plasma lipid analysis 
Plasma lipid analysis was performed at different time points throughout the 
experiments. At the endpoint, mice were not fasted prior to euthanization. Plasma 
concentrations of total cholesterol (TC) and triglycerides (TG) were measured 
using the enzymatic colorimetric assay (Roche Diagnostics, Mannheim, Germany). 
The distribution of cholesterol over different lipoproteins in plasma was determined 
by fast protein liquid chromatography (FPLC) through a Superose 6 column (3.2 x 
30 mm; Smart-System, Pharmacia, Uppsala, Sweden). Cholesterol content of the 
lipoprotein fractions was determined as described above. 
 
RNA isolation and gene expression analysis 
Total RNA from the liver was isolated using acid guanidinium thiocyanate (GTC)-
phenol-chloroform extraction. Briefly, 500 µL of GTC solution (4 M guanidine 
isothiocyanate, 25 mM sodium citrate, 0.5% N-lauroylsarcosine) was added to 
each sample, followed by acid phenol:chloroform extraction. The RNA in the 
aqueous phase was precipitated with isopropanol. The quantity and purity of the 
isolated RNA were examined using an ND-1000 Spectrophotometer (Nanodrop, 
Wilmington, DE, USA). One microgram of the isolated RNA from each sample was 
converted into cDNA by reverse transcription with RevertAid™ M-MuLV Reverse 
Transcriptase (Promega, Madison, WI, USA). Negative controls without addition of 
reverse transcriptase were prepared for each sample. Quantitative real-time PCR 
was carried out using ABI Prism 7700 Sequence Detection system (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
36B4, Beta-actin, and GAPDH were used as internal housekeeping genes. The 
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gene-specific primer sequences used are listed in Table 1. Amplification curves 
were analyzed using 7500 Fast System SDS software V1.4 (Applied Biosystems, 
Foster City, CA, USA). The relative expression of each gene was expressed as fold 
changes compared to baseline group. 
 
Table 1. Primers for quantitative real-time PCR analysis 
Gene Forward primer Reverse Primer 
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 
Beta-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
GAPDH TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA 
ABCA1 GGAGTTCTTTGCCCTCCTGAG AGTTTGCGAATTGCCCATTC 
ABCG1 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 
ABCG5 TGGCCCTGCTCAGCATCT ATTTTTAAAGGAATGGGCATCTCTT 
ABCG8 CCGTCGTCAGATTTCCAATGA GGCTTCCGACCCATGAATG 
ApoA-I ACTCTGGGTTCAACCGTTAGTCA TCCCAGAAGTCCCGAGTCA 
ApoE AGCCAATAGTGGAAGACATGCA GCAGGACAGGAGAAGGATACTCAT 
SR-BI GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 
LPL CCAGCAACATTATCCAGTGCTAG CAGTTGATGAATCTGGCCACA 
FAS GGCATCATTGGGCACTCCTT GCTGCAAGCACAGCCTCTCT 
CYP7A1 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 
SREBP-1c GGAGCCATGGATTGCACATT CCTGTCTCACCCCCAGCATA 
CD68 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA 
 
Histological analysis 
Accumulation of lipids in the atherosclerotic plaques at the aortic root in the heart 
was analyzed. The heart was cut latitudinally and embedded in O.C.T™ 
Compound (Tissue-Tek, Sakura finetek, Tokyo, Japan), and subsequently 
sectioned using a Leica CM 3050S cryostat at 10 µm intervals. Cryostat sections 
were stained with Oil-red O (Sigma-Aldrich) to identify lipids, and counterstained 
with hematoxylin (Sigma-Aldrich) to assist in tissue visualization. Quantitative 
analysis of the atherosclerotic lesion area at the aortic root was performed in a 
blinded fashion. Mean lesion area (in µm
2
 per aortic root per mouse) was 
calculated from 10 Oil-red O stained cryostat sections, starting at the appearance 
of the tricuspid valves. 
 
Immunohistochemistry 
Ten-micrometer cryosections of the aortic root were obtained as described above. 
After incubation with blocking solution (5% goat serum), macrophages were 
detected using MOMA-2 antibody (rat antibody directed against murine 
monocytes/macrophages, Serotec, Oxford, UK). A rabbit anti rat IgG/HRP was 
used as second antibody (Dako, Heverlee, Belgium). Sections were developed 
using NovaRED Peroxidase Substrate Kit (VECTOR LABORATORIES, 
Peterborough, UK) according to kit instructions. Slides were counterstained with 
hematoxylin (Sigma-Aldrich) to assist in tissue visualization. 
 
Masson’s Trichrome Staining 
Tissue sections were prepared as described above and subjected to Masson’s 
trichrome staining using the Masson’s Trichrome Stain kit (Sigma-Aldrich) and 
counterstained with hematoxylin, to assess the extent of collagen deposition and 
the structural integrity of fibrillar collagen in the plaque. 
 
Statistical analysis 
Mean values between two groups were analyzed with the unpaired Student’s t-test; 
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data sets containing multiple groups were analyzed by ANOVA (Instat GraphPad 
software, San Diego, USA). Statistical significance was defined as p<0.05. Data 





To investigate the potential of combined macrophage-specific apoE production and 
LXR agonist treatment to induce atherosclerotic plaque regression, bone marrow 
transplantation was performed to selectively express apoE in bone marrow-derived 
hematopoietic cells, including macrophages. We started our investigation with 
initial atherosclerotic lesions, which was thought to form an easier target for 
regression. Hereto we fed female ApoE
–/–
 mice with regular chow diet for 16 weeks 
and then switched to an atherogenic WTD for another 3 days to develop initial 
atherosclerotic lesions. In addition, we also evaluated the regression of advanced 
atherosclerotic lesions in the same model. Here we fed female ApoE
–/–
 mice with 
regular chow diet for 16 weeks and then switched to an atherogenic WTD for 
another 3 weeks to develop more advanced atherosclerotic lesions. A group of 
mice were sacrificed to obtain baseline data, whilst the remainder of the mice 
received bone marrow from either C57BL/6 mice, or from original ApoE
–/–
 mice as 
a control group for the BMT procedure. After bone marrow transplantation, mice 
were fed low-fat cholesterol-free chow diet with or without LXR agonist 
supplementation for 6 weeks, during which the plasma lipid concentrations were 
monitored over regression period. 
 


























































Figure 1. Overview of changes in plasma total cholesterol level during regression studies in initial 
lesions (A) and advanced lesions (B). We fed female ApoE
–/–
 mice with regular chow diet for 16 weeks 
and then switched to an atherogenic WTD for 3 days (A) or 3 weeks (B) to develop initial and advanced 
atherosclerotic lesions, respectively. A group of mice were then sacrificed to obtain baseline data, whilst 
the remainder of the mice received bone marrow from either C57BL/6 mice, or from original ApoE
–/–
 
mice as a control group for the BMT procedure. After bone marrow transplantation, mice were fed low-
fat cholesterol-free chow diet with or without LXR agonist T0901317 supplementation for 6 weeks, 
during which the plasma lipid concentrations were monitored. Values are means ± SEM (10 mice per 
group). BL/6: Bone marrow from wildtype C57BL/6 mice. ApoE
–/–
: Bone marrow from ApoE
–/–
 mice. T09: 







Reconstitution of macrophage apoE dramatically normalized plasma 





 mice, WTD markedly increased plasma total cholesterol level to 
approximately 730 mg/dL in the initial lesion study (Figure 1A) and 950 mg/dL in 
advanced lesion study (Figure 1B). Bone marrow from apoE containing donor 
C57BL/6 mice was transplanted into ApoE
–/–
 mice and a diet switch to low-fat chow 
diet led to a sharp drop in plasma total cholesterol level within 3 weeks to 188 
mg/dL (-74%) in the initial lesion study and 120 mg/dL (-87%) in advanced lesion 
study, and these levels remained low until 6 weeks after BMT (Figure 1A, 1B). The 
presence of LXR agonist in chow diet did not change the cholesterol levels, and 
actually a similar persistent reduction in plasma total cholesterol concentration was 
noticed (Figure 1A, 1B). In contrast, the cholesterol levels in the control group 
where ApoE
–/–
 mice received bone marrow from original ApoE
–/–
 mice started to 
rise again after an initial drop and displayed a significantly higher plasma total 
cholesterol level compared to ApoE
–/–
 mice with bone marrow from C57BL/6 mice 
(Figure 1B). At 6 weeks after BMT, in both initial and advanced lesion studies, 
ApoE
–/–
 mice with bone marrow from C57BL/6 mice showed approximately 90% 
reduction in plasma cholesterol level compared to baseline and there was no 
significant difference between mice fed chow diet alone or with LXR agonist 
treatment; Control ApoE
–/–
 mice with bone marrow from ApoE
–/–
 mice showed 
significantly higher plasma cholesterol level compared to mice with wildetype 
C57BL/6 bone marrow, especially when treated with LXR agonist (Figure 2A, 2C). 
As expected, LXR agonist significantly increased plasma triglycerides levels as 
compared to mice fed with chow diet alone in both the initial lesion study (1.4-fold, 
Figure 2B) and advanced lesion study (2.3-fold, Figure 2D). 
As determined by FPLC lipoprotein separation, the largely reduced plasma total 
cholesterol concentration in ApoE
–/–
 mice with C57BL/6 bone marrow was primarily 
due to markedly reduced plasma VLDL- (-94%, P < 0.001 in initial lesions; -97%, P 
< 0.001 in advanced lesions) and LDL- (-82%, P < 0.001 in initial lesions; -91%, P 
< 0.001 in advanced lesions) cholesterol level (Figure 3A, 3C). LXR agonist 
treatment increased the plasma HDL-cholesterol concentration in ApoE
–/–
 mice 
with C57BL/6 bone marrow compared to baseline (1.6-fold in initial lesions; 1.7-fold, 
P < 0.05 in advanced lesions; Figure 3B, 3D). In conclusion, after transplanting 
bone marrow from C57BL/6 mice into ApoE
–/–
 mice, combined with a switch to 
chow diet with or without LXR agonist, successfully normalized the plasma 
cholesterol profile. 
 





























































































































































































Figure 2. Plasma concentration of total cholesterol and triglycerides from initial lesion study (A, B) 
and advanced lesion study (C, D) at endpoint of experiments were measured. Values are means ± SEM 


























































































































































































































































Figure 3. Plasma lipoproteins profile in initial lesion study (A, B) and advanced lesion study (C, D) at 
endpoint of experiments. Plasma lipoproteins were separated by FPLC and cholesterol level was 
measured in each fraction. VLDL represents the sum of cholesterol concentrations from fraction 2 to 7 
(VLDL fractions); LDL represents the sum of cholesterol concentrations from fraction 8 to 14 (LDL 
fractions); HDL represents the sum of cholesterol concentrations from fraction 15 to 22 (HDL fractions) 
(B). Values are means ± SEM (10 mice per group). *P<0.05; **P<0.01; ***P<0.001; ns, not significant. 
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LXR agonist regulated hepatic gene expression in ApoE
–/–
 mice reconstituted 
with C57BL/6 bone marrow 
As expected, LXR agonist treatment increased the liver weight (data not shown) 
and strongly up-regulated the hepatic expression of LXR target genes SREBP-1c, 
FAS, and LPL compared to mice fed chow diet alone (Figure 4A, 4B). This LXR 
agonist-induced hepatic lipogenesis has been well established as a positive control 
for LXR activation in mice
31,32
. 
After transplanting C57BL/6 bone marrow into ApoE
–/–
 mice, the mRNA 
expression of apoE showed up in the liver. LXR agonist treatment further up-
regulated the hepatic gene expression of apoE compared to group fed chow diet 
alone (2-fold, P<0.001 in initial lesions; 1.7-fold, P<0.001 in advanced lesions) 
(Figure 5A, 5D). In addition, LXR agonist treatment significantly up-regulated the 
hepatic expression of ABCG5 and ABCG8 compared to group fed chow diet alone 
(Figure 5B, 5E), suggesting promoted biliary cholesterol secretion upon LXR 
activation. 
In line with the significantly elevated plasma HDL-cholesterol level in ApoE-/- 
mice reconstituted with C57BL/6 bone marrow, LXR agonist treatment significantly 
increased the hepatic expression of ABCG1 (1.4-fold, P<0.05 in initial lesions; 2.3-
fold, P<0.001 in advanced lesions) and ApoA-I (1.6-fold, P<0.001 in advanced 
lesions) compared to the chow group (Figure 5C, 5F), suggesting that LXR 






















































































































































































































































































Figure 4. Changes in hepatic gene expression profiles during regression studies in initial lesions 
(A) and advanced lesions (B). Total RNA was extracted from liver, and relative mRNA expression of 
SREBP-1c, FAS, CYP7A1, and LPL were determined by quantitative PCR and presented as fold-
change relative to baseline group (C). Values are means ± SEM (10 mice per group). *P<0.05; **P<0.01; 
***P<0.001; ns, not significant. 
 
 


























































































































































































































































































































































































































































































Figure 5. Changes in hepatic gene expression profiles during regression studies in initial lesions 
(A, B, C) and advanced lesions (D, E, F). Total RNA was extracted from liver, and relative mRNA 
expression of ApoE, ABCG5, ABCG8, ApoA-I, and ABCG1 were determined by quantitative PCR and 
presented as fold-change relative to baseline group (C). Values are means ± SEM (10 mice per group). 
*P<0.05; **P<0.01; ***P<0.001; ns, not significant. 
 




With WTD feeding, ApoE
–/–









 in advanced 
lesion study at baseline (Figure 6B). In control mice reconstituted with ApoE
–/–
 
bone marrow, plaque size did not decrease after 6 weeks of chow diet feeding, with 
or without LXR agonist supplementation (Figure 6B). In contrast, six weeks after 
transplanting wildtype C57BL/6 bone marrow into ApoE
–/–
 mice, with chow diet 











(-23%, P<0.01) in 
advanced lesions (Figure 6B). LXR agonist treatment further reduced lesion size 




 in initial lesions (-71%, P<0.001 compared to Baseline; 





advanced lesions (-36%, P<0.001 compared to Baseline; -17%, P=0.06 compared 
to chow group; Figure 6B). The results indicated that this ApoE-/- mice model 
reconstituted with wildetype C57BL/6 bone marrow is an interesting new model to 






























































































































Figure 6. Changes in atherosclerotic lesion size during regression studies in initial lesions (A) and 
advanced lesions (B), and comparison of lesion size from both studies expressed as percentage of 
baseline lesion (C). Cryostat sections of the aortic root in heart were stained with oil-red O to identify 
lipids, and the lesion size was quantified. Values are means ± SEM (10 mice per group). **P<0.01; 
***P<0.001; ns, not significant. 
 
LXR agonist reduced plaque macrophage content during atherosclerosis 
regression 
Further analysis of atherosclerotic lesion composition showed that the collagen 
content of the plaque in initial lesions decreased after bone marrow reconstitution 
with chow diet alone (-66%, P<0.001), and LXR agonists further reduced the 
collagen amount in initial plaques (-81%, P<0.001 compared to Baseline; -45%, 
P<0.01 compared to chow group (Figure 7A). However, in advanced plaques, 
despite the significant reduction of plaque size after BMT, the collagen content of 
plaque in ApoE
–/–
 mice with wildtype C57BL/6 bone marropw remained the same, 
with or without treatment of LXR agonist (Figure 7B). In contrast, the absolute 
macrophage-positive area and percentile of area of the lesion occupied by 
macrophages decreased dramatically in accordance to the reduction of total lesion 
size. In the initial lesion induced by 3 days of WTD feeding, the size of 




 at aortic root as baseline (Figure 8A). 
In the advanced lesion induced by 6 weeks of WTD feeding, the size of 




 at aortic root as baseline (Figure 8B). 
Six weeks after transplanting wildtype C57BL/6 bone marrow into ApoE
–/–
 mice, the 
macrophage-positive area decreased significantly in both studies with chow diet 
alone (-43%, P<0.05 in initial lesions; -96%, P<0.01 in advanced lesions; Figure 8A, 
8B). LXR agonist treatment further reduced the plaque macrophage content 
significantly in both initial lesions (-70%, P<0.001 compared to Baseline; -50%, 
P<0.01 compared to chow group) and in advanced lesions (-100%, P<0.01 
compared to Baseline; -100%, P<0.01 compared to chow group) (Figure 8A, 8B) 
that no positive macrophage-staining was visible anymore. The results indicated 
that the reduction in plaque size observed in this mouse model was primarily due to 
the decreased macrophage content in the plaques. 
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Figure 7. Changes in size of collagen area in atherosclerotic plaques during regression studies 
in initial lesions (A) and advanced lesions (B) were measured. Cryostat sections of the aortic root in 
heart were stained with Masson’s Trichrome Stain kit and counterstained with hematoxylin to assess the 
extent of collagen deposition and the structural integrity of fibrillar collagen in the plaque. Size of 
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Figure 8. Changes in size of macrophage-positive area in atherosclerotic plaques during 
regression studies in initial lesions (A) and advanced lesions (B) were measured. Cryostat sections of 
the aortic root in heart were stained with MOMA-2 antibody (rat antibody directed against murine 
monocytes/macrophages) and rabbit anti rat IgG/HRP to identify macrophage-positive area. Sections 
were developed using NovaRED Peroxidase Substrate Kit, and the size of macrophage-positive area 






In the current study, we set up a new mouse model to study atherosclerotic lesion 
regression. Our results show that ApoE
–/–
 mice reconstituted with bone marrow 
from wildtype C57BL/6 mice form a promising model to induce rapidly normalized 
plasma lipoprotein profiles and the regression of pre-existing atherosclerotic 
plaques. 
In previous studies where dramatic regression of large advanced lesions was 
achieved with or without LXR agonist
20,21
, surgical aorta transplantation into 
wildtype mice was performed to rapidly improve the atherosclerotic plaque milieu. 
In our study, we used the BMT procedure to induce plaque regression, which 
raises the opportunity to analyze the relative importance of individual genes in 
hematopoietic cells for plaque regression, by using specific knockout mice as bone 
marrow donors. 
Bone marrow transplantation leads to the replacement of bone marrow-derived 
cells, including recipient tissue macrophages by cells of donor origin. After 
transplantation of bone marrow from mice with wildtype apoE expression into 
ApoE
–/–
 mice, we observed rapid improvement and normalization of the plasma 
cholesterol profile. This cholesterol lowering effect of macrophage-derived apoE 
was reported in previous studies, where apoE of donor origin was present in the 
recipient peripheral circulation as early as 2 weeks after transplantation, and by 4 
weeks, apoE production by bone marrow-derived cells was sufficient to normalize 




. The apoE level in circulation after 
BMT was only 12.5% of those in wildtype mice but nevertheless sufficient to reduce 
the severe hypercholesterolemia of ApoE
–/–
 mice, due to accelerated hepatic 
clearance of plasma cholesterol and promoted cholesterol efflux
19,35,36
. 
Raffai et al for the first time addressed the apoE-mediated mechanisms of 
atherosclerosis regression
37
. They demonstrate that apoE promotes the regression 
of atherosclerosis independently of lowering plasma cholesterol levels. In contrast, 
a study from Shi et al concluded differently. They demonstrated that regression of 
atherosclerotic lesions is a slow process and macrophage-derived apoE was 
insufficient to induce significant regression of established atherosclerotic lesions in 
ApoE
–/–
 mice, although it was sufficient to eliminate hypercholesterolemia and 
prevent progression of aortic lesions34. The difference in conclusions between 
their study and our current observations may come from the differences in 
experimental set-up.  
Study from Zhao et al showed that in both LDLr
–/–
 and C57BL/6 mice, switch of 
an atherogenic diet to regular chow diet could not trigger lesion regression despite 
a rapid and dramatic reduction in plasma total cholesterol levels. In LDLr
–/–
 mice, 
lesion sizes even increased despite the cholesterol lowering
38
. Similar observations 
were reported where switching high-fat atherogenic diet to a standard
 
chow diet led 
to markedly reduced plasma (V)LDL-cholesterol without significant reduction in 
lesion size37, or with even significantly increased lesion size
39
. In the current study 
with BMT procedure, chow diet alone induced a significant regression of both initial 
and advanced plaques, which was in accordance with study from Bengtsson et al 
where ApoE
–/–
 mice were transplanted with wildtype bone marrow and a 35% 
plaque regression was observed
40
. Taken together, our data confirmed that ApoE
–
/–
 mice reconstituted with wildtype C57BL/6 bone marrow is a valid regression 
mouse model. 
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We performed this regression study in parallel on initial and advanced lesions. 
The atherosclerotic plaque is a dynamic tissue, where increases in cell number 
(driven by cell proliferation and migration) and decreases in cell number (driven by 
cell death and possibly emigration) are continuous processes
41
. Initial 
atherosclerotic lesions are primarily composed of lipid-loaded macrophages. Stable 
advanced lesion contains a macrophage core, a small necrotic core, if present at 
all, extracellular matrix and a firm fibrous cap of smooth muscle cells (SMCs)
42
. 
Instable advanced atherosclerotic lesions are characterized by a thin fibrous cap 
containing few SMCs and overlying a large necrotic core composed of dead cells, 
lipid deposits, and cellular debris
43
. For long it has been thought that advanced 
lesion could not regress since they contain thick fibrous cap, large amount of 
necrotic material, extracellular lipids and extracellular matrix. In the current study, 
we showed that via the bone marrow transplantation technique, successful plaque 
regression can be induced in both initial and advanced lesion. The current mouse 
model is thus a good model to study atherosclerosis regression in different stages 
of the disease. 
LXR agonists have potent anti-atherogenic effects in different hyperlipidemic 
mouse models. Several studies have demonstrated that activation of LXR 
significantly up-regulated cholesterol efflux activity and inhibited the development 
of atherosclerosis29
,
30. However, the ability of LXR agonists to abrogate pre-
existing cardiovascular disease by inducing regression and stabilization of 
established atherosclerotic lesions has not been widely addressed. We used LXR 
agonist treatment in our mouse model to assess the potential of LXR activation to 
induce atherosclerosis regression. The LXR agonist T0901317 not only reduced 
plasma (V)LDL-cholesterol levels, but also significantly increased HDL-cholesterol. 
This indicates that LXR agonist, supplemented in chow diet, rapidly optimizes the 
plasma lipoprotein profile and achieves a regressive plasma environment in this 
mouse model. In addition, compared to group fed with chow diet alone, LXR 
agonist treatment in this study induced further 48% reduction in initial lesion size, 
17% reduction in advanced lesion size, and also a further 50% reduction in the 
macrophage-positive area size in initial lesions. In advanced lesions, there was 
merely visible macrophage-positive staining observed in LXR agonists treated 
group, indicating the diminishing of macrophages during atherosclerotic regression 
in our mouse model. Combined, our results were in line with findings from Feig et 
al21 that LXR activation is necessary for maximal effects on plaque macrophage 
content reduction during atherosclerosis regression in mice. 
To further analyze the dynamics and the cellular cause of the rapid reduction of 
total plaque size, we examined the lesion composition in detail. The atherosclerotic 
plaque is a complicated structure. In addition to cholesterol-filled macrophage core, 
it contains large numbers of immune cells, SMCs, vascular endothelial cells, and a 
large amount of extracellular
 
matrix products that includes sulfated 
glycosaminoglycans, collagen, fibrin, and extracellular lipids
44
. The complexity of 
atherosclerosis
 
is highlighted by the multifaceted effects that apoptosis and
 
proliferation of specific cell types can have on vessels at
 
different stages of the 
disease
45
. In initial lesions, a 45% reduction in lesion size was observed with chow 
diet alone, and even a 71% reduction with LXR agonist treatment, whilst in 
advanced lesions there was only a 23% reduction with chow diet alone, and a 36% 
reduction with LXR activation. This can be explained by the difference in plaque 
composition and characteristics between initial and advanced lesion. Initial lesions 
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contain primarily cholesterol-filled macrophages, while in advanced lesion, SMCs 
and extracellular
 





. SMCs and extracellular
 
matrix products remained 
unchanged and are more difficult to be modulated during the regression process. 
Therefore, the extent of lesion size reduction was smaller in advanced lesions 
compared to initial lesions. 
Interestingly, our lesion composition analysis showed that the reduction of total 
lesion size during regression was primarily due to the reduction and diminishing of 
macrophage content in the plaque. The fate of the macrophages during lesion 
regression is currently under debate. It has been proposed that regression is not 
merely a rewinding of progression, but instead involves induction of CCR7 
expression, a mediator of leukocyte emigration, in foam cells and emigration of the 
maladaptive macrophage infiltrate, followed by the initiation of influx of healthy 
phagocytes that mobilize necrotic debris and all other components of advanced 
plaques
47
. Interestingly, Ye et al showed that macrophage infiltration into pre-
existing advanced lesions was limited, likely because of the formation of fibrous 
caps
48
. In contrast, Potteaux et al also showed that regression of atherosclerosis 
after apoE complementation in ApoE
–/–
 mice did not involve migratory egress of 
macrophages from plaques or induction of CCR7. Instead, marked suppression of 
monocyte recruitment coupled with a stable rate of apoptosis accounted for loss of 
plaque macrophages, suggesting that therapies to inhibit monocyte recruitment to 
plaques may constitute a viable strategy to reduce plaque macrophage burden 
than attempts to promote migratory egress
49
. Further research is necessary to 
establish the processes and mechanisms underlying the diminished macrophage 
content during regression in our experimental mouse model. 
In conclusion, our current study shows that 1) ApoE
–/–
 mice reconstituted with 
bone marrow from C57BL/6 mice represents a promising mouse model with chow 
diet feeding to study atherosclerosis regression, providing an alternative model to 
investigate plaque regression; and 2) rapidly optimized plasma lipoprotein profiles, 
combined with LXR agonist treatment, induced favorable gene expression profiles 
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GENERAL DISCUSSION AND PERSPECTIVES 
 
 
Atherosclerosis is the underlying cause of most cardiovascular diseases
1
. 
Hypercholesterolemia holds a key role in the development of atherosclerosis and is 
a causative factor for coronary artery disease
2
. Lowering of VLDL- and LDL-
cholesterol levels leads to a reduction in cardiovascular morbidity and mortality
3
. In 
contrast, high levels of HDL-cholesterol are associated with a decreased risk of 
cardiovascular disease
4
. This dissertation is dedicated to the regulation of lipid 
metabolism pathways and its subsequent effects on atherosclerotic lesion 
progression and regression. 
 
 
1. Hepatic lipid metabolism and pharmaceutical interventions in the liver 
Atherosclerosis is a liver disease of the heart
5
. Liver is considered as the major 
organ with significant therapeutic importance for the maintenance of metabolic 
homeostasis
6
. The first part of the thesis focuses on the hepatic lipid metabolism 
and the pharmaceutical interventions in the liver. 
 
1.1 Nuclear receptors in the liver: potential targets for pharmaceutical 
interventions 
Nuclear receptors (NRs) are ligand-activated transcription factors that act as 
sensors for a broad range of natural and synthetic ligands. A growing number of 
NRs have been identified as regulators in lipid metabolism and energy utilization
7
. 
Moreover, NRs control hepatic inflammation, regeneration, fibrosis, and tumor 
formation. Therefore, NRs are crucial for understanding the pathogenesis and 
pathophysiology of a wide range of hepatic disorders. Targeting NRs and their 




In Chapter 2, we have composed the hepatic cell type-specific expression 
profile of NRs to provide the most complete quantitative assessment of NRs 
distribution in the liver reported to date. We have identified several liver-enriched 
orphan NRs as potential novel targets for pharmaceutical interventions. Specifically, 
members of the orphan receptor family COUP-TFs showed distinguished 
distributions in liver. COUP-TF3 was abundantly and exclusively expressed in liver 
parenchymal cells, while the other two members, COUP-TF1 and COUP-TF2, were 
expressed exclusively in non-parenchymal cells. Despite the moderate to high 
expression level in the liver, the physiological functions of COUP-TFs have not 
been fully exploited, and the ligand for COUP-TFs has not been identified. Our 
study suggests a physiologic important role of COUP-TF3 in hepatocytes, and that 
of COUP-TF2 in endothelial cells and macrophages. Previous studies have shown 
that the activity of COUP-TFs is associated with the transcriptional regulation of a 
number of genes expressed mainly in the liver
9
. COUP-TF2 and COUP-TF3 have 
been generally considered to be repressors or regulators for transcription of NRs 
such as RARs, TRs, PPARs, and HNF4alpha
10
. The cellular distribution pattern 
from the present study suggests that COUP-TF3, given its high expression in liver 
parenchymal cells, may have a potential role in hepatic lipid and xenobiotic 
metabolism regulation via cross-talking with other liver-enriched NRs. Our study 
identifies COUP-TF2 as highly expressed in endothelial cells, which is in 
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accordance with published data upon the role of COUP-TF2 in angiogenesis and 
generation of haematopoietic cell clusters
11
. In addition, COUP-TF2 was shown to 
have a potential role in regulation of cholesterol homeostasis
12
. The observation 
from our current study that the expression of COUP-TF2 is as high as NGFIB in 
Kupffer cells raises interest to further investigate whether COUP-TF2 is involved, 
similarly as NGFIB, in lipid metabolism in macrophages.  
We used real-time quantitative PCR to gain the expression profiles of NRs. It is 
a standardized method in the NR field to characterize the expression pattern of 
individual receptors in tissue or cells. It provides a simple but powerful way to 
obtain comprehensive understanding of the distribution and biological functions of 
NRs
13
. Real-time quantitative PCR has been applied in numerous studies to profile 
the expression pattern of NRs in tissues representing diverse anatomical systems 
under various pharmacological conditions and genotypes
14,15
. However, because 
NRs are transcription factors, the regulation of NRs are not only at the mRNA level, 
but also on the protein activity level. Therefore, it is important to further extend the 
gene expression profiles of NRs into their protein expression and/or functionality 
profiles by using immunohistochemical staining or flow cytometry. Furthermore, in 
addition to the hepatic endothelial cells and Kupffer cells, which were investigated 
in the current study, hepatic stellate cells are also major repositories for lipids, 
being activated during chronic liver injury and mediating the fibrotic response
16,17
. It 
is thus interesting to include in future studies the hepatic stellate cells when 
investigating gene expression profiles of NRs in the liver. 
 
1.2 Niacin regulates hepatic lipid metabolism and CETP expression 
The use of statins in patients with high risk for cardiovascular disease (CVD) has 
resulted in a 30-40% decrease in clinical events in the last couple of decades. 
However, despite of a marked reduction (up to 60%) in LDL-C, about 30% of 
patients continue to have CVD events
18
. Therefore, HDL has become the next 
promising therapeutic target. The anti-dyslipidemic drug niacin, also known as 
nicotinic acid, not only lowers plasma levels of pro-atherogenic lipids/lipoproteins
19
, 
but also is the most effective agent available to increase HDL-cholesterol
20,21
. 
Several clinical trials have shown that niacin reduces cardiovascular disease and 
myocardial infarction incidence, providing an emerging rationale for the use of 
niacin in the treatment of atherosclerosis
22,23
. Only recently, it has been shown that 
niacin also reduces the hepatic expression and plasma levels of the pro-
atherogenic CETP
24
. In Chapter 4 we investigated the mechanism underlying the 
CETP-lowering effect of niacin. We propose that the primarily reduced hepatic 
cholesterol accumulation via the lipid-lowering effect of niacin leads to attenuated 
hepatic inflammation, and thus less macrophage infiltration into and/or increased 
macrophage emigration out of the liver. The decreased amount of hepatic 
macrophages, which are significant contributors of CETP, leads to an overall 
reduction in hepatic CETP expression and a lower plasma CETP level. In 
conclusion, we have shown that niacin does not directly alter macrophage CETP 
expression, but attenuates the liver inflammation and macrophage content in 
response to its primary lipid-lowering effect, which leads to a decrease in hepatic 
CETP expression and the plasma CETP mass. Our study sheds a new light on the 
mechanism underlying the CETP-lowering effect of niacin in CETP transgenic mice. 
Niacin receptor GPR109A is highly expressed in adipose tissue. Interestingly, 
adipose tissue appears to be a highly conserved site of CETP expression across 
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species. Adipose tissue CETP makes a major contribution to CETP in the 
circulation, reduces HDL, and increases non-HDL cholesterol levels. Adipose 
tissue CETP plays a local role in adipocyte cholesteryl ester accumulation from 
HDL, indicating a novel role of CETP in modulating adiposity. It is thus of interest to 




 demonstrated for the first time the critical role of CETP in 
niacin-mediated HDL-elevation by using CETP tg mice and suggested that 
transgenic mice expressing the human CETP could be a useful animal model for 
studying the established HDL-regulating effect of niacin. However, in the current 
study we did not observe the HDL-raising effect of niacin in CETP Tg mice. This 
might be due to diet differences. Hernandez et al used regular chow diet 
supplemented with niacin, while we used WTD diet which contains more fat and 
0.25% cholesterol that has been shown to upregulate CETP expression. 
Furthermore, although niacin significantly increased hepatic apoA-I expression in 
our study, the hepatic expression of ABCA1, which is involved in apoA-I-mediated 
cholesterol efflux, significantly decreased by 45% at the same time upon niacin 
treatment, which can ultimately result in unchanged HDL formation in plasma. 
Interestingly, our observations corroborate recent data from Li et al
26
, who showed 
that niacin-mediated activation of GPR109A in liver led to reduced hepatocyte 
ABCA1 expression and thus an unexpectedly reduced plasma HDL-C level in 
C57BL/6J mice. The current study was set out to investigate the mechanism 
underlying the hepatic and plasma CETP-lowering effect of niacin in mice, instead 
of determining the mechanism of HDL-C elevation by niacin. This mechanistic 
approach in a mouse model thus differs from a clinical investigation. 
Recent unexpected termination of AIM-HIGH Clinical Trial on niacin and HDL 
hypothesis has drawn much attention. AIM-HIGH is the first large randomized trial 
to evaluate the effect of niacin on cardiovascular events among statin-treated 
patients with established atherosclerotic cardiovascular disease who are at the 
desired level for LDL-C but who have residual abnormalities in HDL-C and 
triglycerides. It was meant to test whether adding high dose, extended-release 
niacin to a statin (simvastatin) is better than a statin alone in reducing long-term 
cardiovascular events in participants
27
. The trial was started in September 2005, 
but was stopped early due to the lack of incremental benefit on cardiovascular risk 
reduction in the extended-release niacin plus simvastatin treatment group over 
simvastatin alone. At this time, the FDA has made no new conclusions or 
recommendations regarding the use of extended-release niacin alone or in 
combination with simvastatin or other statins
28
. The lack of additional effect of 
niacin on cardiovascular events is unexpected and a striking contrast to the results 
of previous trials and observational studies, despite that niacin in this trial produced 
the predicted effects on all lipid parameters measured including increasing HDL 
levels by 20% and reducing triglycerides by around 25%
29
. The early termination of 
this trial raised questions about the suggested beneficial effects of the HDL-
elevation hypothesis
30
. However, the AIM-HIGH study population was not a very 
high-risk population because the patients were already on statin-treatment and 
their LDL-cholesterol level was already well controlled. The study population in this 
trial does not represent all patient populations in whom the importance of treating 
low HDL and lowering triglycerides with Niaspan may be significant. Therefore, the 
relevance of these results to patients outside the AIM-HIGH study population is 
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currently unknown and it would be premature to extrapolate these results with 
Niaspan to a broader patient population at this time
31
. 
The clinical use of niacin has been limited due to the cutaneous flushing effect, 
which is mediated by the niacin receptor GPR109A in the skin. Therefore, in 
Chapter 5, we assessed the properties of two partial agonists for GPR109A and 
compared them to niacin. We show that these two GPR109A partial agonists of the 
pyrazole class are promising drug candidates to achieve the beneficial lipid-
lowering effects while they successfully avoid the unwanted flushing side effect. 
Interestingly, our flushing results are somewhat complicated due to the unexpected 
skin temperature increase observed in the C57BL/6 mice treated with the vehicle 
DMSO. DMSO is one of the most common solvents used for in vivo administration 
of water-insoluble substances. In literatures, a wide range of pharmacological 
effects of DMSO has been documented in both animal and human experimental 
models, including membrane penetration and vasodilation
32,33,34
. It is proposed that 
DMSO provokes a histamine-like response, possesses potent histamine-liberating 
properties, and increases blood flow
35
. Despite being frequently used as a solvent 
in biological studies and as a vehicle for drug therapy, the undesirable side-effects 





2. Atherosclerotic lesion regression and mouse models 
The second part of the thesis focuses on the concept of atherosclerotic lesion 
regression, shedding insights in the role of LXR activation and application of mouse 
models in regression studies. 
While numerous studies have been dedicated to inhibit the progression of 
atherosclerosis, recent attention has been focused on reversing atherosclerosis, 
which is the regression of existing atherosclerotic plaque. In previous studies, a 
dramatic regression of large advanced lesion was achieved with or without LXR 
agonist
37 , 38
 by utilizing surgical aorta transplantation into wildtype mice. This 
procedure leads to a rapidly improved milieu for the atherosclerotic lesions. In 
another mouse model, apoE*3Leiden mice, LXR agonist were also shown to 
promote regression of moderate lesions
39
. In both Chapter 6 and Chapter 7 we 
investigated other different mouse models to explore technically easier and more 
efficient approaches for plaque regression. 
In Chapter 6 we first fed LDLr
–/–
 mice with high-fat high-cholesterol Western-
type diet (WTD) for 6 weeks to develop atherosclerotic plaques. Subsequently, a 
group of mice was sacrificed to obtain baseline data, whilst the rest of the mice 
were switched to a low-fat cholesterol-free chow diet without or with LXR agonist 
T0901317 supplementation for 3 weeks. Unexpectedly, T-0901317 supplemented 
in regular chow diet largely elevated plasma cholesterol level, and thus the 
atherosclerotic plaque continued its progression. Therefore, we set out to evaluate 
the effects of LXR agonist on plaque regression in C57BL/6 mice. The C57BL/6 
mouse model has been used to study diet-induced atherosclerosis
40,41,42
. This 
murine model of atherogenesis represents an alternative to the use of genetically 
modified mice with impaired lipoprotein clearance, i.e. LDLr
–/–
 mice, for the 
evaluation of anti-hyperlipidemic agents, including LXR agonists
43
. Here we fed 
C57BL/6 mice with cholate-containing cholesterol-enriched atherogenic diet for 16 
weeks to induce atherosclerotic plaque development. Subsequently, a group of 
mice were sacrificed to obtain baseline data, whilst the remainder of the mice was 
Chapter 8 
 128 
switched to low-fat cholesterol-free chow diet without or with LXR agonist 
T0901317 supplementation for 3 weeks. In contrast to data from LDL
–/–
 mice, in 
C57BL/6 mice LXR agonist supplemented in regular chow diet successfully 
reduced the diet-induced hypercholesterolemia rapidly. LXR agonist not only 
reduced plasma (V)LDL cholesterol levels, but also significantly increased HDL 
level, leading to a 10-fold increased ratio between antiatherogenic HDL and 
proatherogenic (V)LDL level. This indicates that LXR agonist, together with chow 
diet, rapidly improved the plasma lipoprotein profile and induced a regression 
environment in C57BL/6 mice. 
LXR agonist exhibited opposite effects on plasma lipoprotein and lesion 
progression in LDLr
–/–
 and C57BL/6 mice, and we propose that this is due to the 
absence of LDL receptor and thus impaired LDL clearance in LDLr
–/–
 mice. The 
LDL receptor-mediated cholesterol uptake and feedback regulation are crucial 
when evaluating LDL-lowering effects of compounds
44
. Studies have show that 
when LDL receptor gene was transferred back into hypercholesterolemic LDLr
–/–
 
mice to restore sustained expression of the LDLr protein in the liver, there was 
drastic reduction of plasma cholesterol and non-HDL cholesterol levels persistently 
and pronounced regression of advanced atherosclerotic
45,46
. Thus, it is proposed 
that C57BL/6 mice is a better model than LDLr
–/–
 to evaluate (V)LDL-lowering 
induced atherosclerotic regression. 
However, the limitation of the C57BL/6 mouse model is that the atherosclerotic 




 in the 
aortic root), and there was hardly any lesion developed in the aortic arch or the 
descending aorta yet. Thus, the effect of LXR-agonist in this study was limited to 
diminishing early atheromatous lesion with small size and less complexity. It is thus 
important to further investigate the potential of LXR activation on diminishing larger 
advanced atherosclerotic plaque in both the aortic root and descending aorta. 
In Chapter 7 we used bone marrow transplantation technique, reconstituting 
ApoE
–/–
 mice with bone marrow from wildtype mice, to restore apoE function in 
macrophages and normalize plasma lipoprotein profiles. This is a novel mouse 
model with chow diet feeding, providing an alternative model to investigate 
atherosclerotic plaque regression without robust surgical measures. We performed 
this regression study in parallel on initial and advanced lesions. We show that the 
bone marrow transplantation technique leads to successful plaque regression of 
both initial and advanced lesions. The current mouse model is thus a good model 
to study atherosclerosis regression in different stages of the disease. However, in 
initial lesions, a 45% reduction in lesion size was observed with chow diet alone, 
and even a 71% reduction with LXR agonist treatment, whilst in advanced lesions 
there was a more limited 23% reduction with chow diet alone, and a 36% reduction 
with LXR activation. This can be explained by the difference in plaque composition 
and characteristics between initial and advanced lesion. Initial lesions contain 
primarily cholesterol-filled macrophages covered by a thin cap, while in advanced 
lesion, SMCs and extracellular
 
matrix products comprise the major structural 
components of
 
the atherosclerotic plaques, covered by a thick fibrous cap
47
, which 
make the advanced lesions more difficult to be modulated during the regression 
process. 
Interestingly, our lesion composition analysis showed that the reduction of total 
lesion size during regression was primarily due to a reduction of the macrophage 
content in the plaque. However, the fate of the macrophages during lesion 
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regression is currently still under debate. It has been proposed that regression is 
not merely a rewinding of progression, but instead involves induction of CCR7 
expression, a mediator of leukocyte emigration, leading to the emigration of the 
lipid-loaded macrophages, followed by the initiation of influx of healthy phagocytes 
that mobilize necrotic debris and all other components of advanced plaques
48
. 
Interestingly, Ye et al showed that macrophage infiltration into pre-existing 
advanced lesions was limited, likely because of the formation of fibrous caps
49
. In 
contrast, Potteaux et al also showed that regression of atherosclerosis after apoE 
complementation in ApoE
–/–
 mice did not involve migratory egress of macrophages 
from plaques or induction of CCR7. Instead, marked suppression of monocyte 
recruitment coupled with a stable rate of apoptosis accounted for loss of plaque 
macrophages, suggesting that therapies to inhibit monocyte recruitment to plaques 
may constitute a viable strategy to reduce plaque macrophage burden than 
attempts to promote migratory egress
50
. Further research is necessary to establish 
the processes and mechanisms underlying the diminished macrophage content 
during regression in our experimental mouse model. 
In conclusion, the second part of this thesis, focusing on novel mouse models to 
induce atherosclerotic lesion regression, shows that 1) intact LDL receptor function 
is crucial to overcome LXR-induced hyperlipidemia as to achieve plaque regression; 
2) ApoE
–/–
 mice reconstituted with bone marrow from C57BL/6 mice represents a 
promising mouse model with chow diet feeding to study the regression of 
atherosclerosis, providing an alternative model to investigate plaque regression 
without robust surgical measures; and 3) rapidly optimized plasma lipoprotein 
profiles, combined with LXR agonist treatment, induced favorable gene expression 
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Atherosclerosis is the underlying cause of most cardiovascular diseases. It is a 
progressive inflammatory disease which has a clinical onset by vascular 
obstruction from the deposits of plaque, subsequently developing into athero-
thrombosis and abnormal blood flow. The evidence to support a cholesterol-
atherosclerosis link has been revealed in the past three decades. There is a 
growing consensus that therapeutic lowering of plasma VLDL- and LDL-cholesterol 
levels and raising of HDL-cholesterol level will reduce the risk of cardiovascular 
incidence. This dissertation is dedicated to the regulation of lipid metabolism 
pathways, both in plasma and liver, and its subsequent effects on atherosclerotic 
lesion progression and regression. In Chapter 1, established mechanisms 
underlying lipid metabolism and atherosclerotic pathology are reviewed, including 
the important players involved in plasma and hepatic lipoprotein metabolism 
pathways and the atherosclerotic plaque progression / regression process. 
 
 
1. Hepatic lipid metabolism and pharmaceutical interventions in the liver 
The first part of the thesis focuses on the hepatic lipid metabolism and the 
pharmaceutical interventions in the liver.  
In Chapter 2, we used real-time quantitative PCR to compose the hepatic cell 
type-specific expression profile of nuclear receptors (NRs), providing the most 
complete quantitative assessment of NRs distribution in liver reported to date. We 
have identified several liver-enriched orphan NRs as potential novel targets for 
pharmaceutical interventions. Specifically, members of the orphan receptor family 
COUP-TFs showed distinguished distributions in liver. COUP-TF3 was abundantly 
and exclusively expressed in liver parenchymal cells, while the other two members, 
COUP-TF1 and COUP-TF2, were expressed exclusively in non-parenchymal cells. 
Despite the moderate to high expression level in the liver, the physiological 
functions of COUP-TFs have not been fully exploited, and the ligand for COUP-TFs 
has not been identified. Our study suggests a physiologic important role of COUP-
TF3 in hepatocytes, and that of COUP-TF2 in endothelial cells and macrophages.  
In Chapter 3, we have determined the hepatic expression profile of NAFLD-
related gene PNPLA3. To gain insight into the potential function of PNPLA3 in liver, 
we have determined the effect of diet change on the hepatic expression profile of 
PNPLA3 in mice, using microarray and real-time PCR analysis. Cellular distribution 
analysis revealed that PNPLA3 is expressed in hepatocytes but not in liver 
endothelial or Kupffer cells. Microarray-based gene profiling showed that the 
expression level of PNPLA3 is highly influenced by the intra-hepatic lipid status. 
Furthermore, our study suggests an essential function of PNPLA3 in hepatic 
lipogenesis. 
In addition to lipid-lowering therapies, HDL has become the next promising 
therapeutic target. The anti-dyslipidemic drug niacin, also known as nicotinic acid, 
not only lowers plasma levels of pro-atherogenic lipids/lipoproteins, but also is the 
most effective agent available to increase HDL-cholesterol. Recently, it has been 
shown that niacin also reduces the hepatic expression and plasma levels of the 
pro-atherogenic CETP. In Chapter 4 we investigated the mechanism underlying 
the CETP-lowering effect of niacin. We propose that the primarily reduced hepatic 
                                                                                                        English summary 
 135 
cholesterol accumulation via the lipid-lowering effect of niacin leads to attenuated 
hepatic inflammation, and thus less macrophage infiltration into and/or increased 
macrophage emigration out of the liver. The decreased amount of hepatic 
macrophages, which are significant contributors of CETP, leads to an overall 
reduction in hepatic CETP expression and a lower plasma CETP level. In 
conclusion, we have shown that niacin does not directly alter macrophage CETP 
expression, but attenuates the liver inflammation and macrophage content in 
response to its primary lipid-lowering effect, which leads to a decrease in hepatic 
CETP expression and the plasma CETP mass. 
The clinical use of niacin has been limited due to the cutaneous flushing effect, 
which is mediated by the niacin receptor GPR109A in the skin. Therefore, in 
Chapter 5, we assessed the properties of two partial agonists for GPR109A and 
compared them to niacin. We show that these two GPR109A partial agonists of the 
pyrazole class are promising drug candidates to achieve the beneficial lipid-
lowering effects while they successfully avoid the unwanted flushing side effect. 
 
 
2. Atherosclerotic lesion regression and mouse models 
The second part of the thesis focuses on the concept of atherosclerotic lesion 
regression, shedding insights in the role of LXR activation and application of mouse 
models in regression studies. 
While numerous studies have been dedicated to inhibit the progression of 
atherosclerosis, recent attention has been focused on reversing atherosclerosis, 
which is the regression of existing atherosclerotic plaque. In previous studies, a 
dramatic regression of large advanced lesion was achieved with or without LXR 
agonist by utilizing surgical aorta transplantation into wildtype mice. This procedure 
leads to a rapidly improved milieu for the atherosclerotic lesions. In both Chapter 6 
and Chapter 7 we investigated other mouse models to explore technically easier 
and more efficient approaches for plaque regression. 
In Chapter 6 we first used LDLr
–/–
 mice with high-fat high-cholesterol Western-
type diet (WTD) for 6 weeks to develop atherosclerotic plaques. Subsequently, a 
group of mice was sacrificed to obtain baseline data, whilst the rest of the mice 
were switched to a low-fat cholesterol-free chow diet without or with LXR agonist 
T0901317 supplementation for 3 weeks. In addition, we fed C57BL/6 mice with 
cholate-containing cholesterol-enriched atherogenic diet for 16 weeks to induce 
atherosclerotic plaque development and perform regression study with LXR agonist 
T0901317. In Chapter 7 we used bone marrow transplantation technique, 
reconstituting ApoE
–/–
 mice with bone marrow from wildtype mice, to restore apoE 
function in macrophages and normalize plasma lipoprotein profiles. This is a novel 
mouse model with chow diet feeding, providing an alternative model to investigate 
atherosclerotic plaque regression without robust surgical measures. We performed 
this regression study in parallel on initial and advanced lesions. In conclusion, both 
of these two chapters, focusing on novel mouse models to induce atherosclerotic 
lesion regression, demonstrate that 1) intact LDL receptor function is crucial to 
overcome LXR-induced hyperlipidemia and to achieve plaque regression; 2) ApoE
–
/–
 mice reconstituted with bone marrow from C57BL/6 mice represents a promising 
mouse model with chow diet feeding to study the regression of atherosclerosis, 
providing an alternative model to investigate plaque regression without robust 
surgical measures; and 3) rapidly optimized plasma lipoprotein profiles, combined 
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with LXR agonist treatment, induced favorable gene expression profiles, leading to 
regression of both initial and more advanced atherosclerotic plaques. 
In Chapter 8, the results obtained from all the experiments mentioned above 











Atherosclerose is de onderliggende oorzaak van de meeste hart- en vaatziekten. 
Het is een progressieve aandoening die vernauwing van de bloedvaten 
veroorzaakt door de afzetting van vetten (lipiden) in de vaatwand. De afgelopen 
drie decennia is het bewijs geleverd voor een verband tussen cholesterol in 
bloedplasma en atherosclerose. Er is een groeiende consensus dat de 
therapeutische verlaging van VLDL- en LDL-cholesterolwaarden en verhoging van 
de HDL-cholesterol in het plasma het risico op hartinfarcten kan verminderen. Dit 
proefschrift is gewijd aan studies naar de regulatie van het lipidenmetabolisme, 
zowel in plasma als de lever, en de effecten daarvan op de progressie en regressie 
van de vernauwingen van het bloedvat, de zogenaamde atherosclerotische 
plaques. In hoofdstuk 1 wordt een overzicht gegeven van de mechanismen die 
ten grondslag liggen aan het lipidenmetabolisme en de pathologie van 
atherosclerose, inclusief de belangrijke factoren die een rol spelen bij de regulatie 
van lipoproteïnen in plasma en lever en de progressie en regressie van 
atherosclerotische plaques.  
 
 
1. Lipidenmetabolisme in de lever en farmaceutische interventies 
Het eerste deel van dit proefschrift richt zich op het lipidenmetabolisme en de 
farmaceutische interventies in de lever. 
In hoofdstuk 2 gebruikten we kwantitatieve PCR (polymerase-kettingreactie) in 
real-time om het levercelspecifieke expressieprofiel van nucleaire receptoren (NRs) 
samen te stellen, wat heeft geresulteerd in de meest complete kwantitatieve 
analyse van de distributie van NRs in de lever die tot op heden is gepubliceerd. We 
hebben een aantal wees-NRs, die veelvuldig voorkomen in de lever, 
geïdentificeerd als mogelijk nieuwe targets voor farmaceutische interventies. In het 
bijzonder vertoonden de leden van de weesreceptorfamilie COUP-TFs een 
specifieke distributie in de lever. COUP-TF3 kwam in grote mate en exclusief tot 
expressie in de leverparenchymcellen, terwijl COUP-TF1 en COUP-TF2 uitsluitend 
tot expressie kwamen in niet-parenchymcellen. Ondanks de matige tot hoge 
expressieniveaus in de lever, zijn de fysiologische functies van COUP-TFs nog niet 
volledig onderzocht en is het ligand voor de verschillende COUP-TFs nog niet 
geïdentificeerd. Onze studie suggereert een fysiologisch belangrijke rol van de 
COUP-TF3 in levercellen (hepatocyten), en voor COUP-TF2 in endotheelcellen en 
macrofagen. 
Hoofdstuk 3 beschrijft het expressieprofiel van PNPLA3 in de lever, een gen 
dat gerelateerd is aan niet-alcoholische leververvetting (NAFLD). Om inzicht te 
krijgen in de mogelijke functie van PNPLA3 in de lever, hebben wij het effect van 
dieetverandering op de expressie van PNPLA3 in de lever van muizen onderzocht, 
met behulp van microarray en real-time PCR. Uit analyse van de cellulaire 
distributie is gebleken dat PNPLA3 vooral tot expressie komt in hepatocyten, maar 
niet in leverendotheelcellen of Kupffercellen. Genprofilering gebaseerd op 
microarray toont aan dat de expressie van PNPLA3 in hoge mate beïnvloed wordt 
door lipiden in de lever. Bovendien suggereert onze studie een essentiële functie 
van PNPLA3 in hepatische lipidensynthese. 
Naast lipidenverlagende therapieën is het verhogen van de concentratie HDL in 
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het bloed uitgegroeid tot een belangrijk therapeutisch doel. Niacine of nicotinezuur, 
een geneesmiddel tegen dyslipidemie, verlaagt niet alleen plasmaspiegels van 
proatherogene lipiden en lipoproteïnen, maar is momenteel ook het meest 
effectieve middel om HDL-cholesterol te verhogen. Onlangs is aangetoond dat 
niacine ook de expressie van het proatherogene eiwit CETP (choleseryl ester 
transfer protein) in de lever en de plasmaspiegels daarvan verlaagt. In hoofdstuk 
4 onderzochten we het onderliggende mechanisme van het CETP-verlagende 
effect van niacine. Wij suggereren dat het lipidenverlagende effect van niacine leidt 
tot minder ophoping van cholesterol in de lever, waardoor het ontstekingsproces in 
de lever wordt afgeremd en er minder macrofagen infiltreren in de lever en/of er 
meer macrofagen emigreren uit de lever. De vermindering van de hoeveelheid 
macrofagen in de lever, die een belangrijke bron zijn van CETP, leidt tot een 
algemene daling van de CETP-expressie in de lever en een lager CETP-gehalte in 
het plasma.  
De klinische toepassing van niacine is beperkt vanwege de plotselinge roodheid 
van de huid, de zogenaamde flushing, die het kan veroorzaken via activatie van de 
niacinereceptor GPR109A in de huid. In hoofdstuk 5 zijn de eigenschappen van 
twee partiële agonisten voor GPR109A vergeleken met niacine. Deze twee partiële 
GPR109A-agonisten uit de klasse van pyrazolen blijken veelbelovende 
kandidaatgeneesmiddelen te zijn omdat ze een verlaging van het lipidengehalte 
kunnen bewerkstelligen zonder de ongewenste flushing. 
 
 
2. Regressie van de atherosclerotische laesie en muismodellen 
Het tweede deel van het proefschrift draait om regressie van de atherosclerotische 
plaque.en geeft inzicht in de rol van de lever X receptor (LXR) en de toepassing 
van muismodellen in regressiestudies. 
Terwijl vele studies zijn gewijd aan het afremmen van de progressie van 
atherosclerose is recentelijk de aandacht gericht op de mogelijkheid om via 
regressietherapie bestaande atherosclerotische plaques te verkleinen. In eerdere 
studies werd een dramatische vermindering van grote geavanceerde laesies 
bereikt door middel van aortatransplantatie in wild-type muizen, al dan niet in 
combinatie met LXR-agonisten. Dit leidt tot zeer snelle verbetering van de 
omgeving rondom de plaque. In zowel hoofdstuk 6 en hoofdstuk 7 onderzochten 
we alternatieve muismodellen waarin gemakkelijker en efficiënter plaqueregressie 
is te bewerkstelligen 
In hoofdstuk 6 werd gebruik gemaakt van LDL-receptordeficiënte muizen die 
een vet- en cholesterolrijk westers dieet kregen om atherosclerotische plaques te 
ontwikkelen. Vervolgens werd een groep muizen opgeofferd om plaques te 
analyseren; de rest van de muizen werd gedurende 3 weken overgezet op een vet- 
en cholesterolarm dieet dat al dan niet verrijkt was met de LXR-agonist T0901317. 
Daarnaast zijn in C57BL/6 muizen door middel van een cholaatbevattend 
cholesterolrijk dieet atherosclerotische plaques ontwikkeld gedurende 16 weken, 
waarna een regressiestudie werd uitgevoerd met de LXR-agonist T0901317. In 
hoofdstuk 7 werd beenmergtransplantatie toegepast om de functie van apoE in 
macrofagen van apoE-deficiënte muizen te herstellen en de plasmaspiegels van 
lipoproteïnen te normaliseren. Deze techniek levert een alternatief muismodel voor 
plaqueregressie zonder intensieve chirurgische ingrepen. Deze regressiestudie 
werd uitgevoerd met zowel initiële als geavanceerde laesies. De data beschreven 
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in beide hoofdstukken ondersteunen de conclusies dat 1) normale LDL-
receptorfunctie cruciaal is om LXR-geïnduceerde hyperlipidemie te verminderen en 
plaqueregressie te bereiken, 2) apoE-deficiënte muizen gereconstitueerd met 
beenmerg van C57BL/6 muizen een veelbelovend muismodel vormen voor studies 
naar het mechanisme van de regressie van atherosclerose zonder intensieve 
chirurgische ingrepen, en 3) een snel geoptimaliseerd lipoproteïnenprofiel in 
plasma in combinatie met een LXR-agonist leidt tot regressie van zowel initiële als 
meer geavanceerde atherosclerotische plaques. 
In hoofdstuk 8 worden de resultaten van alle experimenten samengevat en 
worden de consequenties van deze studies voor de toekomstige behandeling van 
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ABCA1 ATP binding cassette transporter A1 
ABCG1 ATP binding cassette transporter G1 
ACAT acyl-cholesterol acyl transferase 
AD atherogenic diet 
ADPN adiponutrin 
ApoA-I apolipoprotein A-I 




ATGL adipose triglyceride lipase 
BMT bone marrow transplantation 
CCR C-C chemokine receptor 
CE cholesteryl ester 
CETP cholesterol ester transfer protein 
COUP-TF chicken ovalbumin upstream promoter-transcription factor 
CVD cardiovascular disease 
CYP7A1 cholesterol 7 alpha-hydroxylase 
DGAT1 acyl-coenzyme A:diacylglycerol transferase 1 
DMSO dimethyl sulphoxide 
EC endothelial cell 
FAS fatty acid synthase 
FC free cholesterol 
FCS fetal calf serum 
FFA free fatty acids 
FPLC fast protein liquid chromatography 
FXR farnesoid X receptor 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GTC guanidinium thiocyanate 
HCA2 hydroxy-carboxylic acid receptor 2 
HDL high-density lipoprotein 
HEK human embryonic kidney 
HFD high-fat Diet 
HPRT  hypoxanthine-guanine phosphoribosyltransferase 
ICAM  intercellular adhesion molecule 
IDL intermediate-density lipoprotein 
IL interleukin 
KC Kupffer cell 
KO knockout 
LCAT lecithin-cholesterol acyltransferase 
LDL low-density lipoprotein 
LDLr LDL receptor 
LDLr
–/–
 LDL receptor-deficient 
LPL lipoprotein lipase 
LRP LDLr-related protein 
LXR liver X receptor 
MCP monocyte chemoattractant protein 
MTP microsomal transfer protein 
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NAFLD non-alcoholic fatty liver disease 
NASH non-alcoholic steatohepatitis 
NR nuclear receptor 
Ox-LDL oxidized LDL 
PBS phosphate buffered saline 
PC parenchymal cell 
PCR polymerase chain reaction 
PGD2 prostaglandin D2 
PGE2 prostaglandin E2 
PL phospholipids 
PNPLA3 patatin-like phospholipase domain-containing protein 3 
PPAR peroxosimal proliferator activating receptor 
RCT reverse cholesterol transport 
ROR retinoid-related orphan receptor 
RXR retinoid X receptor 
SMC smooth muscle cell 
SR-BI  scavenger receptor class B, type I 
SREBP sterol regulatory element binding protein 
TC total cholesterol 
TG triglycerides 
Tg transgenic 
TNF tumor necrosis factor 
TRL triglyceride-rich lipoproteins 
VCAM  vascular cell adhesion molecule 
VLDL very-low-density lipoprotein 
WT wild-type 
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behorende bij het proefschrift 
 
Intervention in Hepatic Lipid Metabolism: Implications for Atherosclerosis 
Progression and Regression 
 
 
1. Their specific cellular activity and localization suggest that the orphan nuclear receptors 
COUP-TF2, COUP-TF3, and TR4 may be of significant importance as novel targets for 
pharmaceutical interventions in liver. (this thesis) 
 
2. Niacin does not directly alter CETP expression in the macrophage, but attenuates liver 
inflammation and macrophage content in response to its primary lipid-lowering effect, 
leading to a decrease in hepatic CETP expression and plasma CETP mass. (this thesis) 
 
3. Mouse models are not the most suitable platform to study the mechanism of the 




 mice, reconstituted with bone marrow from C57BL/6 mice, represent a promising 
mouse model to study regression of atherosclerosis. (this thesis) 
 
5. Improvement in the plasma lipid profile, specifically large reductions in plasma 
concentrations of apoB-lipoproteins, is crucial to trigger atherosclerotic plaque 
regression. (Williams KJ et al., Nat Clin Pract Cardiovasc Med. 2008;5:91-102) 
 
6. The relevance of the results from the AIM-HIGH trial for patients outside this study 
population is currently unknown, and it would be premature to extrapolate the current 
results with Niaspan to a broader patient population at this time. (Wise J. BMJ. 
2011;342:d3400) 
 
7. Characterizing the tissue expression pattern of nuclear receptors and their gene 
regulation pathways may identify novel drug targets. (Chawla A et al., Science. 
2001;294:1866-1870) 
 
8. ‘Inburgeren’ is important, because it feels good when you pass a Dutch billboard and 
actually know what it’s talking about. 
 
9. We can’t run away from who we are. So, check Careertest.net, a website telling you who 
you are. 
 
10. In the hope of reaching the moon, we may fail to see the flowers that blossom at our feet. 
 
11. More than often, we are more disappointed by the things that we didn't do than the ones 
we did do. 
 
Zhaosha Li 
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